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 Chapter 1 
Introduction 
 
 
 
   
   
 Introduction 
 
1. Bone metabolism 
From its development and mineralization / ossification during gestation to-
wards the end of life multiple processes take place in bone, making it a dy-
namic tissue [1]. In the embryonic stage bone develops in roughly two 
different ways, either via differentiation of the mesenchymal stem cell into 
osteoblasts, which are cells that are able to produce bone tissue (intramem-
branous bone formation), or via the ossification of cartilage (endochondral 
bone formation) after the mesenchymal stem cell has differentiated into a 
chrondrocyte [2-5]. After birth, bones grow longitudinally, gain mass, and are 
shaped through the process of modeling. Modeling is the formation of lamel-
lar bone on bone surfaces by osteoblasts, and the removal of bone at other 
surfaces by osteoclasts, whereby osteoclast activity is independent from oste-
oblast activity [6]. When longitudinal bone growth ceases at the end of puber-
ty, until around the age of 30 when peak bone mass is attained, the skeleton 
will continue to build up in both mass and strength. The maximum strength 
of the bone mass reached by an individual depends on genetics and environ-
mental factors such as exercise and diet [7-12]. While bone formation and 
bone resorption are balanced until the 4-6th decade of life, a steady decline of 
bone mass occurs thereafter, with a more rapid decline in women around the 
time of menopause due to a sharp decrease in estrogen levels [13, 14]. 
 
1.1 Bone remodeling 
Even after the attainment of peak bone mass bone remodeling (Figure 1) 
takes place, a process whereby osteoclasts remove damaged and brittle parts 
of bone, followed by osteoblast-mediated formation of new bone [15]. This 
process continues throughout life and is influenced and mediated by different 
cytokines, chemokines, and hormones [1, 11, 15, 16].  
 
Figure1: schematic representation of bone remodeling 
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 1.2 Osteoclasts, Osteoblasts and Osteocytes 
There are three major cell types in bone: osteoblasts, osteoclasts and osteo-
cytes. Osteoblasts are bone-forming cells. They are derived from mesenchy-
mal stem cells and differentiate into osteoblasts via a complex mechanism 
involving several transcription factors such as runt-related transcription 
factor 2 (RUNX2), osterix (SP7), ß-catenin, low-density lipoprotein receptor-
related protein 5 (LRP5) and the Wnt signaling pathway [17, 18]. Mesen-
chymal stem cells differentiate into osteoprogenitor cells, which will prolifer-
ate and differentiate into pre-osteoblasts able to produce alkaline 
phosphatase, an important enzyme for the generation of inorganic phosphate 
at this stage [19]. In addition, pre-osteoblasts start generating an extracellu-
lar matrix (ECM), which mainly consists of collagens such as collagen type I, 
as well as non-collagenous proteins. Upon differentiation of pre-osteoblasts 
into osteoblasts, the ECM is subsequently mineralized through formation of 
calcium and phosphate containing crystals (hydroxyapatite; Ca10(PO4)6(OH)2). 
The majority of the osteoblasts will undergo apoptosis or become bone-lining 
cells, while only a minority will be incorporated into bone as osteocytes [20]. 
Osteocytes are the most abundant cell types in bone. They are derived from 
the mesenchymal stem cell line and constitute terminally differentiated oste-
oblasts. To become embedded as an osteocyte in bone, an active invasive 
process cleaving collagens and other matrix proteins takes place, whereby 
the osteoblast transforms from a polygonal cell into a dendritic osteocyte [21].  
Osteocytes are key signal transducers of mechanical loading. Mechanosens-
ing results in the inhibition of the expression of sclerostin, an inhibitor of the 
Wnt-canonical signaling pathway, thereby leading to stimulation of osteo-
blast activity [22]. It is thought that osteocytes are the key regulators for 
bone remodeling due to the fact that they stimulate osteoclast formation and 
activation, as well as osteoblast and mesenchymal stem cell differentiation 
[23-25]. The discovery of osteocyte-secreted fibroblast growth factor 23 
(FGF23) as a factor that plays an important role in proper calcium and phos-
phate homeostasis has renewed some interest in studying the metabolic roles 
of osteocytes in bone remodeling [22, 26, 27]. 
Bone resorption is primarily the function of osteoclasts. Osteoclasts are spe-
cialized multinucleated cells that are derived from the hematopoietic lineage. 
Their precursors are mononuclear cells, predominantly monocytes, that dif-
ferentiate into osteoclasts in a paracrine manner by osteoblast-produced 
cytokines such as macrophage colony-stimulating factor (M-CSF) and recep-
tor-activator of nuclear factor kappa-B ligand (RANKL) [28-31]. Osteopro-
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 tegerin (OPG), which is also released by osteoblasts, serves as a decoy for the 
RANKL receptor, thereby blocking osteoclast formation and thus acting as a 
negative regulator of osteoclastic bone resorption [30, 31]. After fusion of the 
mononuclear precursors into multinucleated cells, osteoclasts are capable of 
attaching tightly to the bone surface done with a so-called sealing zone and 
resorb bone [28]. They do so by releasing H+ and Cl- ions into a resorption pit 
which is a lacuna underneath the osteoclast adjacent to the bone. These ions 
form acidic HCl and dissolve the inorganic bone matrix into calcium and 
phosphate molecules that are taken up by the osteoclasts and are excreted 
into the bloodstream [31]. In order to degrade the organic matrix, including 
collagens, osteoclasts release the enzyme cathepsin K, amongst others, into 
the resorption pit [32]. The initiation for development of osteoclasts is trig-
gered by multiple hormones, of which parathyroid hormone (PTH) and 1,25-
dihydroxyvitamin D3 (1,25-(OH)2D3) are the most familiar ones [31]. It is 
possible to culture osteoclasts from human peripheral blood mononuclear 
cells [33]. Previously there have been two small studies evaluating differ-
ences in the ability of mononuclear cells to become osteoclasts between osteo-
porotic subjects and healthy controls [34, 35], D 4Amelio et al. found that 
both osteoclastogenesis and osteoclastic bone resorption was enhanced in 
osteoporotic women versus a control group [34]. Jevon et al. found no increase 
in osteoclastogenesis but increased osteoclastic bone resorption capacity in 
osteoporotic subjects versus healthy controls [35]. However, it is not known 
whether these differences in osteoclast formation ability and resorption ca-
pacity are still present in the case of longstanding osteoporosis when com-
pared to healthy controls. 
 
2. Osteoporosis 
Osteoporosis is a condition characterized by low bone mineral density (BMD) 
and a deterioration of the bone microarchitecture, leading to frailty of bone 
and an increased risk of fractures [36]. Women are affected more often than 
men. This is partly due to the attainment of a lower peak bone mass in wom-
en. Furthermore, women have a rapid decline of estrogen levels after the 
menopause, resulting in increased bone resorption, which is not fully 
matched by bone formation. In 2015, the prevalence of osteoporosis in the 
Netherlands was 43.1 per 1000 for women and 7.5 per 1000 for men [37]. 
Osteoporosis is correlated with increased morbidity and mortality and a low-
er quality of life [38-40]. In the Netherlands in 2010, the direct costs dedicat-
ed to the treatment of osteoporosis were estimated at 200 million Euro [41]. 
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 In order to evaluate people at risk for fractures, BMD is measured at both 
the hip and the lumbar spine. Lower BMD is associated with an increased 
fracture risk. A BMD, (measured either at the femoral neck, lumbar spine or 
forearm) below -2.5 standard deviations (SD) of that of a 30-year-old with the 
same gender and race (T-score) is defined as osteoporosis by the World 
Health Organization (WHO) [42-44]. Moreover, the presence of a previous 
low-impact fracture of the spine, hip, wrist or humerus is a good predictor of 
consecutive fractures [45]. Therapy to reduce fracture risk is indicated when 
the T-score is below -2.5, when a T-score is below -1 in the presence of a ver-
tebral fracture, or when there are additional risk factors like a recent frac-
ture, disease and/or the use of medication associated with bone loss, 
recurrent falls and a T-score < -2, (CBO “richtlijn osteoporose en fractuur 
preventie 2011”). In order to identify those in need of therapy an online tool 
to calculate fracture risk (http://www.shef.ac.uk/FRAX/) was launched [46, 
47]. Currently, the Dutch osteoporosis and fracture prevention guideline from 
2011 advises the use of the FRAXporosis tool to calculate fracture risk cur-
rent fallsst or um>91, without additional risk factors, to assess whether 
therapy should be indicated (“CBO richtlijn osteoporose en fractuur preventie 
2011”). However, there are currently no cut-off levels defined in the Nether-
lands when using FRAX to commence treatment. 
 
3. Calcium and phosphate metabolism and its regulating hor-
mones 
Calcium and phosphate are stored in bone in the form of hydroxyapatite 
(Ca10(PO4)6(OH)2), which constitutes the vast majority of both ions in the 
body [48]. Calcium and phosphate are vital for many processes in the body. 
Calcium plays an important role in blood coagulation, nerve excitability, 
muscle contraction, membrane permeability and stability, secretion of vari-
ous hormones, and various other processes related to the aforementioned. 
Calcium levels in the circulation are tightly regulated [49]. In order to main-
tain stable serum calcium concentrations the parathyroid glands contain the 
calcium-sensing receptor (CaSR). The CaSR senses the free concentration of 
calcium in the blood and subsequently responds by either increasing or de-
creasing the secretion of PTH from the parathyroid glands [50-52]. When 
calcium levels decrease, increased PTH levels leads to both increased calcium 
re-absorption in the kidney and to increased bone resorption, thereby releas-
ing calcium and phosphate from the bone into the bloodstream. Furthermore, 
PTH induces the 1α-hydroxylase enzyme in the kidney, thereby enhancing 
the conversion of 25-hydroxyvitamin D3 into its active form                       
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 1,25-dihydroxyvitamin D3, which results in increased intestinal calcium (and 
phosphate) absorption [53]. 
Figure 2: schematic representation of hormones and organs involved in the mainte-
nance of adequate serum calcium levels. In response to decreased free calcium concen-
trations PTH is secreted from the parathyroid glands. PTH stimulates calcium release 
from the bone and it stimulates calcium reabsorption in the kidney. Furthermore, PTH 
induces the 1α-hydroxylase enzyme.  The 1α-hydroxylase enzyme stimulates the hy-
droxylation of 25-hydroxyvitamin D3 into 1,25-dihydroxyvitamin D3, which has the ability 
to increases intestinal calcium absorption. 
 
Phosphate is an important component of the backbone structure of DNA and 
several other types of molecules such as phospholipids. Moreover, it is an 
important molecule in energy consuming processes in the body by being part 
of adenosine triphosphate (ATP). Despite phosphate being less tightly regu-
lated compared to calcium, PTH and 1,25-dihydroxyvitamin D3 are also es-
sential in the maintenance of stable serum phosphate concentrations [54]. On
the one hand, PTH and 1,25-dihydroxyvitamin D3 stimulate phosphate re-
lease from the bone and intestinal phosphate absorption; on the other hand 
PTH facilitates phosphate excretion via the kidneys [53-55]. Recently, FGF23 
was shown to play a crucial role in phosphate metabolism as well. It is pre-
dominantly produced by osteoblasts and osteocytes, and inhibits renal tubu-
lar phosphate reabsorption and PTH synthesis. Furthermore, it inhibits the 
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 conversion of 25-hydroxyvitamin D3 into its active form 1,25-dihydroxy-
vitamin D3 by reducing 1!-hydroxylase synthesis [53].  
With aging, alterations occur in calcium, phosphate, and bone homeostasis 
[56-59]. Both sexual dimorphism in phosphate levels and bone homeostasis 
with aging (e.g. menopause) have been extensively studied [59-64], but there 
have been contradicting and less comprehensive data on sexual dimorphism 
of calcium homeostasis [60, 65-69]. Additionally, little is known how the sex 
hormones estradiol and testosterone influence calcium and phosphate metab-
olism in men and women at older age. 
 
Phosphate levels and health 
Phosphate is present in numerous food products, especially in protein rich 
food products such as meat and dairy, as organic esters and only about 40 to 
60 percent of this form of phosphate are absorbed in the intestines [70]. 
Phosphate is also supplemented as phosphoric acid, phosphates and poly-
phosphates to a large number of food products ranging from soft drinks and 
meat products to pre-packed food items [71]. These non-organically bound 
forms of phosphate are easily absorbed in the intestines and multiple reports 
have indicated that this absorption can increase serum phosphate levels [72]. 
High phosphate levels can lead to ectopic calcifications e.g., in arteries [73]. 
Several studies have reported increased cardiovascular morbidity and mor-
tality related to higher phosphate levels in patients with chronic kidney dis-
ease [74, 75], and recently even in persons without chronic kidney disease 
[62, 64, 76]. Based on these findings, Ritz et al. raised awareness about the 
possible detrimental effects of phosphate additives in food for the general 
population [72]. The European Food Safety Authority (EFSA) set out to eval-
uate the concerns postulated by Ritz et al. and found only little evidence for 
detrimental health effects of phosphate additives, disallowing advise regard-
ing the restriction of the usage of the aforementioned phosphate additives at 
this point in time. However, they will keep a close watch and have said to re-
evaluate phosphates in food additives in 2018, as they will have gathered 
more data by then [71]. To date, it is unclear whether a relationship exists 
between phosphate levels, with either BMD or fracture risk at population 
level.  
 
4. Vitamin D 
Vitamin D is a steroid hormone that is synthesized in the body by a series of 
metabolic reactions, which start in the skin under the influence of sunlight, 
and it can be derived from nutritional sources and supplements. One of the 
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 first metabolites in the body for the formation of Vitamin D is 7-de-
hydrocholesterol, even though the mechanism and location of its synthesis 
are still a matter of debate [77]. Under the influence of UV-B light 7-
dehydrocholesterol is converted into pre-Vitamin D3, which under influence 
of heat rapidly transforms into Vitamin D3 (cholecalciferol). Vitamin D3 is 
bound to vitamin D binding protein in the circulation and can be stored in 
body fat. Next, 25-hydroxyvitamin D3 is formed by hydroxylation of cholecal-
ciferol in the liver [78] and constitutes the major circulating form of Vitamin 
D. Upon demand of the body, 25-hydroxyvitamin D3 is further hydroxylated 
to 1,25-dihydroxyvitamin D3 through 1α –hydroxylase (CYP27B1), an enzyme 
most predominantly expressed by the kidney but also reported in multiple 
other cell types throughout the body [79, 80]. Being the most bioactive form 
of vitamin D, 1,25-dihydroxyvitamin D3 signals in target cells by binding to 
the vitamin D receptor (VDR), a member of the nuclear receptor family. After 
binding to the VDR, VDR heterodimerizes with retinoid X receptor (RXR) and 
subsequently binds to vitamin D responsive Elements (VDREs) of target gene 
promoters in order to regulate their transcription. These include FGF23 and 
RANKL, which play a role in the regulation of calcium and phosphate home-
ostasis [81]. Besides, 1,25-dihydroxyvitamin D3 controls both its own level 
and activity in all its target cells by stimulating 24-hydroxylase (CYP24A1), 
which initiates the conversion of 25-hydroxyvitamin D3 and 1,25-
dihydroxyvitamin D3 [78] into less active forms of vitamin D. 
Whilst 1 α-hydroxylase in the kidney is responsible for the majority of the 
circulating 1,25-dihydroxyvitamin D3, the presence of 1α-hydroxylase in other 
cell types and tissues is thought to have a more auto- or paracrine function 
[79, 80].  
During aging, vitamin D deficiency may occur due to diminished synthesis in 
the skin as a result of decreased exposure to sunlight, which can be observed 
in nursing home populations, but also the decreased ability of the skin to 
synthesize vitamin D [82]. The bioavailability of vitamin D can lessen with 
age as the result of decreased intestinal uptake due to intestinal microvilli 
atrophy, and a reduced synthesis of 1,25-dihydroxyvitamin D3 due to de-
creased kidney function might also be observed with senectitude [78, 83, 84]. 
The combination of the factors mentioned above predisposes elderly subjects 
to vitamin D deficiency, resulting in increased risk of osteoporosis and dis-
turbances in calcium- and phosphate-metabolism.  
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 5. TRPV5 and aging  
Transient Receptor Potential channel V5 (TRPV5) is a member of the TRP 
superfamily, which is a group of highly homologous genes involved in the 
active transport of ions across the cell membrane. The TRPV5 gene encodes a 
calcium-selective channel present at the luminal site in the distal convoluted 
tubule and the connecting tubule cells in the kidney [85], where it is respon-
sible for calcium reabsorption from urine. Besides, it is located at the ruffled 
border membrane in osteoclasts, where bone resorption takes place, and may 
well be involved in calcium transport from the bone towards the circulation. 
Hence, mice lacking TRPV5 display hypercalciuria with compensatory in-
creased intestinal calcium absorption through vitamin D-induced upregula-
tion of the TRPV5 homologue TRPV6. In addition, these mice display a bone 
phenotype of reduced trabecular and cortical bone thickness [86-88], suggest-
ing that TRPV5 deficiency does not only affect calcium homeostasis, but 
might also have a direct effect on bone homeostasis. Although the function of 
TRPV5 is known, it is currently unclear what the impact of TRPV5 deficiency 
is on calcium homeostasis and bone metabolism within the process of aging. 
 
6. Aims and scopes of this thesis 
Our understanding of the variations in calcium and phosphate homeostasis 
throughout the lifespan is currently incomplete. As alluded to before, bone 
health is vital for healthy aging, and calcium and phosphate are crucial com-
ponents that are incorporated in bone as hydroxyapatite. Disturbances in 
their regulation are associated with aging-related diseases. The general aim 
of this thesis was to study calcium and phosphate homeostasis in relation to 
aging and to the age-related disorder osteoporosis. Firstly, we addressed 
sexual dimorphisms of calcium and phosphate homeostasis by comparing 
calcium and phosphate homeostasis between men and women (Chapter 2) 
above 45 years of age. For this we used three population-based cohorts of 
community dwelling subjects from the Rotterdam Study, with ages ranging 
from 45 to 99 years [89]. In Chapter 3 we addressed alteration in serum 
calcium and phosphate levels over time by assessing three cohorts derived 
from hospital records of Erasmus MC in 2005, 2010 and 2014, with ages 
ranging from 1 until 97 years of age. In Chapter 4 we assessed whether 
differences in phosphate levels influenced BMD and fracture risk. In order to 
do so, we studied serum phosphate levels in relation to BMD and fractures in 
three different cohorts from the Rotterdam study [89] and one cohort from 
the Osteoporotic Fractures in Men (MrOs) study [90, 91]. The three different 
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 cohorts from the Rotterdam Study are the same cohorts as described in 
Chapter 2. The Osteoporotic Fractures in Men (MrOs) study is a population 
based study with the aim to identify those factors influencing fracture risk in 
5994 male subjects aged 65 years or older [90, 91]. We were able to include 
sex-specific effects on the relation of phosphate levels with BMD and fracture 
risk exclusively in the Rotterdam study. In Chapter 5 we described the ef-
fects of genetically defined lactose intolerance on calcium and bone metabo-
lism, as it can influence calcium intake, [92, 93]. This was performed by 
associating the T-13910C polymorphism upstream of the Lactase Phlorizin 
Hydrolase gene (LPH) with bone parameters, including fracture risk, BMD, 
and bone size and geometry, as well as calcium and vitamin D metabolism. 
Moreover, we assessed gene interaction between the T-13910C LPH poly-
morphism and genetic variations in the VDR gene to assess whether minor 
but lifelong differences in the handling of calcium and vitamin D can affect 
bone parameters. We made use of the same elderly population from the Rot-
terdam Study as described in Chapter 2 and a different elderly population 
cohort from the Longitudinal Aging Study Amsterdam (LASA).  In Chapter 
6, we assessed a patient with severe vitamin D deficient rickets due to a 
mutation in the 1α -hydroxylase gene CYP27B1, and investigated the ability 
of peripheral mononuclear cells (PBMCs) to convert 25-hydroxyvitamin D3 
into 1,25-dihydroxyvitamin D3. We also compared the ability of both parents, 
who were carrier of only one mutation, and healthy controls for their ability 
to convert 25-hydroxyvitamin D3 into 1,25-dihydroxyvitamin D3. 
In Chapter 7, studies on PBMC-derived osteoclast formation and osteoclast 
activity in vitro in two extreme bone phenotypes are described. We studied 
women, on average 25 years after menopause, with osteoporosis with at least 
1 fracture, and compared their osteoclast formation and osteoclast activity in 
vitro with age-matched healthy controls. In Chapter 8, we described a study 
on a TRPV5 deficient mouse model with disturbed calcium homeostasis. We 
assessed the impact of TRPV5 deficiency on calcium homeostasis and bone 
metabolism during aging. Amongst other analyses, we focused on bone mi-
crostructure and mineralization, as both are potentially affected as a conse-
quence of disturbed life-long calcium challenges. Chapter 9 contains a 
general discussion and presents future perspectives. Chapter 10 concludes 
with a summary and presents the conclusions of this thesis. Chapter 11 
presents the summary and conclusions in Dutch. 
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Abstract 
Extreme phosphate levels (P) have been associated with mineralization de-
fects and increased fracture risk. Whether P within normal range is related 
to bone health in the general population is not well understood. To investi-
gate the association of P with bone mineral density (BMD) and fracture risk, 
we assessed two population-based cohorts: the Dutch Rotterdam Study (RS-I, 
RS-II, RS-III; n=6791) and the US Osteoporotic Fractures in Men (MrOS; 
n=5425) study. The relationship of P with lumbar spine (LS) and femoral 
neck (FN) BMD was tested in all cohorts via linear models; fracture risk was 
tested in RS-I, RS-II, and MrOS through Cox models, after follow-up of 8.6, 
6.6, and 10.9 years, respectively. Adjustments were made for age, body mass 
index, smoking, serum levels of calcium, potassium, 25-hydroxyvitamin D, 
estimated glomerular filtration rate (eGFR), FN-BMD, prevalent diabetes, 
and cardiovascular disease. Additional adjustments were made for phosphate 
intake, parathyroid hormone, and fibroblast growth factor 23 levels in MrOS. 
We further stratified by eGFR. Results were pooled through study-level me-
ta-analyses. Hazard ratios (HR) and betas (β) (from meta-analyses) are ex-
pressed per 1 mg/dL P increase. P was positively associated with fracture 
risk in men and women from RS, and findings were replicated in MrOS 
(pooled HR all [95% CI]: 1.47 [1.31-1.65]). P was associated with fracture risk 
in subjects without chronic kidney disease (CKD): all (1.44 [1.26-1.63]) and in 
men with CKD (1.93 [1.42-2.62]). P was inversely related to LS-BMD in men  
(β: -0.06 [-0.11 to -0.02]) and not to FN-BMD in either sex. In summary, se-
rum P was positively related to fracture risk independently from BMD and 
phosphate intake after adjustments for potential confounders. P and LS-
BMD were negatively related in men. Our findings suggest that increased P 
levels even within normal range might be deleterious for bone health in the 
normal population.  
 
 
Introduction 
Phosphorus is the main mineral in the bone, where it is deposited together 
with calcium [1]. The intracellular compartment contains approximately 14% 
of phosphorus, and only 1% circulates freely in plasma as phosphate (P) [2]. 
Within bone, phosphorus accumulates in the form of hydroxyapatite [3]. 
Phosphorus bioavailability is crucial for appropriate mineralization [4]; con-
ditions of low phosphate are characterized by defective mineralization and 
excessive amount of unmineralized bone, or osteoid, typical of rick-
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ets/osteomalacia [5, 6].  On the other hand, extreme hyperphosphatemia in-
duces tumoral calcinosis, characterized by ectopic calcifications but also min-
eralization defects [7-9].  
The recent finding that P regulation is exerted also by the phosphatonins !-
Klotho and the osteocyte-derived fibroblast growth factor 23 (FGF23) has 
established the concept that bone is not only a P reservoir but also acts as an 
endocrine organ, regulating P levels and mineralization [3, 7, 10]. Therefore, 
a potential bidirectional relationship between P levels and bone can be postu-
lated, in which adequate P availability allows bone mineralization while os-
teocytes regulate P levels through FGF23 synthesis and through master 
control of bone remodeling [1, 11, 12].  
Despite this important role of P in bone, it is not known whether serum P is 
associated with bone mineral density (BMD) or fracture risk at the popula-
tion level. This research has been scarce and assessed mostly in chronic kid-
ney disease (CKD) patients [13, 14]. The aims of this research were to study 
the relation between P and BMD and fractures in two population-based co-
horts, to study the influence of potential confounders, and to assess the exist-
ence of sex-specific effects, which have been previously described for some 
clinical outcomes mainly in the field of cardiovascular disease [15, 16]. 
 
 
Materials and methods 
This research was performed in three cohorts from the Dutch Rotterdam 
Study (RS-I, recruitment period 1989-1993, original n = 7983; RS-II, recruit-
ment period 2000-2001, original n = 3011; RS-III, recruitment period 2006-
2008, original n = 3932; all subjects aged 45 or more) and in the US Osteopo-
rotic Fractures in Men (MrOS) study (recruitment period 2000-2002, original 
n = 5994; all male subjects aged 65 or older) [17-19]. Fasting serum P levels 
were measured in the third follow-up visit of RS-I, and in baseline visits of 
RS-II, RS-III and MrOS (Fig. 1). Fasting P levels were chosen because the 
fasting state might modify the association of P with clinical outcomes [20]. 
Fracture incidence was collected prospectively until January 1, 2007, in RS-I 
and RS-II; and until January 8, 2015, in MrOS. Fracture incidence was not 
assessed in RS-III. A total of 12.216 and 11.196 participants were included 
for the BMD and fracture analyses, respectively, all with signed informed 
consent. The Rotterdam Study was approved by the Medical Ethics Commit-
tee of Erasmus Medical Center; MrOS was approved by the Institutional Re-
view Board of each of the six clinical centers that enrolled participants. 
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Laboratory measurements 
 
The Rotterdam Study  
The concentration of phosphorus in serum corresponds to the inorganic frac-
tion, or phosphate (P), based on the formation of ammonium phosphomolyb-
date [1]. Total calcium (Ca) determination was performed through a 
colorimetric o-cresolphthalein complexone method. Levels of 25-hydroxy-
vitamin D (25OHD) were determined through an electrochemiluminescence-
based immunoassay (Elecsys Vitamin D Total, Roche Diagnostics, Mann-
heim, Germany); the test sensitivity was 10 nmol/L, the test range was 7.5 
nmol/L to 175 nmol/L, the within-run precision < 6.5% and the total precision 
< 11.5%. We applied cosinor regressions to adjust 25OHD levels for season 
and year [21]. Creatinine was determined through a sarcosine-based colori-
metric assay and standardized against isotope dilution mass spectrometry 
(ID-MS). 
 
MrOS  
Serum P, creatinine, and Ca were measured using a Roche COBAS Integra 
800 automated analyzer. P detectable range was 0.3 to 20.0 mg/dL, creati-
nine was 0.2 to 15.0 mg/dL, and Ca was 0.1 to 20.0 mg/dL. Concentrations of 
25OHD2 and 25OHD3 were analyzed by liquid chromatography/tandem 
mass spectrometry (MS) in a subgroup (n = 2351) and added together to ob-
tain total 25OHD levels using multiple reaction monitoring as previously 
described [22]. Additionally, free concentrations of 25OHD were measured in 
a subgroup (n = 541) by ELISA (DIAsource ImmunoAssays, Louvain-la-
Neuve, Belgium) at Future Diagnostics Solutions (Wijchen, The Nether-
lands). This measurement was validated by comparison with equilibrium 
dialysis at 37°C in 15 normal samples, yielding a correlation of 0.83. The 
lower limit of detection was 1.9 pg/mL and its precision was less than 6% 
[23]. Serum 25OHD levels were adjusted by season.  Measurements were 
performed at the Mayo Medical Laboratories in Rochester, MN, USA.   
Parathyroid hormone (PTH) levels were completed using fasting morning 
blood samples, and samples were frozen until measurement. Immunoradio-
metric Assay from Scantibodies (3KG600) at Columbia University was used 
to measure total intact PTH (pg/mL). Fibroblast growth factor 23 (FGF23) 
levels were completed at the UC Davis Medical Center by two-site monoclo-
nal antibody ELISA using the millipore method. The lower limit of detection 
was 3.3 pg/mL. Bone turnover markers were measured in a specialized la-
boratory (CCBR, Synarc, Lyon, France); type I collagen N-propeptide (PINP, 
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Roche Diagnostics) was measured as marker of bone formation, with intra- 
and interassay coefficient of variation (CV) of < 4.4%. For bone resorption, 
βC-terminal cross-linked telopeptide of type I collagen (βCTX, Roche Diag-
nostics) was measured, with intra- and interassays CVs < 4.2% [24]. 
 
DXA scanning 
Trained radiographic technicians performed BMD measurements using dual-
energy X-ray absorptiometry (DXA). RS-I participants were assessed at base-
line (lumbar spine-LS-BMD, RS-I-1, 1989-1991) and at the third visit (femo-
ral neck FN-BMD, RS-I, 1997-1999), whereas RS-II and RS-III participants 
were assessed at both skeletal sites at baseline visits (2000-2001; 2006-2008; 
respectively), as depicted in Fig. 1. A GE Lunar DPX-L densitometer was 
used in the assessments of RS-I and RS-II, and a Prodigy total body fan-
beam densitometer  in RS-III (GE Lunar Corp, Madison, WI, USA) [25]. 
MrOS participants were assessed at both skeletal sites at the baseline visit; 
each US center used a DXA machine of the same model and manufacturer 
(QDR 4500, Hologic Inc, Waltham, MA, USA) [18]. Machines across all six 
sites were cross-calibrated. 
 
Fracture assessment 
In the Rotterdam Study, information on incident clinical fracture events (of 
all skeletal sites) was obtained from computerized records of general practi-
tioners (GPs) and hospital registries in the research area (covering 80% of the 
cohort) which are regularly checked by research physicians who review and 
code the fracture information according to ICD-10, in addition, research phy-
sicians regularly followed participant information in the GP’s records outside 
the research area and made an independent review and encoding of all re-
ported events [26, 27]. All fractures are described by a radiologist, and in case 
of doubt the actual radiographs were reviewed. Finally, an expert in osteopo-
rosis reviewed all coded events for final classification [28, 29]. 
Because access to medical specialists in The Netherlands is possible only 
through the GP, we do not anticipate that a considerable number of fractures 
could have been treated by orthopedic or traumatology surgeons without pre-
vious notification by GP. In the Netherlands, there is a 24-hour general prac-
titioner evening and night center available after regular working hours and 
the GP is automatically informed after discharge with a report about the di-
agnosis. Additionally, insurance companies do not cover expenses from the 
emergency room when patients have not been referred by the GP. Therefore, 
a significant underestimation of fractures is not anticipated in RS cohorts.  
72
  
 
Figure 1. Flowchart for time line, design and sample size for the analyses, the Rotterdam 
Study cohorts 
 
LAB*: includes fasting phosphate levels 
FN – BMD: femoral neck BMD 
LS – BMD: lumbar spine BMD 
P: fasting phosphate levels 
Fx risk: fracture risk 
 
Incident fracture events were reported by participants in MrOS at 4-month 
intervals on brief mailed questionnaires [30]. The response rates exceeded 
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99%. Subsequently, study physicians centrally adjudicated reported fractures 
from medical records. Incident fractures were confirmed by radiology reports 
or radiographic images when reports were not available [31]. Only fractures 
that are confirmed by the adjudication process are included in MrOS dataset. 
Health care service providers sent a film copy or digital image of the X-ray to 
the Coordinating Center for review and confirmation by a radiologist. 
Fracture outcomes 
Initially, we tested the association between P and all-fracture incidence; sub-
sequently, we analyzed fractures located at the hip, vertebrae, wrist, humer-
us and rib. We also included osteoporotic fractures, defined as fractures at 
any skeletal site except fingers, toes, skull, and facial fractures [32].  
 
Covariates 
Because of previously reported differences in P levels for men and women we 
compared its distribution across sexes in the Rotterdam Study applying t 
tests [33]. We assessed the distribution of potential confounders in subjects 
with FN-BMD information available across P quintiles, applying age-
adjusted tests for trend. We included age, body mass index (BMI), smoking 
status, FN-BMD, prevalent diabetes mellitus, and levels of total Ca, 25OHD, 
potassium, creatinine and estimated glomerular filtration rate (eGFR).  
Prevalent diabetes mellitus and cardiovascular disease were determined as 
previously described [34]. Alcohol intake was estimated at baseline through a 
validated food frequency questionnaire. The Chronic Kidney Disease Epide-
miology Collaboration equations based on creatinine levels and the Modifica-
tion of Diet in Renal Disease (MDRD) study equation were applied to 
estimate eGFR (mL/min) in the Rotterdam Study and MrOS, respectively 
[35, 36]. Phosphate intake information collected at the same visit as fasting P 
was available in a subgroup from MrOS. This dietary information is from the 
Block Dietary Systems Food Frequency Questionnaire (FFQ), which was spe-
cially designed for the MrOS study as a brief FFQ for older adults, based on 
the NHANES III dietary recall data and including 69 items.  
 
Statistical analyses 
A potential association between P levels and BMD was tested through gener-
alized linear models, allowing Gaussian but also non-normal distributions. 
BMD in sex-specific standard deviations (SD) was set as the dependent vari-
able, and P levels in mg/dL (1mg/dL = 0.32 mmol/L) was set as the independ-
ent variable, adjusted for age, BMI and smoking; site and race adjustments 
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were included in MrOS. Betas (β) are expressed per 1 mg/dL increase in P 
levels. Fitness of different models was compared through the Akaike Infor-
mation Criteria AIC; linear models with normal distributions displayed lower 
AIC values, corresponding to a better fit [37]. The results from these analyses 
were meta-analyzed. LS-BMD was not measured simultaneously to P as-
sessment in RS-I (Fig.1).  
We explored associations of P levels with fracture risk applying Cox models, 
testing the proportionality of the hazards through Schoenfeld residuals tests 
[38]. Results from RS-I, RS-II and MrOS were pooled through study-level 
meta-analysis, applying a fixed-effects model because of the small number of 
studies involved [39]. The analysis time was set at the date of blood draw for 
fasting P levels. Subjects were followed until the first of the following events 
happened: first fracture, death, loss to follow-up, or censoring. Hazard ratios 
(HRs) are expressed per 1 mg/dL increase of P levels or in study-specific 
quintiles.  
Adjustments were made first for a basic model including age, BMI, and 
smoking; site and race were also included in MrOS (Model I) [40-42]. Anal-
yses in RS cohorts were also adjusted for a dummy variable to account for 
different DXA machines. We further adjusted the analyses for additional co-
variates included in a full model (Model II), composed of FN-BMD, calcium, 
potassium, eGFR, alcohol intake, and prevalent cardiovascular disease and 
diabetes mellitus; additionally, this model included season-corrected 25OHD 
adjustment in the full RS cohorts. We have adjusted for total 25OHD levels 
in MrOS in a subgroup with this information available. 
Because of sex differences in P levels and in the association of P with several 
outcomes we explored relations of P with bone traits in sex-combined and in 
sex-stratified models in RS cohorts [15, 16, 33, 43].  
 
Sensitivity analyses 
To account for the potential confounding effect of renal impairment in the 
association between P levels and bone traits, we stratified the fracture anal-
yses at an eGFR threshold of 58 mL/min, the estimated cut-off for P coun-
terregulatory hormones triggering in early kidney disease [44]. In MrOS, 
subgroup analyses were performed in subjects with laboratory results of total 
and free 25OHD, PTH and FGF23. Also in MrOS, we adjusted the fracture 
analyses for phosphate intake  (available in 99.3% of the study population). 
In addition, we repeated analyses including only subjects from both cohorts 
with P levels within normal range (0.81 to 1.45 mmol/L; 2.5 to 4.5 mg/dL).  
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Table 1. General Characteristics of Subjects with Femoral Neck BMD Information  
Available in RS-I, RS-II and RS-III According to Quintiles of Fasting Phosphate Levels 
 
 Men Women 
 Phosphate in quintiles  Phosphate in quintiles  
 1 2 3 4 5 p* 1 2 3 4 5 p* 
I) RS-I             
N Mean  
(mg/dL) 
242 
(2.56) 
243 
(2.92) 
243 
(3.14) 
243 
(3.37) 
243 
(3.76) 
 
 
322 
(3.02) 
322 
(3.40) 
322 
(3.62) 
322 
(3.84) 
322 
(4.22)  
Range  
(mg/dL) 1.9-2.8 2.8-3.0 3.0-3.3 3.3-3.5 3.5-4.9  2.3-3.3 3.3-3.5 3.5-3.7 3.7-3.9 3.9-5.1  
Age  
(y) 71.9 72.3 71.7 72.3 71.9 0.982 72.8 72.2 72.9 72.1 72.3 0.297 
BMI 
(kg/m2) 26.6 26.5 26.4 26.1 26.1 0.020 28.7 27.7 27.2 26.6 25.8 <0.001 
Smoke  
(%) 87% 87% 93% 92% 94% 0.002 47% 49% 52% 52% 48% 0.615 
Calcium  
(mg/dL) 9.58 9.66 9.62 9.64 9.72 0.001 9.77 9.79 9.77 9.80 9.86 0.006 
25OHD  
(nmol/L) 63.4 61.7 60.5 58.3 59.1 0.013 47.2 47.7 45.9 49.7 50.5 0.057 
FN-BMD  
(g/cm2) 0.90 0.90 0.91 0.90 0.88 0.124 0.82 0.80 0.79 0.79 0.78 <0.001 
Glucose  
(mmol/L) 6.07 6.01 5.99 5.99 6.16 0.593 6.13 5.83 5.93 5.72 5.76 0.001 
Prevalent  
DM 12% 14% 13% 9% 15% 0.623 16% 10% 12% 8% 9% 0.003 
Creatinine  
(mg/dL) 1.04 1.05 1.02 1.03 1.06 0.548 0.82 0.82 0.82 0.81 0.82 0.977 
eGFR  
(mL/min) 73.5 72.3 74.7 73.9 73.3 0.676 73.2 73.5 73.5 74.2 73.9 0.632 
Na+  
(mmol/L) 142.3 142.1 142.4 141.8 142.1 0.218 142.3 142.5 142.7 142.3 142.5 0.957 
K+  
(mmol/L) 4.32 4.41 4.45 4.43 4.53 <0.001 4.30 4.37 4.44 4.43 4.49 <0.001 
II) RS-II             
N Mean  
(mg/dL) 
181 
(2.48) 
182 
(2.84) 
182 
(3.06) 
182 
(3.29) 
182 
(3.70)  
209 
(2.91) 
209 
(3.31) 
210 
(3.52) 
209 
(3.76) 
210 
(4.14)  
Range  
(mg/dL) 1.4-2.7 2.7-2.9 2.9-3.2 3.2-3.4 3.4-4.7  1.8-3.2 3.2-3.4 3.4-3.6 3.6-3.9 3.9-5.1  
Age  
(y) 63.4 64.1 64.5 63.5 63.2 0.555 64.2 64.5 63.4 63.8 62.2 0.002 
BMI  
(kg/m2) 27.2 26.7 26.7 26.8 27.1 0.791 28.8 27.7 27.4 26.5 26.1 <0.001 
Smoke  
(%)  87% 78% 82% 88% 89% 0.052 57% 63% 60% 57% 63% 0.690 
Calcium  
(mg/dL) 9.52 9.58 9.54 9.57 9.62 0.014 9.64 9.65 9.69 9.68 9.74 0.005 
25OHD  
(nmol/L) 65.5 68.5 66.3 65.7 63.8 0.355 59.0 56.8 59.6 58.2 63.4 0.294 
FN-BMD  
(g/cm2) 0.98 0.98 0.95 0.98 0.97 0.478 0.89 0.88 0.91 0.88 0.87 <0.001 
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Glucose  
(mmol/L) 6.06 5.98 6.17 5.89 6.49 0.041 6.13 5.81 5.77 5.83 5.87 0.194 
Prevalent  
DM 12% 9% 15% 11% 20% 0.024 13% 8% 10% 10% 9% 0.450 
Creatinine  
(mg/dL) 0.98 0.99 0.99 0.98 0.99 0.571 0.78 0.77 0.79 0.77 0.78 0.640 
eGFR  
(mL/min) 81.8 81.3 80.2 81.9 82.4 0.714 80.8 81.7 80.4 82.3 82.4 0.843 
Na+  
(mmol/L) 140.9 141.1 141.2 141.1 141.1 0.318 141.2 141.4 141.5 141.6 141.7 0.032 
K+  
(mmol/L) 4.16 4.21 4.21 4.27 4.26 <0.001 4.17 4.23 4.24 4.25 4.28 <0.001 
III) RS-III             
N Mean  
(mg/dL) 
174 
(2.56) 
174 
(2.94) 
174 
(3.20) 
174 
(3.45) 
174 
(3.87)  
228 
(2.97) 
228 
(3.39) 
  228 
(3.63) 
228 
(3.85) 
229 
(4.26)  
Range  
(mg/dL) 1.6-2.8 2.8-3.0 3.0-3.3 3.3-3.6 3.6-5.4  2.1-3.2 3.2-3.5 3.5-3.7 3.7-3.9 3.9-5.1  
Age 
 (y) 57.4 57.6 57.4 56.6 55.8 0.008 56.2 57.5 57.2 57.6 56.8 0.304 
BMI  
(kg/m2) 28.2 28.2 27.6 27.4 27.4 0.017 29.2 27.9 27.1 27.1 26.9 <0.001 
Smoke  
(%)  77% 74% 83% 76% 72% 0.640 64% 67% 69% 60% 69% 0.720 
Calcium  
(mg/dL) 9.68 9.79 9.82 9.87 9.88 <0.001 9.74 9.78 9.85 9.90 10.0 <0.001 
25OHD  
(nmol/L) 57.5 60.0 59.1 63.1 63.4 0.011 56.3 58.1 62.3 59.9 62.3 0.014 
FN-BMD  
(g/cm2) 0.98 0.99 0.99 1.00 0.98 0.902 0.93 0.92 0.92 0.91 0.92 0.701 
Glucose  
(mmol/L) 5.92 5.71 5.74 5.78 5.92 0.661 5.40 5.50 5.38 5.41 5.72 0.346 
Prevalent  
DM 12% 8% 10% 12% 14% 0.364 5% 7% 4% 6% 5% 0.764 
Creatinine  
(mg/dL) 0.94 0.97 0.99 0.97 0.97 0.140 0.78 0.77 0.77 0.77 0.78 0.671 
eGFR  
(mL/min) 88.0 85.7 85.9 86.5 88.2 0.391 85.4 86.0 86.2 85.6 85.5 0.664 
Na+  
(mmol/L) 141.6 141.9 142.1 142.3 142.3 0.017 141.8 142.0 142.2 142.0 142.9 <0.001 
K+  
(mmol/L) 4.29 4.39 4.42 4.41 4.45 <0.001 4.30 4.33 4.38 4.38 4.44 <0.001 
*  P values corresponds to age-adjusted significance of trend across quintiles. BMI: body 
mass index. Smoke: ever smoke. 25OHD: 25-hydroxyvitamin D levels; FN-BMD: femoral 
neck bone mineral density; prevalent DM: prevalent diabetes mellitus; creatin: creati-
nine; eGFR: estimated glomerular filtration rate according to Chronic Kidney Disease 
Epidemiology Collaboration equations based on creatinine levels. Conversion to SI 
Units: to convert 25-hydroxyvitamin D levels to ng/mL multiply by 0.4; to convert glu-
cose to mg/dL multiply by 18.02 
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Primary analyses were performed with subjects with complete information 
on covariates. The completeness of information on covariates for those partic-
ipants with available P samples was more than 99% in MrOS (with the ex-
ception of subgroup analyses) and approximately 75% in the Rotterdam 
Study cohorts. Subsequently, missing values in the Rotterdam Study cohorts 
were imputed via multiple imputation with chained equations, following 
guidelines for imputation for the Cox model. 
Analyses were performed with SPSS (version 21.0, IBM Corp, Armonk, NY, 
USA), Stata (version 13, StataCorp LP, College Station, TX, USA) and Com-
prehensive Meta-Analysis (version 2.0). 
 
 
Results 
The distribution of relevant covariates across quintiles of P is depicted in 
Tables 1 and 2. P and Ca levels were higher in women than in men in the 
three RS cohorts (p < 0.001).  
P levels lie within normal range (0.81 to 1.45 mmol/L; 2.5 to 4.5 mg/dL) in the 
vast majority (~95%) of each study population. 
 
Phosphate is not associated with FN-BMD; it is negatively correlated 
with LS-BMD in men from Rotterdam Study but not MrOS 
Tables 3 and 4 show the relationship between P levels and BMD. We found 
no association between P and FN-BMD (Table 3) in men (pooled β [95% CI]) 
(β: -0.04 [-0.08 to 0.01], p = 0.096). In women, a negative association was 
found in the age-only adjusted model (β: -0.15 [-0.22 to -0.08)], p  < 0.001), but 
it became non-significant after adjustment for BMI.  
 
We found a negative relationship between P levels and LS-BMD (Table 4) in 
the pooled results from men (β: -0.06 [-0.11 to -0.02], p = 0.007), which was 
driven by men from RS cohorts (β: -0.12 [-0.19 to -0.04], p = 0.002) and not 
significant in men from MrOS (β: -0.03 [-0.09 to 0.03], p = 0.360). In women, a 
negative association was found in the age-adjusted model (pooled β: -0.15 [-
0.22 to -0.08], p<0.001), but this became non-significant after adjustment for 
BMI. Therefore, the significant association between P levels and LS-BMD in 
sex-combined analysis (β: -0.06 [-0.09 to -0.02], p=0.004) was driven by a sig-
nificant negative association in men. 
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Table 2. General Characteristics of Subjects with Femoral Neck BMD Information Availa-
ble in Men from MrOS According to Quintiles of Fasting Phosphate Levels 
 Men 
 Phosphate in quintiles  
 1 2 3 4 5 p* 
MrOS       
    N Mean (mg/dL) 1086 (2.6) 1085 (2.9) 1085 (3.2) 1085 (3.4) 1084 (3.8)  
Range 1.8-2.8 2.8-3.0 3.1-3.3 3.3-3.5 3.5-6.8  
Age (y) 73.2 73.2 73.7 73.9 73.7 0.002 
BMI (kg/m2) 27.3 27.3 27.4 27.5 27.6 0.006 
Smoke (%) 61% 60% 63% 63% 67% <0.001 
Calcium (mg/dL) 9.28 9.30 9.31 9.32 9.37 <0.001 
25OHD (nmol/L) 63.3 65.5 65.4 63.6 62.8 0.534 
FN-BMD (g/cm2) 0.79 0.79 0.79 0.78 0.79 0.723 
Glucose (mmol/L) 5.79 5.89 5.80 5.85 6.00 0.003 
Prevalent DM 7% 10% 10% 11% 18% <0.001 
Creatinine (mg/dL) 0.99 0.99 1.02 1.02 1.07 <0.001 
eGFR (mL/min) 88 89 86 85 82 <0.001 
Na+ (mmol/L) 141.4 141.3 141.4 141.5 141.4 0.296 
K+ (mmol/L) 4.19 4.21 4.25 4.30 4.36 <0.001 
*P values corresponds to age-adjusted significance of trend across quintiles 
eGFR: estimated glomerular filtration rate according to Modification of Diet in Renal 
Disease (MDRD) study equation   
 
Phosphate is associated with all-type fracture risk in men and wom-
en 
Table 5 shows results from analyses of P levels and fracture risk in RS-I, RS-
II and MrOS after follow-up of 8.6, 6.6 and 10.9 years, respectively. During 
the follow-up period, a total of 1825 cases of incident fractures were recorded. 
In the basic model, each 1 mg/dL increase in P levels was significantly asso-
ciated with an increase in all-type fracture risk in male subjects from the 
Rotterdam Study and in MrOS and borderline significantly in women. In the 
full model, the associations were statistically significant in all groups: Re-
sults for men were hazard ratio (HR) = 1.52 (1.34 to 1.74), p < 0.001; results 
for women were 1.32 (1.04 to 1.67), p = 0.023; results for sex and study-
combined analyses were HR = 1.47 (1.31 to 1.65), p < 0.001.In MrOS, further 
adjustments for season-corrected total 25OHD in the full model yielded simi-
lar results: HR=1.49 (1.17 to 1.90), p = 0.001; n=2345). In both cohorts, ad-
justments for vitamin D (using different methods) did not influence results; 
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furthermore, season adjustment in MrOS did not change results. In the full 
model, there was no statistical evidence for sex interaction in the association 
between P and fracture risk in RS cohorts (pheterogeneity = 0.258). 
 
Table 3. Phosphate Levels and Femoral Neck BMD in RS-I, RS-II, RS-III and MrOS 
 Model I Model II 
 n 
β  
(95% CI)a p N 
β  
(95% CI)a p 
RS-I 
Men 1214 -0.11 (-0.24 to 0.01) 
0.084 1204 -0.06 
(-0.18 to 0.06) 
0.328 
Women 1610 -0.24 (-0.35 to -0.13) 
<0.001 1596 -0.05 
(-0.16 to 0.05) 
0.314 
RS-II 
Men 909 -0.09 (-0.23 to 0.06) 
0.232 905 -0.07 
(-0.21 to 0.07) 
0.311 
Women 1047 -0.19 (-0.32 to -0.05) 
0.005 1040 -0.01 
(-0.13 to 0.12) 
0.916 
RS-III       
 Men 870 -0.03 (-0.17 to 0.11) 
0.692 870 0.01 
(-0.12 to 0.15) 
0.849 
Women 1141 -0.02 (-0.13 to 0.10) 
0.762 1140 0.07 
(-0.04 to 0.19) 
0.196 
RS combinedb       
Men 2993 -0.08 (-0.16 to 0.00) 
0.050 2979 -0.04 
(-0.12 to 0.03) 
0.287 
Women 3798 -0.15 (-0.22 to -0.08) 
<0.001 3776 0.01 
(-0.06 to 0.07) 
0.988 
MrOS       
Men 5425 -0.02 (-0.08 to 0.04) 
0.458 5422 -0.03 
(-0.09 to 0.02) 
0.215 
Studies combinedb       
Men 8418 -0.04 (-0.09 to 0.01) 
0.079 8401 -0.04 
(-0.08 to 0.01) 
0.096 
Women 3798 -0.15 (-0.22 to -0.08) 
<0.001 3776 0.01 
(-0.06 to 0.07) 
0.988 
Sex-combined 12216 -0.08 (-0.11 to -0.04) 
<0.001 12177 -0.03 
(-0.06 to 0.01) 
0.171 
Model I: age adjusted               
Model II: age, body mass index and smoking adjusted; additional race and site adjust-
ments in MrOS 
a. Βetas are expressed per 1 mg/dL increase in P levels; BMD is expressed in SD 
b. Studies were pooled applying a fixed effects model 
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Table 4. Phosphate Levels and Lumbar Spine BMD in RS-I, RS-II, RS-III and MrOS 
 Model I Model II 
 n β (95% CI)a p n β (95% CI)a p 
RS-I       
Men 
1458 -0.13 
(-0.24 to -0.02) 
0.021 1437 -0.10 
(-0.21 to 0.01) 
0.084 
Women 
2003 -0.21 
(-0.31 to -0.11) 
<0.001 1943 -0.09 
(-0.19 to 0.01) 
0.084 
RS-II       
Men 
910 -0.19 
(-0.34 to -0.04) 
0.012 906 -0.18 
(-0.32 to -0.03) 
0.017 
Women 
1059 -0.15 
(-0.28 to -0.02) 
0.027 1051 -0.02 
(-0.15 to 0.11) 
0.730 
RS-III       
Men 
766 -0.12 
(-0.27 to 0.03) 
0.126 766 -0.09 
(-0.24 to 0.06) 
0.238 
Women 
1039 -0.06 
(-0.18 to 0.07) 
0.374 1038 0.02 
(-0.10 to 0.14) 
0.772 
RS combinedb       
Men 3134 -0.14 (-0.22 to -0.07) 
<0.001 3109 -0.12 
(-0.19 to -0.04) 
0.002 
Women 4101 -0.15 (-0.22 to -0.08) 
<0.001 4032 -0.04 
(-0.10 to 0.03) 
0.247 
MrOS       
Men 
5390 -0.02 
(-0.08 to 0.04) 
0.495 5387 -0.03 
(-0.09 to 0.03) 
0.360 
Studiescombinedb       
Men 
8524 -0.07 
(-0.11 to -0.02) 
0.005 8496 -0.06 
(-0.11 to -0.02) 
0.007 
Women 
4101 -0.15 
(-0.22 to -0.08) 
<0.001 4032 -0.04 
(-0.10 to 0.03) 
0.247 
Sex-combined 
12625 -0.10 
(-0.13 to -0.06) 
<0.001 12528 -0.06 
(-0.09 to -0.02) 
0.004 
Model I: age adjusted             
Model II: age, body mass index and smoking adjusted; additional race and site adjust-
ments in MrOS 
a. Betas are expressed per 1 mg/dL increase in P levels; BMD is expressed in SD 
b. Studies were pooled applying a fixed effects model 
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Table 5. Risk of Incidence of All Types of Fractures as a Function of Phosphate Levels in 
RS-I, RS-II and MrOS 
 Model I Model II 
 nofxs/ 
total n 
HR a,b 
(95% CI) p 
nofxs/ 
total n 
HR a,b 
(95% CI) p 
RS-I       
Men 
152/ 
1476 
1.95 
(1.37-2.77) 
<0.001 116/ 
1094 
1.74 
(1.12-2.69) 
0.013 
Women 
390/ 
1828 
1.33 
(1.05-1.69) 
0.017 279/ 
1325 
1.48 
(1.11-1.97) 
0.007 
Sex-combined 
542/ 
3304 
1.50 
(1.23-1.83) 
<0.001 395/ 
2419 
1.54 
(1.21-1.95) 
<0.001 
RS-II       
Men 
75/ 
1127 
1.33 
(0.78-2.25) 
0.292 51/ 
876 
1.58 
(0.84-2.95) 
0.153 
Women 
162/ 
1356 
0.90 
(0.62-1.31) 
0.583 116/ 
1012 
1.02 
(0.66-1.56) 
0.937 
Sex-combined 
237/ 
2483 
1.03 
(0.76-1.40) 
0.829 167/ 
1888 
1.18 
(0.83-1.69) 
0.351 
RS combinedb   
 
  
 
Men 
227/ 
2603 
1.73 
(1.29-2.32) 
<0.001 167/ 
1970 
1.69 
(1.18-2.41) 
0.004 
Women 
552/ 
3184 
1.19 
(0.97-1.45) 
0.092 395/ 
2337 
1.32 
(1.04-
1.67) 
0.023 
MrOS         
 
  
 
Men 
1046/ 
5409 
1.54 
(1.34-1.77) 
<0.001 1046/ 
5409 
1.50 
(1.30-1.72) 
<0.001 
Studies combinedc   
 
  
 
Men 
1273/ 
8012 
1.57 
(1.39-1.78) 
<0.001 1213/ 
7379 
1.52 
(1.34-1.74) 
<0.001 
Women 
552/ 
3184 
1.19 
(0.97-1.45) 
0.092 395/ 
2337 
1.32 
(1.04-1.67) 
0.023 
Sex-combined 
1825/ 
11196 
1.45 
(1.31-1.62) 
<0.001 1608/ 
9716 
1.47 
(1.31-1.65) 
<0.001 
no fxs: number of fractures 
 Model I: age, body mass index (BMI) and smoking adjusted; additional race and site 
adjustments in MrOS 
Model II: adjusted for age, BMI, smoking, FN-BMD, alcohol intake, prevalent diabetes 
mellitus, prevalent cardiovascular disease, eGFR and serum levels of potassium, and
calcium; additional adjustments for season-adjusted 25(OH)D in RS cohorts and race 
and site adjustments in MrOS 
a. Hazard ratios are expressed per increase in 1 mg/dL of P levels. 
b.  HRs from Cox models 
c. Studies combined applying a fixed effects model 
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Phosphate in quintiles and fracture risk 
Analyses of P in quintiles and fracture risk suggested a dose-effect relation in 
both RS-I (the RS cohort with more fracture events) and MrOS (Tables 6 and 
7). After adjustments in Model I, data from RS-I showed a significant trend 
for increasing P and fracture risk in both men (HRs for the fourth quintile = 
2.07 [1.21 to 3.57], p = 0.008, and for the fifth quintile= 2.27 [1.33 to 3.90], p 
= 0.003 against the first quintile; ptrend < 0.001) and women (HRs for the 
fourth quintile= 1.50 [1.08-2.09], p = 0.016, and for the fifth quintile= 1.47 
[1.05 to 2.05], p = 0.026, against the first quintile; ptrend = 0.022).  A similar 
trend was observed in MrOS (HRs for the fourth quintile = 1.23 [1.01 to 1.49], 
p = 0.040, and for the fifth quintile: 1.59 [1.32 to 1.93], p < 0.001, against the 
first quintile; p trend < 0.001).  
 
Table 6. Risk of Incidence of All Types of Fractures as a Function of Phosphate Levels 
Categorized in Quintiles in Men and Women From RS-I 
 Men  Women 
P levelsa 
mean  
(range) 
events 
/ no risk 
HRb,c 
(95% CI) p 
P levelsa 
mean  
(range) 
events 
/ no risk 
HRb,c  
(95% CI) P 
2.6  
(1.9-2.8) 
20/ 
295 
1.00  
(reference)  
3.0  
(2.3-3.3) 
59/ 
365 
1.00  
(reference)  
2.9 
(2.8-3.0) 
22/ 
295 
1.12  
(0.61-2.06) 0.708 
3.4  
(3.3-3.5) 
78/ 
366 
1.33  
(0.95-1.87) 0.099 
3.1  
(3.1-3.2) 
32/ 
295 
1.66  
(0.95-2.91) 0.075 
3.6  
(3.5-3.7) 
76/ 
365 
1.25  
(0.89-1.76) 0.197 
3.4  
(3.3-3.5) 
38/ 
295 
2.07  
(1.21-3.57) 0.008 
3.8  
(3.7-3.9) 
90/ 
366 
1.50  
(1.08-2.09) 0.016 
3.8  
(3.5-7.6) 
40/ 
296 
2.27  
(1.33-3.90) 0.003 
4.2  
(4.0-5.2) 
87/ 
366 
1.47  
(1.05-2.05) 0.026 
 p trend 0.001  p trend = 0.022 
a. P levels expressed in mg/dL  
b. Hazard ratios are age, body mass index and smoking adjusted; first quintile was set as 
reference   
c. Hazard ratios are derived from Cox models 
 
Subtypes of fractures 
Results of different subtypes of fractures can be found in Supplemental Table 
S1. In studies and sexes combined we found that P levels were related to all 
types of fractures. Although effects sizes could not be compared due to the 
difference in numbers of fractures, it appeared that the strongest associa-
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tions were found for (clinical) vertebral fractures in men while women dis-
played a stronger association for humerus fractures. 
 
Table 7. Risk of Incidence of All Types of Fractures as a Function of Phosphate Levels 
Categorized in Quintiles in Men from MrOS 
 Men 
P levels a 
mean (range) events/ no risk HR 
b,c(95% CI) p 
2.6 (1.8-2.8) 188/1085 1.00 (reference)  
2.9 (2.8-3.0) 206/1081 1.14 (0.94-1.39) 0.194 
3.2 (3.1-3.3) 190/1081 1.06 (0.87-1.30) 0.558 
3.4 (3.3-3.5) 213/1083 1.23 (1.01-1.49) 0.040 
3.8 (3.5-6.8) 249/1079 1.59 (1.32-1.93) <0.001 
  p trend <0.001  
a. P levels expressed in mg/dL         
b. Hazard ratios are age, body mass index, smoking, site and race adjusted; first quintile 
was set as reference  
c. Hazard ratios are derived from Cox models 
 
Sensitivity analyses 
The stratified fracture analyses according to eGFR (Supplemental Table S2) 
showed that the association between P and fractures was not abolished after 
restricting the analyses to subjects with eGFR > 58 mL/min (pooled results 
for sex and studies combined: Model I HR= 1.43 [1.27 to 1.61], p < 0.001; 
Model II HR = 1.44 [1.26 to 1.63], p < 0.001).             
Additionally, men with eGFR ≤ 58mL/min from both populations displayed a 
significant relation between P and fracture risk in both the basic and full 
models (RS men, Model I HR= 2.24 [1.01 to 4.98], p = 0.048; Model II HR = 
4.05 [1.38 to 11.9], p = 0.011; men from MrOS, Model I HR = 1.90 [1.40 to 
2.58], p < 0.001; Model II HR = 1.81 [1.32 to 2.49], p < 0.001). The pooled re-
sult for men yielded: Model I HR = 1.94 (1.46 to 2.58), p < 0.001, and Model II 
HR = 1.93 (1.42 to 2.62), p < 0.001.  
Women with eGFR ≤ 58 mL/min displayed no significant association between 
P and fracture risk.  
Results for P and fracture risk after excluding subjects with abnormal values 
of P were significant in men (RS men HR = 1.79 [1.26 to 2.56], p = 0.001; 
MrOS men HR = 1.55 [1.33 to 1.81], p = 0.001) (data not shown). The pooled 
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results yielded HR = 1.59 (1.38 to 1.83), p < 0.001. In women, the relation 
between normal P and fracture risk was not statistically significant (HR = 
1.12 [0. 89 to 1.40], p = 0.330). In study and sex-combined analyses, the re-
sults were HR = 1.44  (1.28 to 1.62), p < 0.001. 
Analyses after applying multiple imputation did not substantially modify the 
results obtained in the analyses with the complete cases (data not shown). 
 
Additional adjustments in MrOS 
The additional adjustments for total and free 25OHD, FGF23, and PTH lev-
els in a subgroup of men from MrOS (Supplemental Table S3) did not sub-
stantially modify the significant association between serum P and fracture 
risk (PTH-adjusted HR = 1.50 [1.18 to 1.90], p = 0.001; FGF23-adjusted HR = 
1.69 [1.25 to 2.29], p = 0.001; total 25OHD-adjusted HR = 1.49 [1.18 to 1.89], 
p = 0.001; free 25OHD-adjusted HR = 1.73 [1.16 to 2.59], p = 0.008). The mul-
tivariate analyses showed no modification in the results either.  
The same pattern was observed after stratification by kidney function (eGFR 
58 mL/min; Supplemental Table S4) in both strata. 
Further adjustments for dietary phosphate intake in men from MrOS did not 
change results (Model I HR = 1.53 [1.33 to 1.76] n = 5394, Model I adjusted 
for dietary phosphate, calcium, and energy intake HR = 1.53 [1.33 to 1.76], n 
= 5394; Model II HR = 1.48 [1.16 to 1.89] n = 2333, Model II adjusted for die-
tary phosphate, calcium, and energy intake HR = 1.48 [1.16 to 1.89], n = 
2333).  
Additional analyses performed in MrOS in a subset (n = 988) with bone turn-
over markers available did not change results: Model I HR = 1.34 (0.94 to 
1.90) n = 937, Model I adjusted for PINP and βCTX HR = 1.34 (0.94 to 1.90), 
n = 933; Model II HR = 1.35 (0.94 to 1.95) n = 933, Model II adjusted for 
PINP and βCTX HR = 1.36 (0.94 to 1.97), n = 933.  
 
 
Discussion 
In these population-based cohorts, serum P levels were positively and signifi-
cantly associated with fracture risk in both sexes. These associations were 
independent of BMD and not explained by multiple potential confounders. 
Although associations appeared stronger in men than in women in the Rot-
terdam Study, there was no statistical evidence for a sex difference. P was 
inversely associated with LS-BMD only in men from the Rotterdam Study, 
although in combined analyses of sexes and cohorts, this association re-
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mained significant. No associations were found with FN-BMD. In women, a 
relation between P and BMD at both skeletal sites was completely explained 
by a previously described association of P with BMI [43]. 
The results from fracture analyses with P in categories suggested a potential 
threshold of P (3.3 mg/dL [1.1 mmol/L] in men –consistent in both cohorts- 
and 3.7 mg/dL [1.2 mmol/L] in women) above which fracture risk was in-
creased. However, trend analysis suggests that risk may start to increase 
even at lower levels. Analyses restricted to subjects with P levels within 
normal range still showed a significant relation between P and fracture risk 
although results were statistically significant in men only. 
Previous cross-sectional studies reported P levels to be higher in elderly sub-
jects and in CKD patients on hemodialysis with previous fragility fractures 
compared with subjects without fractures, but to the best of our knowlegde, 
no prospective studies have been reported at the population level [13, 14, 45]. 
Regarding the mechanisms underlying the relation between P levels and 
bone traits, several potential pathways can be hypothesized, namely: 1) ef-
fects through P regulatory hormones; 2) direct effects of P on BMD and/or 
bone quality (and vice versa) and/or fracture risk; and 3) P as a reflection of 
bone turnover. Regarding the first possibility, P levels are regulated by a 
complex set of hormones that play an important role in bone metabolism, 
such as FGF23, PTH and 1,25-hydroxyvitamin D. Abnormal FGF23 levels 
have been associated with impaired mineralization, through P-dependent 
and independent effects [6, 7, 46-48]. However, consistent with previous re-
search, adjustments for FGF23 levels did not influence the association of P 
with fracture risk in men from MrOS [49]. 
High PTH levels in hypovitaminosis D may also increase fracture risk [50]. 
Nevertheless, we found that adjustments for 25OHD in RS cohorts and addi-
tionally for total and free 25OHD and PTH levels in a subgroup of men from 
MrOS did not basically modify the association between P and fracture risk. 
The exclusion of subjects with CKD yielded similar results both in men and 
women; therefore, we conclude that our findings are not likely explained by 
secondary elevations of FGF23 or PTH in CKD or by vitamin D deficiency.  
On the other hand, we also observed a strong relation between P and fracture 
risk in men from RS cohorts with CKD, which was replicated in men from 
MrOS. These results are consistent with an increased gradient of risk for 
fracture stemming from the increased P load, that patients with CKD dis-
play, even without overt hyperphosphatemia [51]. This finding was not abol-
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ished or even attenuated after adjustment for FGF23 and PTH levels in 
MrOS, suggesting that high P itself and not underlying hormonal disturb-
ances may explain the increased fracture risk in this group. As a potential 
therapeutic possibility, the feasibility of a multicenter randomized trial test-
ing whether P lowering is able to decrease several clinical outcomes in pa-
tients with CKD, including bone pain and fracture risk, is currently being 
evaluated [52]. In contrast, the association between P and fracture risk in 
women with CKD was not statistically significant. 
Regarding our findings of a negative association between P levels and LS-
BMD in the pooled results from men, which was driven by men from RS co-
horts, we can only speculate whether this is a chance finding or related to the 
fact that LS-BMD contains more trabecular than cortical bone. It has been 
previously described that FGF23 expression differs across human bone tissue 
and that it tends to cluster in osteocytes near the trabecular periphery and 
the lacuna-canalicular systems, in contrast to the expression pattern of other 
osteocytes (DMP1 
osteocytes), which are diffusely located throughout bone [53-58]. This obser-
vation needs to be tested in other cohorts and if confirmed, it deserves fur-
ther research. Because LS-BMD measurements can be affected by 
degenerative changes, more accurate techniques for trabecular volumetric 
bone assessment might be desirable as well as novel methods to assess more 
accurately bone microarchitecture that might be influenced by serum phos-
phate [7, 8, 59, 60]. 
It is also possible that P may have direct effects on bone metabolism. P itself 
exerts key roles in growth plate maturation, secondary ossification center 
formation, and osteoblast differentiation [2, 4].  Moreover, high P diets have 
been shown to increase bone resorption and development of osteoporosis in 
senescent mice [61-63]. Studies on rats fed high P showed disturbances in P 
homeostasis and reduced bone mineralization over short- and long-term peri-
ods [64]. Therefore, a direct negative effect of increased P intake on bone is 
quite well possible. In MrOS, adjustment for dietary phosphate intake did 
not influence the associations between P and fracture risk, but it is currently 
difficult to accurately estimate phosphorus intake for example, because phos-
phorus additives from processed food are often not labeled on food products 
[65]. But if a relation can be shown between dietary phosphate intake and 
(bone) health, this may have implications in light of the increasing use of P 
additives in our diet [65].  
87
  
It is important to emphasize that fracture risk was found to be increased 
within normal values of serum phosphate, suggesting that for bone health 
the current upper limit may be too high. It has been shown that high dietary 
intake of P is related to postprandial elevation of serum P which may not be 
reflected as fasting P [66]. Indeed, there was no association between dietary 
P intake and fasting serum P levels in MrOS. Interestingly, the same thresh-
old above which fracture risk was increased in men from both populations 
(3.3 mg/dL) was previously related to increased cardiovascular risk [67]. To 
the best of our knowledge, this is the first report to describe this association 
in a prospective fashion and it may have important clinical consequences for 
subjects with and without CKD [13, 14]. 
In addition, we cannot exclude the possibility that high serum P is merely a 
reflection of high bone turnover, although we think this is not very likely be-
cause under normal circumstances, P exchange with the skeleton yields a 
neutral balance and bone turnover abnormalities rarely give rise to clinically 
relevant disturbances in P homeostasis [11, 68, 69]. Also, the results from 
adjustments for bone turnover markers in MrOS suggest that bone turnover 
does not explain the association between P and fracture risk. 
Lastly, we cannot rule out that P levels were associated with fracture risk 
through non-skeletal effects, but an effect through falling appears to be un-
likely because P levels were also strongly related to vertebral fractures and 
these fractures are often not preceded by a fall. Nevertheless, we cannot dis-
card that other potential mechanisms through muscle mass or function might 
play a role in our findings. 
Although there was no statistical evidence for an interaction by sex in the 
main analysis, the relations between P and bone traits seemed stronger in 
men than in women with larger effect sizes. Such an observation has been 
reported before for other clinical outcomes, such as all-cause mortality, sub-
clinical atherosclerosis, CKD progression, and incident coronary disease [15, 
16, 70]. More research is needed to fully elucidate if the relation of P and 
fractures (and other outcomes) is indeed stronger in men.  
Our study has some limitations. LS-BMD and fasting P levels were not as-
sessed simultaneously at RS-I and only 75% of individuals from RS cohorts 
had complete data for all covariates of interest. But results were similar after 
applying multiple imputation. There are several strengths, though, namely 
the availability of several well-characterized and large cohorts with BMD and 
prospective fracture information and the ability to replicate the association 
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between P and fracture risk in another large population-based cohort. Alt-
hough no DXA cross-calibration between MrOS and RS cohorts was per-
formed, statistical adjustments to account for use of different machines did 
not materially change results. 
 Additionally, the association between P and fracture risk was significant 
despite multiple adjustments, including levels of FGF23 and PTH in men 
from MrOS. Therefore, we consider it unlikely that our results are explained 
by residual confounding. 
In conclusion, we found that in two population-based studies, increasing P 
levels were positively associated with fracture risk in men and women. These 
results were independent from BMD, although there was an inverse associa-
tion between P and LS-BMD in men. The association between P and frac-
tures was also independent of dietary phosphate intake. Results were also 
not explained by serum levels of calcium, 25OHD, PTH, FGF23, or by comor-
bidity, including CKD, but associations between P and fractures were also 
found in men with CKD. The association between P and fractures calls for 
future research testing whether lowering of serum P or reducing P intake 
may reduce the risk of fracture. Additionally, further well-powered studies 
are needed to clarify if there is a sex difference in the relation between P and 
bone traits.  
The findings of our study also suggest that the current upper limit of serum 
P may be too high and they call for more research into the effects of high P 
diets and the use of P as food additives on bone health.  
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Supplemental Tables 
Supplemental Table S1. Risk of incidence of fractures by fracture location as a function 
of phosphate levels in RS-I, RS-II and MrOS 
  Model I Model II 
  n HR (95% CI)1,2 p n HR (95% CI) 1,2 p 
Hip fractures 
Men 275/8113 1.44 (1.09-1.91) 0.010 265/7443 1.36 (1.02-1.82) 0.037 
Women 111/3472 1.06 (0.67-1.67) 0.797 77/2548 1.12 (0.65-1.93) 0.687 
Sex-combine      386/11585     1.32 (1.04-1.68)     0.021    342/9991    1.30 (1.01-1.68)     0.042 
Vertebral fractures 
Men 242/8120 1.85 (1.39-2.48) <0.001 219/7447 1.73 (1.27-2.37) 0.001 
Women 167/3467 1.17 (0.81-1.70) 0.405 116/2543 1.16 (0.73-1.83) 0.533 
Sex-combined 409/11587 1.55 (1.24-1.95) <0.001 335/9990 1.52 (1.18-1.97) 0.001 
Wrist fractures 
Men 112/8111 1.73 (1.14-2.63) 0.010 104/7439 1.90 (1.20-2.99) 0.006 
Women 151/3400 1.06 (0.72-1.55) 0.772 105/2497 1.18 (0.74-1.89) 0.477 
Sex-combined    263/11511     1.33 (1.00-1.76)     0.050    209/9936    1.51 (1.09-2.09)     0.014 
Humerus fractures 
Men 86/8115 1.65 (1.01-2.70) 0.047 83/6568*   1.61 (0.99-2.62) 0.055 
Women 59/3462 1.96 (1.08-3.56) 0.027 42/2539 2.16 (1.06-4.40) 0.035 
Sex-combined    145/11577 1.77 (1.21-2.58) 0.003 125/9107 1.77 (1.18-2.64) 0.005 
Rib fractures 
Men 251/8110 1.35 (1.01-1.80) 0.044 246/7441 1.40 (1.05-1.88) 0.022 
Women 27/3483 0.79 (0.32-1.96) 0.619 21/2556 1.09 (0.37-3.23) 0.873 
Sex-combined 278/11593 1.28 (0.98-1.69) 0.074 267/9997 1.38 (1.04-1.82) 0.026 
Osteoporotic fractures3 
Men 1223/8050 1.58 (1.39-1.80) <0.001 1167/7395 1.52 (1.33-1.74) <0.001 
Women 525/3237 1.22 (0.99-1.49) 0.060 374/2385 1.28 (1.00-1.64) 0.050 
Sex-combined 1748/11287 1.47 (1.32-1.64) <0.001 1541/9780 1.46 (1.30-1.64) <0.001 
Model I.  age, BMI and smoking adjusted; additional race and site adjustments in MrOS 
Model II: adjusted for age, BMI, smoking, FN-BMD, alcohol intake, prevalent diabetes melli-
tus, prevalent cardiovascular disease and serum levels of eGFR, potassium and calcium; addi-
tional adjustments for season-adjusted 25(OH)D in RS cohorts and  race and site adjustments 
in MrOS 
1.Hazard ratios derive from meta-analysis from RS-I, RS-II and MrOS applying a fixed effects 
model 
2. HRs from Cox models 
3. Osteoporotic fractures are defined as fractures in any skeletal site except fingers, toes, 
facial and skull fractures 
* Pooled result from RS-I and MrOS, due to low number of humerus fracture events (n=1) in 
men from RS-II (Model II) 
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Supplemental Table S2. Risk of incidence of all types of fractures as a function of phos-
phate levels in RS-I, RS-II and MrOS stratified by kidney function 
 eGFR>58 cc/min eGFR<58 cc/min 
 nofxs 
/total n 
HR1,2  
(95% CI) p 
nofxs 
/total n 
HR1,2  
(95% CI) P 
RS cohorts 
Model I 
Men 
198 
/2349 
1.74  
(1.25-2.43) 0.001 
29 
/254 
2.24  
(1.01-4.98) 0.048 
Women 
487 
/2847 
1.25  
(1.01-1.55) 0.037 
65 
/337 
0.84  
(0.47-1.51) 0.563 
Sex-combined 
685 
/5196 
1.39  
(1.16-1.66) <0.001 
94 
/591 
1.07  
(0.68-1.70) 0.758 
Model II 
Men 
146 
/1789 
1.58  
(1.07-2.32) 0.020 
21 
/183 
4.05  
(1.38-11.9) 0.011 
Women 
349 
/2107 
1.37  
(1.06-1.77) 0.016 
46 
/235 
1.10 
 (0.55-2.18) 0.790 
Sex-combined 
495 
/3896 
1.43  
(1.16-1.78) 0.001 
67 
/418 
1.39  
(0.79-2.44) 0.252 
MrOS 
Model I, men 900 /4646 
1.48  
(1.27-1.73) <0.001 
146 
/763 
1.90  
(1.40-2.58) <0.001 
Model II, men 900 /4646 
1.44  
(1.23-1.69) <0.001 
146 
/763 
1.81  
(1.32-2.49) <0.001 
Studiescombined 
Model I 
Men 1098 /6995 
1.52  
(1.32-1.75) <0.001 
175 
/1017 
1.94  
(1.46-2.58) <0.001 
Women 487 /2847 
1.25  
(1.01-1.55) 0.037 
65 
/337 
0.84  
(0.47-1.51) 0.563 
Sex-combined 1585 /9842 
1.43 
(1.27-1.61) <0.001 
240 
/1354 
1.65  
(1.28-2.13) <0.001 
Model II 
Men 1046 /6435 
1.46  
(1.26-1.69) <0.001 
167 
/946 
1.93  
(1.42-2.62) <0.001 
Women                    349 /2107 
1.37  
(1.06-1.77) 0.016 
46 
/235 
1.10  
(0.55-2.18) 0.790 
Sex-combined 1395 /8542 
1.44  
(1.26-1.63) <0.001 
213 
/1181 
1.76  
(1.33-2.33) <0.001 
Model I.  age, BMI and smoking adjusted; additional race and site adjustments in MrOS 
Model II: adjusted for age, BMI, smoking, FN-BMD, alcohol intake, prevalent diabetes 
mellitus, prevalent cardiovascular disease and serum levels of potassium and calcium; 
additional adjustments for season-adjusted 25(OH)D in RS cohorts and  race and site 
adjustments in MrOS 
1.Hazard ratios  derive from meta-analysis applying a fixed effects model 
2. HRs from Cox models 
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 Supplemental Table S3. Additional analyses of the risk of incidence of all-type of frac-
tures as a function of phosphate levels in men from MrOS 
Men 
Model N HR1,2(95% CI) p 
PTH + total 25OHD 
Base 406/2351 1.49 (1.18-1.89) 0.001 
Base + PTH 406/2351 1.50 (1.18-1.90) 0.001 
Base + total 25OHD 406/2351 1.49 (1.18-1.89) 0.001 
Base + PTH + 25OHD 406/2351 1.50 (1.18-1.90) 0.001 
FGF23    
Base 252/1339 1.69 (1.25-2.29) 0.001 
Base + FGF23 252/1339 1.69 (1.25-2.29) 0.001 
PTH + FGF23 + free 25OHD    
Base 146/541 1.74 (1.16-2.60) 0.007 
Base + PTH 146/541 1.77 (1.19-2.65) 0.005 
Base + free 25OHD 146/541 1.73 (1.16-2.59) 0.008 
Base + FGF23 146/541 1.74 (1.16-2.60) 0.007 
Base + PTH + free 25OHD 146/541 1.77 (1.18-2.64) 0.005 
Base + PTH + FGF23 146/541 1.78 (1.19-2.67) 0.005 
Base + free 25OHD + FGF23 146/541 1.73 (1.15-2.59) 0.008 
Base + PTH + free 25OHD + FGF23 146/541 1.78 (1.19-2.66) 0.005 
 
1. Models are adjusted for age, BMI, site, smoking and race 
2. Hazard ratios from Cox models 
All models are restricted to non-missing variables 
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eGFR>58 cc/min eGFR≤58cc/min 
Model n HR
1,2 
(95% CI) p 
n HR1,2 
(95%CI) 
p 
PTH + total 25OHD 
Base 347 /2004 
1.42  
(1.09-1.84) 0.009 
59 
/347 
1.81 
(1.02-3.20) 0.043 
Base + PTH 347 /2004 
1.41  
(1.08-1.84) 0.010 
59 
/347 
1.86  
(1.05-3.28) 0.033 
Base +   
25OHD 
347 
/2004 
1.42  
(1.09-1.84) 0.008 
59 
/347 
1.81 
(1.02-3.21) 0.043 
Base + PTH +  
25OHD 
347 
/2004 
1.41  
(1.08-1.84) 0.011 
59 
/347 
1.85  
(1.05-3.27) 0.034 
FGF23       
Base 211 /1136 
1.70  
(1.22-2.37) 0.002 
41 
/203 
1.58  
(0.74-3.34) 0.234 
Base + FGF23 211 /1136 
1.70 
 (1.22-2.37) 0.002 
41 
/203 
1.62  
(0.76-3.47) 0.211 
PTH + FGF23 + free 25OHD 
Base 127 /461 
1.80  
(1.17-2.79) 0.008 
19 
/80 
1.78  
(0.50-6.30) 0.373 
Base + PTH 127 /461 
2.04  
(1.30-3.17) 0.002 
19 
/80 
1.76  
(0.50-6.27) 0.380 
Base + 25OHD 127 /461 
1.79  
(1.16-2.77) 0.008 
19 
/80 
1.95 
(0.55-7.00) 0.303 
Base + FGF23 127 /461 
1.81  
(1.17-2.79) 0.008 
19 
/80 
1.75  
(0.48-6.31) 0.393 
Base + PTH +  
25OHD 
127 
/461 
2.03  
(1.30-3.17) 0.002 
19 
/80 
1.95  
(0.54-7.00) 0.306 
Base + PTH +  
FGF23 
127 
/461 
2.04  
(1.31-3.18) 0.002 
19 
/80 
1.75  
(0.48-6.34) 0.394 
Base + free 25OHD +  
FGF23 
127 
/461 
1.79  
(1.16-2.77) 0.008 
19 
/80 
1.96  
(0.53-7.16) 0.310 
Base + PTH +  
25OHD + FGF23 
127 
/461 
2.03  
(1.30-3.17) 0.002 
19 
/80 
1.98  
(0.54-7.29) 0.303 
1.  Models are adjusted for age, BMI, site, smoking and race 
2.  Hazard ratios from Cox models 
All models are restricted to non-missing variables 
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Supplemental Table S4. Additional analyses of the risk of incidence of all-type of frac-
tures as a function of phosphate levels in men from MrOS, stratified by kidney function 
 Chapter 5 
The T-13910C polymorphism in the lactase phlorizin 
hydrolase gene is associated with differences 
in serum calcium levels and calcium intake 
W Nadia H Koek1, Joyce BJ van Meurs1, Bram CJ van der Eerden1, 
F Rivadeneira1,2, M Carola Zillikens1, Albert Hofman2, 
Barbara Obermayer-Pietsch3, Paul Lips4 
Huibert AP Pols1,2, André G Uitterlinden1,2, Johannes PTM van Leeuwen1 
1 Department of Internal Medicine, Erasmus MC, 
University Medical Center, Rotterdam the Netherlands 
2 Department of Epidemiology, Erasmus MC, 
University Medical Center, Rotterdam, the Netherlands 
3 Division of Endocrinology and Nuclear Medicine, 
Department of Internal Medicine, Medical University, Graz, Austria 
4 Department of Endocrinology, 
VU University Medical Center, Amsterdam, the Netherlands 
J Bone Miner Res. 2010 Sep;25(9):1980-7 
 
 
  
  
Abstract 
The C-variant of a T-13910C polymorphism (rs4988235; NT_022135. 
15:g.25316568G > A) upstream of the lactase phlorizin hydrolase (LPH) gene 
causes lactose intolerance. Association studies with differences in bone pa-
rameters and fracture risk have been inconclusive. The objective of this study 
was to examine the association of LPH rs4988235 with body height and bone 
parameters and calcium homeostasis in two elderly populations of Dutch 
Caucasians and assess interaction with vitamin D receptor (VDR) polymor-
phisms. 
Genotyping of LPH and VDR polymorphisms was performed in 6367 individ-
uals from the Rotterdam Study and 844 from the Longitudinal Aging Study 
Amsterdam (LASA). Associations with age, height, weight, bone mineral 
density (BMD), skeletal morphometric parameters and serum vitamin D and 
calcium levels, and dietary calcium intake were assessed using ANOVA or 
analysis of covariance, and allele dose effect was assessed using linear re-
gression analysis. Fracture risk was analyzed using Cox’s proportional haz-
ard regression analysis. Associations with body height (p = 2.7x10-8) and 
vertebral area (p = .048) found in the Rotterdam study were explained by 
population stratification, as assessed by principal component analyses, and 
disappeared after additional adjustments. No associations with femoral neck 
or lumbar spine BMD or with fracture risk were detected. Calcium intake 
and ionized serum calcium were significantly lower in C-homozygotes (p = 
9.2x10-7, p = .02, respectively). For none of the parameters studied was inter-
action between the T-13910C polymorphism and VDR block 5 haplotype 1 
observed. We show that the C-allele of the T-13910C polymorphism causing 
lactose intolerance is associated with lower dietary calcium intake and serum 
calcium levels but not with BMD or fractures. The associations observed with 
height and vertebral area were the result of population stratification. This 
demonstrates the impact of population stratification and urges researchers to 
carefully take this into account in genetic associations, in particular, in die-
tary intake-related phenotypes, of which LPH and lactose intolerance are a 
strong example. 
 
 
Introduction 
Lactose intolerance (OMIM 603202) is a condition in which lactose is not 
converted into galactose and glucose owing to decreased intestinal lactase 
levels. Consequently, the undigested lactose causes gastrointestinal com-
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plaints that lead to avoiding consumption of milk and milk products and 
therefore to lower calcium intake [1-3].  
Lactose intolerance evolves in infancy after weaning when lactase enzyme 
activity is downregulated. In 2002, Enattah and colleagues identified a poly-
morphism, NT_022135.15:g.25316568G > A, 13910 bp upstream of the lac-
tase phlorizin hydrolase (LPH) gene (2q21) that is responsible for lower 
lactase enzyme activity [4]. This polymorphism will be referred to as T-
13910C throughout the article. C-homozygotes are 100% associated with 
lactase nonpersistence, that is, genetically defined lactose intolerance. The 
current thought is that the T-variant became established in response to 
changing dietary habits during the early days of cattle, sheep and goat herd-
ing when populations started to consume milk containing lactose as part of 
their dietary habits [5]. The prevalence of lactose intolerance worldwide 
shows a distribution pattern that is associated with dietary intake habits [5, 
6]. In Europe, this is represented by a rather steep incline in the prevalence 
of lactose intolerance from northern toward southern Europe, with a preva-
lence ranging from 2% in Sweden up to 70% in Italy and Turkey [5].  
Osteoporosis is a multifactorial disorder caused by the interaction of genetic 
and environmental factors such as body weight and nutrition. Important 
nutrients for bone metabolism are calcium and vitamin D. Because of the 
importance of calcium intake for bone metabolism, one can hypothesize that 
the C-allele is associated with decreased bone mineral density (BMD) and, as 
a result, also with increased fracture risk. Yet no consistent results in epide-
miological studies have been found. Table 1 summarizes the outcome of sev-
eral studies that assessed lactose intolerance with BMD and / or fracture risk 
in countries with high (Finland) or low (Austria) calcium intake [7-11].  
The vitamin D receptor (VDR) gene mediates the actions of the vitamin D 
endocrine system in calcium homeostasis and bone metabolism [12-14]. VDR 
knockout mice suffer from hypocalcaemia, hyperparathyroidism, rickets, and 
osteomalacia, a phenotype that can be rescued when these mice are fed a 
high-calcium, high-lactose, and high-phosphorus diet [15, 16]. In a previous 
examination of VDR polymorphisms in relation to osteoporosis in the Rotter-
dam Study, VDR block 5 haplotype 1 was associated with increased fracture 
risk [17]. In a functional study, the VDR block 5 haplotype 1 allele was found 
to be associated with a 15% lower VDR mRNA expression level than block 5 
haplotype 2 [17]. Therefore, we hypothesized that carrying VDR block 5 hap-
lotype allele 1 in lactose-intolerant subjects, that is, LPH C-homozygotes 
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subjects, could result in even stronger associations with BMD and / or frac-
ture risk. 
In this study we have evaluated the influence of genetically defined lactose 
intolerance on bone parameters, including fracture risk, BMD, and bone size 
and geometry, and on calcium and vitamin D metabolism in both genders in 
a large prospective population-based study of elderly Dutch Caucasians with 
relatively high dietary calcium intake. Furthermore, we assessed gene inter-
action between the T-13910C LPH polymorphism and genetic variations in 
the VDR gene.  
 
Table 1: Overview of studies where lactose intolerance was assessed in relation to bone 
parameters 
Study Sample  size (n) 
Mean age 
(age range) Gender 
Diagnostic tool  
of Lactose 
 intolerance 
Main outcome 
Ennattah et al.,  
2005 [31]  
(Finland) 
483 89 (85-98) ♂ 106 
♀ 377 
Allelic  
discrimination 
Increased risk for hip and 
wrist fractures in  
C-homozygotes. 
No difference in self-
reported milk consump-
tion between the  
genotypes. 
Obermayer-Pietsch  
et al.,  
2004 [11]  
(Austria) 
258 62 ± 9 ♀ 258 Allelic  discrimination 
Increased fracture risk 
and lower BMD for  
C-homozygotes. 
55% lower calcium intake 
from milk but not from 
yoghurt and other  
nutrients  
Gugatschka et al., 
2005 [8]  
(Austria) 
228 56 ± 12 ♂ 278 Allelic  discrimination 
No associations with BMD 
parameters and anthro-
pometric characteristics 
found. 
No differences in overall 
calcium intake, calcium 
intake from milk and 
calcium intake from 
yoghurt. 
Kudlacek et al.,  
2002 [34]  
(Austria) 
218 58.2 ± 11.5 ♂ 43 
♀ 175 
H2 breath  
hydrogen test 
No difference in bone 
loss. 
Calcium intake from milk 
lower in lactose  
malabsorbers. 
Honkanen et al., 
1996 [9]  
(Finland) 
2025 53.5 ± 3.0  (48-95) ♀2025 
Self-reported  
lactose  
intolerance 
Lower BMD at the site of 
the femoral neck and at 
the lumbar spine. 
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Material and Methods 
 
Rotterdam Study population 
Subjects were participants of the Rotterdam Study, a large prospective popu-
lation-based cohort study of white subjects aged 55 years and older living in 
the Ommoord district of Rotterdam, The Netherlands [18]. The Rotterdam 
Study was approved by the Medical Ethics Committee of the Erasmus Uni-
versity Medical Center, and written informed consent was obtained from 
each subject. This study is based on 6146 subjects (3777 females) for whom 
genotype data were available for the LPH T-13910C polymorphism.  
 
Clinical examination 
Height and weight were measured in the standing position wearing indoor 
clothing without shoes. Body Mass Index (BMI) was computed as weight in 
kilograms divided by height in meters squared (kg/m2) 
At baseline, BMD (expressed in g/cm2) was measured at the site of the femo-
ral neck and lumbar spine. The average vertebral area (cm2) was measured 
over the L2-L4 region of the lumbar spine by posteroanterior scanning using 
dual energy X-ray absorptiometry (DEXA, Lunar DPX-L Densitometry, Lu-
nar Corp., Madison, WI, USA), as described previously [19]. Hip structural 
analysis also was assessed as described previously [20]. 
 
Vertebral fracture assessment and incident nonvertebral fracture 
assessment 
The assessment of vertebral fractures and incident nonvertebral fractures 
was described in detail previously by Rivadeneira and colleagues. [20]. 
 
Dietary assessment of semiquantitative food frequency question-
naire (SFFQ) 
Nutrient intake assessment in the Rotterdam Study was performed in two 
steps. First, a modification of a mailed self-administered semiquantitative 
food frequency questionnaire was sent to subjects. Second, a dietary assess-
ment was done by a dietician during a visit of the subject to the research 
facility that took place about 22 days after the first step [21].  Sources of 
calcium intake were divided into three types of food groups: milk, milk deriv-
atives and nonmilk derivatives. Calcium intake from milk constitutes “raw” 
milk, fat milk, half-fat milk and nonfat milk. Milk derivatives are modified 
milk products such as yogurt, buttermilk, sour cream, and so on. Products in 
the nonmilk-derivatives group include fruit, vegetables, nuts, and cheese, 
among others. This subdivision is based on the Dutch Food Composition As-
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sociation (NEVO) tables of 1993 [22]. The conversion from foods to energy 
and nutrient intake was established with a computerized version of the 
Dutch Food Composition table [22]. 
 
Serum measurements 
Serum calcium was measured with a colorimetric detection assay using the 
Hitachi 917 (Roche, Mannheim, Germany). 125I radioimmunoassay (RIA) was 
used for the quantitative determination of serum 1!-25-dihydroxyvitamin D3 
(1,25(OH)2-D3; IDS, Boldon, UK) and serum 25-hydroxyvitamin D (25-
(OH)D3; DiaSorin, Stillwater, MN, U.S.A). 
 
LASA population  
The Longitudinal Aging Study Amsterdam (LASA) is an ongoing cohort study 
of elderly persons aged 55 to 85 years. The sampling and data-collection pro-
cedures have been described in detail elsewhere [23]. In brief, a random sam-
ple stratified by age, sex, and expected 5-year mortality rate was drawn from 
the population registers of 11 municipalities in three regions of the Nether-
lands. In total, 3107 persons were enrolled in the baseline examination in 
1992-1993. For this study, persons who participated in the medical inter-
views were selected. Of these, 844 subjects were genotyped for the LPH T-
13910C polymorphism. The study was approved by the Medical Ethics Com-
mittee and all participants signed informed consent 
 
Fracture assessment. 
Information on incident fractures and falls was obtained for 1289 respond-
ents between the second cycle of data collection in 1995-1996 and the third 
cycle of data collection in 1998-1999.  
 
Serum measurements 
Blood samples were obtained in 1995-1996. Serum 25-(OH)D3 was measured 
according to a competitive binding-protein assay (Nichols Diagnostics, San 
Capistrano, CA, USA). 
 
Genotyping 
Genotyping of Rotterdam Study and LASA participants were performed in 
the same laboratory (Department Internal Medicine, Erasmus MC, Rotter-
dam). Details on genotyping procedures are described previously by Stolk 
and colleagues [24].  Assay-by-design service (www.appliedbio-systems.com) 
was used to set up a Taqman allelic discrimination assay (Applied Biosys-
tems Inc., Foster City, CA, USA) for the LPH T-13910C polymorphism 
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 (Forward primer: CTCTGCGCTGGCAATACAG; Reverse primer: 
AAATGCAACCTAAGGAGGAGAGTTC); FAM (carboxyfluorescein dye) 
probe: ATAAGATAATGTAGTCCCTGGC; VIC (a proprietary fluorescent dye) 
probe: ATAAGATAATGTAGCCCCTGGC.  
VDR genotypes in the 3’ UTR region were determined, and haplotype blocks 
were constructed as described in detail by Fang and colleagues [25].  
To address the possibility of genotyping errors, 5% of the Rotterdam Study 
and the LASA was regenotyped for the LPH T-13910C polymorphism. 
 
Data analysis 
Subjects were classified according to LPH genotypes, with the TT and TC 
genotypes being lactose tolerant and the CC genotype being lactose intoler-
ant [4]. 
We allowed for three possible models to explain differences between groups, 
that is, an allele dose effect, a dominant effect, or a recessive effect. Allele 
dose was defined as the number of copies of a certain allele in the genotype. 
In case of a dominant or recessive effect of the test allele, analysis of 
(co)variance [AN(C)OVA] was performed to test for differences between two 
genotype groups. To analyze dominant effects, we compared C-allele carriers 
versus non-C-allele carriers, while for recessive effects, homozygous subjects 
for the C-allele were compared with heterozygous carriers combined with 
noncarriers. All analyses were adjusted for age and gender.  
Allele and genotype frequencies of the polymorphisms were tested for Hardy-
Weinberg equilibrium proportions using the ARLEQUIN package [26].  
Data of the Illumina array (Illumina Infinium HumanHap550 Chip Array 
[27]) containing 561466 single-nucleotide polymorphisms (SNPs) were used 
to study the presence of population stratification and unrecognized relation-
ships between individuals. The possibility of population stratification affect-
ing our results was assessed from the genomic inflation factor λ [28]. 
obtained from the genome-wide analysis of body height in the Rotterdam 
Study. In addition, considering that the relation of this LPH polymorphism 
with height is known to be subject to important stratification [29], we cor-
rected the analyses using principal components (PC) to minimize the possibil-
ity of spurious findings owing to population-stratification effects. The PC 
method allows one to correct for ancestry differences leading to spurious 
associations in disease-association studies [30]. Four PCs derived from ge-
nome-wide information were estimated from multidimensional scaling of the 
identity-by-state (IBS) pair-wise distances between Rotterdam Study indi-
viduals. All subsequent analyses in the Rotterdam Study were adjusted for 
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these four PCs. To estimate nonvertebral fracture risk, we used Cox propor-
tional-hazard models, thereby taking potential differences in follow-up into 
account. To estimate the risk of vertebral fractures, odds ratios (ORs) with 
95% confidence intervals (CIs) were calculated using logistic regression mod-
els. p Values were two-sided, and .05 or less was considered significant. 
To assess differences in the effects of the LPH T-13910C polymorphism anal-
yses among carriers and noncarriers of the block 5 haplotype 1 of the VDR 
gene, an interaction term was included together with main effects in the 
models. 
All statistical analyses were performed using SPSS 11.0 for Windows (SPSS, 
Inc., Chicago, IL, USA).  
 
 
Results 
Genotyping showed a 31% and 29% allele frequency of the T-13910C poly-
morphism in the Rotterdam Study and in LASA, respectively, with no signifi-
cant differences between genders; prevalence of the C-homozygous genotype 
was about 10% in both populations (Table 2). The genotype distribution of 
the T-13910C polymorphism did not follow Hardy-Weinberg equilibrium 
proportions in the Rotterdam Study (p = .0001) and in LASA (p = .03) No 
genotyping errors were observed after regenotyping 5% of both populations. 
To address the possibility of population admixture affecting the results, the 
genomic inflation factor λ for height was calculated in the RotterdamSstudy.  
 
Table 2: LPH T-13910C genotype frequencies in the Rotterdam Study and in the LASA 
population 
 Genotype    
 TT TC CC T-allele C-allele HWE* 
Rotterdam Study      
P<0.0001 Men  1248(48%) 1061(41%) 281(11%) 69% 31% 
Women 1816(48%) 1577(42%) 384(10%) 69% 31% 
LASA      
P<0.03 Men  227(55%) 149(36%) 39(9%) 73% 27% 
Women 208(48%) 175(41%) 46(11%) 69% 31% 
*HWE: Hardy-Weinberg equilibrium 
 
The genomic inflation factor for body height was 1.013, which, being close to 
unity, is unlikely to reflect important population stratification. The genomic 
inflation factor for BMD was also close to unity, as reported by Richards and 
colleagues. [27]. Despite the low genomic inflation, as assessed by the λ, we 
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identified by PC analyses four independent components. The second and 
third PCs were shown to be significantly associated with differences in height 
(p = 2.8x10-5 and p = 3.4x10-23, respectively) but with none of the other end-
points examined. The other components (C1 and C4) were not associated with 
height or any of the other endpoints presented in this study. However, since 
all components are independent, we corrected all analyses for all four compo-
nents.  
 
LPH genotype and height  
The baseline characteristics of both study populations are described in Table 
3. In the Rotterdam Study, the T-13910C polymorphism was significantly 
associated with height, with CC-homozygotes having a lower height (p = 
4.8x10-8). The association was driven by principal components C2 and C3 and 
was lost after adjustment (p = .72), indicating that the initial association 
likely was driven by population-stratification effects (Table 3).  
A significant association with weight (p = .0006) was found, with C-
homozygotes having lower weight than carriers of the T-allele. Adjustment 
for the PCs (ie, height) showed this association to be due to stratification 
effects as well (p = .18). For BMI, no association was found for the T-13910C 
polymorphism in either men or women.   
In the LASA, no associations with weight and BMI were found (Table 3). An 
allele dose effect for height towards a smaller stature for the C-allele was 
observed (1.7 cm, 1.1%, p trend = .048) but not for weight and BMI. In the 
LASA, we did not have the means to correct for possible stratification effects.  
 
LPH genotype and bone-related end-points 
No significant associations with femoral neck or lumbar spine BMD were 
detected in either the Rotterdam Study or the LASA (Table 3). When study-
ing the femoral bone geometry data from the Rotterdam Study, that is, nar-
row neck width, cortical thickness, and the buckling ratio, only narrow neck 
width was significantly associated with LPH (p = .004) and remained signifi-
cant after adjustments. The vertebral area also was associated with the LPH 
polymorphism (p = .048). Similar to height, the association with vertebral 
area was driven by the components C2 and C3 (p = .62) after adjustment for 
population stratification. No associations with vertebral or osteoporotic frac-
tures were found in the Rotterdam Study or with osteoporotic fractures in 
LASA (data not shown).  
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Table 3: Baseline characteristics of the study populations by LPH T-13910C genotype 
 Total TT TC CC ANOVA 
Rotterdam Study Mean ±SD 
Mean 
±SD 
Mean 
±SD 
Mean 
±SD 
p-value  
crude 
p-value  
adjusted 
p-value  
adjustede 
Age (years) 69.0 ±8.8 
69.1 
±8.8 
69.1 
±8.8 
68.5 
±8.8 0.26 
  
Height (cm) 166.8 ±9.4 
167.2 
±9.4 
166.6 
±9.4 
166.0 
±9.9 4.4x10
-6 4.8x10-8a 0.72a 
Weight (kg) 73.2 ±11.9 
73.7 
±11.9 
73.0 
±12.0 
72.2 
±11.8 0.0006 0.13
b 0.18b 
BMI (kg/m2) 26.3 ±3.7 
26.4 
±3.7 
26.2 
±3.7 
26.2 
±3.9 0.32 0.32
a 0.23a 
LS BMD (g/cm2) 1.09 ±0.2 
1.09 
±0.2 
1.09 
±0.2 
1.08 
±0.2 0.47 0.78
c 0.69c 
FN BMD (g/cm2) 0.87 ±0.1 
0.87 
±0.1 
0.87 
±0.1 
0.86 
±0.1 0.16 0.91
c 0.72c 
LASA        
Age (years) 75.7 ±6.6 
75.7 
±6.5 
75.7 
±6.6 
75.4 
±6.7 0.91   
Height (cm) 166.3 ±9.3 
167.2 
±9.1 
165.4 
±9.6 
165.5 
±8.6 0.13 0.096
a NA 
Weight (kg) 74.4 ±12.7 
75.4 
±12.7 
72.9 
±12.5 
74.7 
±12.8 0.067 0.19
b NA 
BMI (kg/m2) 26.9 ±4.2 
27.0 
±4.0 
26.7 
±4.2 
27.4 
±4.7 0.24 0.25
a NA 
LS BMD (g/cm2) 0.97 ±0.2 
0.98 
±0.2 
0.97 
±0.2 
0.93 
±0.2 0.28 0.23
d NA 
FN BMD (g/cm2) 0. 69 ±0.1 
0.71 
±0.1 
0.69 
±0.1 
0.70 
±0.1 0.37 0.84
d NA 
a adjusted for age    
b adjusted for age and height 
c adjusted for age, height, weight and calcium intake 
d  adjusted for age, height and weight 
e additionally adjusted for the principal components (PCA) 
NA not applicable 
 
LPH genotype and calcium intake 
Data on nutrition intake were available only for subjects of the Rotterdam 
Study. As shown in Table 4, the T-13910C polymorphism is associated with 
dietary calcium intake, with C-homozygotes having lower dietary calcium 
intake (p trend = 3.0x10-5). C-homozygotes had, on average, a 93 mg/day 
(8.1%) lower calcium intake than T-homozygotes and a 62 mg/day (5.5%) 
lower calcium intake than heterozygotes. When we distinguished calcium 
intake from three different sources, we observed similar associations within 
the calcium intake from milk and from other dairy products groups but not in 
the non-dairy product group. All associations with calcium intake remained 
significant after adjustment for the PCs (Table 4). In the overall study popu-
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lation, calcium intake and the bone-related endpoints studied were correlat-
ed; however, this was independent of lactose intolerance, as assessed by gen-
otyping (data not shown). No associations between the T-13910C 
polymorphism and overall energy intake or protein intake were observed. 
 
Table 4: Dietary calcium intake by LPH T-13910C genotype in the Rotterdam Study 
 Total TT TC CC ANOVA 
 Mean 
±SD 
Mean 
±SD 
Mean 
±SD 
Mean 
±SD 
p-value  
crude 
p-value  
adjusted 
p-value  
adjustedc 
Dietary calcium intake (mg/day)       
Overall 1129 ±359 
1151 
±352 
1120 
±369 
1058 
±339 2.8x10
-7 8.8x10-7a 3.0 x10-5a 
Milk  240 ±259 
244 
±257 
243 
±267 
207 
±239 0.011 0.014
a 0.032a 
Milk-derivatives  256 ±203 
268 
±209 
252 
±197 
214 
±191 2.6x10
-7 1.7x10-7a 0.004a 
Non-milk-derivatives  586 ±215 
593 
±214 
576 
±215 
589 
±219 0.032 0.078
a 0.05a 
Total energy intake (MJ) 8.3 ±2.1 
8.3 
±2.2 
8.2 
±2.1 
8.3 
±2.0 0.74 0.76
b 0.24b 
Total protein intake (g) 81.5 ±19 
81.8 
±20 
81.0 
±19 
81.4 
±19 0.59 0.70
a 0.64a 
a adjusted for gender and age 
b adjusted for gender, age and weight 
c additionally adjusted for the principal components (PCs) 
 
LPH genotype and serum calcium and vitamin D levels 
In Table 5, data on serum calcium and vitamin D levels in both the Rotter-
dam Study and LASA are presented. In the Rotterdam Study, regression 
analyses showed a borderline significant trend towards lower total serum 
calcium levels for the C-variant (p = .09). Ionized calcium levels were lower in 
the C-homozygotes with evidence for an allele dose effect (p trend = .02). As 
in the Rotterdam Study, in LASA, serum calcium levels in C-homozygotes 
tended to be lower but regression analysis was not significant (p = .39). In the 
Rotterdam Study serum 25(OH) D3 and 1,25(OH)2D3 as well as serum 
25(OH) D3 in LASA study were not associated with the T-13910C polymor-
phism. Adjustment of PCs did not change the p values for both serum calci-
um and vitamin D levels associations  
 
Interaction of the T-13910C polymorphism with the VDR 
In the Rotterdam Study, interaction of the LPH T-13910C polymorphism 
with variants in the 3’ UTR region of the VDR were tested. Of about 1.5% of 
the subjects either only the VDR block 5 haplotype 1 was available or only 
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the LPH polymorphism could be determined. This left 6047 subjects for in-
teraction analyses between VDR and LPH. 
  
Table 5: Serum total and ionized calcium levels and 25(OH)D and 1,25α(OH)2D3 
 Total TT TC CC Linear Regression  analysis 
 Mean 
±SD 
Mean 
±SD 
Mean 
±SD 
Mean 
±SD 
p-value  
crude 
p-value  
adjusteda 
Rotterdam Study       
Total serum calcium  
(mmol/l) 
2.39 
±0.15 
2.39 
±0.15 
2.38 
±0.15 
2.38 
±0.15 0.12  0.09  
Ionized serum calcium  
(mmol/l) 
1.29 
±0.07 
1.29 
±0.6 
1.29 
±0.05 
1.28 
±0.07 0.02  0.02  
Serum 25(OH)D  
(nmol/l) 
66.0 
±27.6 
66.7 
±27.9 
64.9 
±27.1 
66.9 
±28.1 0.57  0.59  
Serum 1,25α(OH)2D3 ( 
pmol/l) 
108.9 
±29.5 
108.1 
±28.8 
108.8 
±29.9 
112.7 
±31.8 0.18  0.25  
LASA       
Total serum calcium  
(mmol/l) 
2.34 
±0.10 
2.34 
±0.08 
2.34 
±0.11 
2.31 
±0.11 0.46 0.39 
Serum 25(OH)D  
(nmol/l) 
51.4 
±23.4 
51.4 
±22.4 
50.9 
±24.1 
52.8 
±25.2 0.80 0.62 
a adjusted for gender, age, height and weight 
 
The VDR block 5 haplotype 1 consists of 10 SNPs and is identified by three 
tagging SNPs. The carriers of the block 5 haplotype 1 allele had an increased 
fracture risk [25]. Thus 70.5% of the subjects who were genotyped for LPH 
were carriers of the VDR block 5 haplotype 1. The association found between 
the T-13910C polymorphism and height in the VDR block 5 haplotype 1-
carrying subgroup was due to stratification (Table 6). Furthermore, interac-
tion analyses did not detect interactions between the two genotypes.  
 
Discussion 
This study demonstrates that some of the highly significant associations with 
the LPH T-13910C polymorphism, that is, height and vertebral area, were 
the result of population-stratification effects. However, dietary calcium in-
take and ionized calcium levels remained significant after adjusting for the 
population stratification. Analyses of the interaction between the LPH T-
13910C polymorphism and the VDR block 5 haplotype 1 polymorphism did 
not show an interaction between these two polymorphisms. 
In both the Rotterdam Study and LASA populations, genotype and allele 
frequencies did not follow Hardy-Weinberg equilibrium (HWE) proportions. 
Since the possibility of genotyping error is unlikely given the repeated geno-
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typing and stringent quality control, ancestral selection at this locus may be 
underlying the observed HWE deviation. The possibility of ancestral selection 
affecting the LPH locus in our population is also supported by the strong 
attenuation of the effects on height after correction for principal components, 
which, in contrast to the global correction for genetic background assessed by 
the genomic inflation factor, takes into account more subtle and regional 
selection effects.  
 
Table 6: Baseline characteristics by LPH T-13910C genotype stratified for VDR block 5 
genotype in the Rotterdam Study 
 VDR block 5  haplotype 1 non-carriers   
VDR block 5  
haplotype 1 carriers   
 LPH T-13910C genotype   LPH T-13910C genotype ANOVA 
 TT TC CC ANOVA ANOVA PC adjusted TT TC CC 
p-value  
crude 
p-value 
adjustede 
Age  
(years)a 
68.9 
"8.7 
69.1 
"8.8 
69.0 
"8.8 0.74 0.70 
69.1 
"8.8 
69.0 
"8.8 
68.5 
"8.8 0.32 0.63 
Height  
(cm)b 
166.9 
"9.3 
167.5 
"9.6 
166.7 
"8.8 0.23 0.28 
167.3 
"9.5 
166.4 
"9.2 
166.4 
"10.0 0.002 0.24 
Weight  
(kg)c 
73.9 
"11.9 
73.3 
"12.0 
73.0 
"13.0 0.19 0.30 
73.8 
"11.8 
73.0 
"11.9 
72.8 
"11.4 0.71 0.46 
BMI  
(kg/m2)b 
26.5 
"3.8 
26.1 
"3.6 
26.2 
"3.6 0.14 0.20 
26.3 
"3.7 
26.3 
"3.7 
26.4 
"4.0 0.92 0.68 
LS BMD  
(g/cm2)d 
1.09 
"0.2 
1.09 
"0.2 
1.11 
"0.2 0.33 0.40 
1.09 
"0.2 
1.09 
"0.2 
1.08 
"0.2 0.46 0.44 
FN BMD  
(g/cm2)d 
0.86 
"0.1 
0.87 
"0.1 
0.88 
"0.1 0.44 0.44 
0.87 
"0.1 
0.87 
"0.1 
0.86 
"0.1 0.85 0.91 
a  adjusted for gender 
b  adjusted for gender and age 
c adjusted for gender, age and height 
d adjusted for gender, age, height, weight and calcium intake 
e adjusted for the principal component 
 
This study shows an 8.1% lower calcium intake in C-homozygotes with evi-
dence for an allele dose effect of the C-allele with an average of 1058 mg/day 
in the lactose-intolerant CC-group compared with 1120 mg/day in TC and 
1151 mg/day in the TT group, that is, the lactose tolerant groups. Protein 
intake and energy intake were not different between the different genotypes. 
Most other studies that assessed the relationship between genetically defined 
lactose intolerance and calcium intake did show significantly lower calcium 
intake from milk but not lower overall dietary calcium intake (Table 1). In a 
group of young Finnish men, total dietary calcium intake was similar for the 
112
three different genotypes, although calcium intake from milk and yogurt was 
lowest for the C-homozygotes [31]. These inconsistent findings could be ex-
plained at least in part by the low power of the studies. Another explanation 
for the observed discrepancies is that dietary habits between the various 
populations are different. In the study of Gugatschka and colleagues, calcium 
intake from milk and yogurt was only about 15% of the total daily calcium 
intake, whereas in our study calcium intake from yogurt and milk products, 
not including cheese, comprised about 50% of total daily calcium intake [8]. 
In addition, the overall calcium intake in several independent studies in 
Austria was approximately 600 g/day, which is about half the Dutch daily 
calcium intake [10].  
Studies that have investigated the influence of lactose intolerance in relation 
to bone (Table 1) are conflicting and inconclusive. Differences in the preva-
lence, as well as social and cultural differences between populations, might 
have contributed to this, and selection criteria for the inclusion of partici-
pants may have diluted or enhanced associations. The sizes of these studies 
were small compared with our study, analyzing over 6000 individuals. An 
overall conclusion from both the Rotterdam Study and LASA is that the LPH 
T-13910C polymorphism is not associated with femoral neck and lumbar 
spine BMD or fracture risk. Although our study is a large population-based 
study, a limitation of our study is that we were not able to assess the severity 
of the lactose intolerance. Since complaints among lactose-intolerant persons 
vary, it is likely that persons with severe symptoms from lactose intolerance 
have even lower calcium intake levels and that in this subgroup there might 
be an effect on BMD and fracture risk.  
None of the studies that assessed genetically defined lactose intolerance 
reported differences in height and / or weight [8, 11, 31, 32]. Our study clear-
ly shows that the height and weight effects are probably not driven by the T-
13910C polymorphism, but are more likely explained by differences in the 
genetic background of individuals and population stratification. Nonetheless, 
calcium and, more specifically, milk intake is suggested to influence height 
and weight, as demonstrated by Gugatschka and colleagues, who observed 
differences between milk and nonmilk drinkers in men on low calcium in-
take. The latter were 4 cm shorter and had a 5 kg lower body weight [8]. 
Milk-drinking habits therefore might influence bone and body dimensions on 
the basis of given genetic predisposition.  
Fang and colleagues studied a comprehensive set of polymorphisms in the 
VDR gene and found the block 5 haplotype 1 to be associated with fractures 
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and body height [17, 25]. We studied whether carrying VDR block 5 haplo-
type 1 in LPH C-homozygotes would influence the observed associations 
because both genes are involved in intestinal calcium handling. A study by 
Obermayer-Pietsch and colleagues found intestinal calcium uptake to be 
impaired in lactose-intolerant subjects, when calcium was administered con-
comitantly with lactose [33]. Therefore, one might hypothesize that when 
expression of VDR is lower, such as might be the case for VDR block 5 haplo-
type 1 carriers and dietary calcium intake as well as uptake is lower in lac-
tose-intolerant subjects, that is, C homozygotes for the T-13910C 
polymorphism, this might lead to interaction in association studies. However, 
the interaction term was not significant for the parameters analyzed in this 
study between the LPH T-13910C polymorphism and block 5 haplotype 1 (p = 
.20).  
This is the first study to report pronounced differences in serum ionized cal-
cium levels considering the T-13910C polymorphism. The physiologic mecha-
nism behind this observed association regarding ionized calcium levels is 
unclear because ionized calcium levels are regulated primarily by sensing 
calcium levels in the parathyroid gland. However, the final regulation of 
proper calcium levels takes place via interplay among the parathyroid 
glands, kidneys, and intestines. Since parathyroid hormone (PTH) values are 
lacking, one can only speculate about possible explanations. One possibility 
might be an alteration of the setpoint for calcium within the parathyroids. 
Another explanation might be a subclinical secondary hyperparathyroid state 
owing to diminished intestinal uptake of calcium either by impaired intake of 
calcium or by impaired uptake, as suggested by Obermayer-Pietsch and col-
leagues [33].  Underlying this hypothesis is the observation by Di Stefano 
and colleagues that young adults suffering from a symptomatic lactose intol-
erance have low BMD values and increased PTH levels [2].  
 
 
Conclusion 
From this study we conclude that in a Dutch population with overall high 
calcium intake, the presence of the CC variant of the LPH polymorphism 
causing lactose intolerance is not associated with BMD and fracture risk. 
However, there is a clear association with dietary calcium intake and ionized 
calcium levels. 
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Abstract 
Background: Pseudovitamin D deficiency is the consequence of a genetic 
defect in the CYP27B1 gene resulting in diminished or absent conversion of 
25-hydrovitamin D3 (25-(OH)D3) into 1,25-dihydroxyvitamin D3 (1,25-
(OH)2D3) and leads to growth retardation and rickets, usually in the first two 
years of life.  
Patient and methods: DNA obtained from human leucocytes from a patient 
suspected of pseudovitamin D deficiency and her healthy parents was se-
quenced for a genetic defect in the CYP27B1 gene. In silico analyses on the 
mutations were performed using online available software. The 1α-
hydroxylase activity of the patient, her parents and a sample derived from a 
mixed buffy coat of healthy blood donors was measured by culturing periph-
eral blood mononuclear cells with 25-(OH)D3 and measuring 1,25-(OH)2D3 
production.  
Results: DNA sequencing of the patient suspected of pseudovitamin D defi-
ciency revealed compound heterozygosity in the CYP27B1 gene for a 
(c413G>T) mutation in exon 3 (R138L) and a (c1232G>A) mutation in exon 8 
(C411Y). In silico analyses confirmed that mutations at these positions are 
probably damaging for the protein since the amino acids are situated in a 
highly conserved region. In vitro analyses showed a nearly absent 1α-
hydroxylase activity in the patient compared to the healthy blood donors. Her 
healthy parents each of whom carried one of the mutations also had compro-
mised conversion of 25-(OH)D3 into 1,25-(OH)2D3 in peripheral blood mono-
nuclear cells, being only marginally higher than the patient. 
Conclusion: We discovered novel compound heterozygous mutations in the 
CYP27B1 gene in a young girl presenting with pseudovitamin D-deficient 
rickets, leading to severely decreased 1,25-(OH)2D3 production. Furthermore, 
both heterozygous parents showed a diminished 1α-hydroxylase activity. 
 
 
Introduction 
Vitamin D-dependent rickets has been classified in type 1 and type 2 rickets. 
Both types are subdivided in two forms, based on the underlying genetic 
defect. Type 1a, also called pseudovitamin D deficiency, comprises genetic 
defects in the CYP27B1 gene, a member of the p450 cytochrome family locat-
ed at position 13.1-13.3 on the long arm of chromosome 12 (OMIM *609506). 
This genetic defect results in defective or diminished hydroxylation of 25-
hydroxyvitamin D3 (25-(OH)D3) into 1,25-dihydroxyvitamin D3 (1,25-
(OH)2D3) in the kidney. Physiologically, this leads to high 25-(OH)D3 and low 
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1,25-(OH)2D3 levels, impaired calcium absorption in the intestines and ele-
vated parathyroid hormone (PTH) resulting in hyperphosphaturia [1,2]. 
Pseudovitamin D defiency usually presents around 6-12 months after birth 
with severe skeletal disease, rachitic rosary, long bone bowing and enlarged 
metaphyses, failure to thrive, and growth retardation [3]. Biochemically, 
hypocalcaemia sometimes associated with tetany and mild-to-moderate hy-
pophosphatemia can be found with elevated PTH levels. In this case report, 
we present a female patient with a severe form of pseudovitamin D-deficient 
rickets.  
 
 
Patient & methods 
Medical history and laboratory measurements 
We studied a patient of Surinam-Hindustani origin who was admitted to the 
pediatrics ward at 11 months because of growth failure. On admission, she 
presented with remarkable thickness of the wrists and fusiform finger joints, 
bowing of the lower limbs, and a mild form of a rachitic rosary. Moreover, she 
suffered from hypotonia and anorexia, but there were no signs of motor de-
velopment delay. None of her relatives had similar symptoms and her par-
ents were healthy and unrelated. 
Her laboratory values on admission are listed in Table 1, showing decreased 
serum calcium and phosphate levels with increased PTH, highly elevated AF 
levels, and decreased levels of 25-(OH)D3 and 1,25-(OH)2D3. An initial diag-
nosis of 1-alpha hydroxylase deficiency was considered. 
 
Table 1: Laboratory measurements in the patient at 11 months of age. 
Serum measurements Pre-treatment  values 
After daily alfacalcidol  
administration 
Reference  
values 
Calcium (mmol/l) 1.79 2.29 2.10-2.60 
Phosphate (mmol/l)  0.84 0.83 1.20-2.10 
Alkaline phosphatase (U/l)  10,600 6,600 < 510 
PTH (pmol/l) 1.14  <0.75 
25-hydroxyvitamin D3 (nmol/l)  12.5 117.5 50-120 
1,25-dihydroxyvitamin D3 (pmol/l)  7.5 177.5* 38-183 
* After daily administration of 2000IU cholecalciferol. 
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We do not know why the 25-(OH)D3 levels of the patient were so low, but we 
can hypothesize that this was due to anorexia in combination with a hyper-
pigmented skin. It is also possible that the parents did not comply with the 
supplementation advice of 500IU daily of cholecalciferol for infants at that 
time [4].  
On treatment with 1α-hydroxyvitamin D3 (alfacalcidol 0.5 mcg/day) and 
phosphate (8.1 mmol/ per day), she developed normally. Menarche was at age 
12. Her final height was 1.50 m, which she attained at age 13 with a weight 
of 36.2 kg. 
At age 17, she was transferred form the children’s out-patient clinic to inter-
nal medicine adult out-patient clinic. Laboratory results were not consistent 
with adequate treatment and patient was considered to be under treated (low 
serum calcium and phosphate, increased AF and PTH), which was thought to 
be due to decreased compliance. After restarting alfacalcidol and phosphate, 
patients’ laboratory values normalized. At the age of 18, she developed auto-
immune hypothyroidism, for which she was treated with levothyroxin. Phos-
phate supplementation was stopped at age 24 while alfacalcidol was 
continued.  
In 2009 we invited her parents for further analysis. The father had a 25-
(OH)D3 level of 32 nmol/l with a 1,25-(OH)2D3 level of 62.9 pmol/l, while her 
mother had 70 nmol/l and 71.6 pmol/l levels of 25-(OH)D3 and 1,25-(OH)2D3, 
respectively. Serum PTH level was 6.6 pmol/l in the father and 2.8 pmol/l in 
the mother (reference values PTH: 1.4-7.3 pmol/l, data not shown). For the 
clinical and genetic evaluation, the patient and her parents gave informed 
consent.  
Strategies in Analyzing DNA and Assessing Mutations In Silico and 
In Vitro. 
Methods on the collection of DNA and sequencing and details concerning the 
in silico and in vitro analyses can be found as a supplementary file. 
 
 
Results 
Sequence Analyses 
Sequence analyses of all exons revealed compound heterozygous mutations in 
the CYP27B1 gene of the patient. The first is a c413G > T missense mutation 
found in exon 3 resulting in an arginine to leucine amino acid change at posi-
tion 138. The second is a c1232G > A missense mutation in exon 8 leading to 
a cysteine to tyrosine amino acid change at position 411. The father was 
heterozygous carrier for the mutation in exon 3, whereas the mother was 
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heterozygous for the exon 8 mutation. The position of both mutations relative 
to the full protein have been schematically presented in Fig. 1a. 
 
Figure 1: G413T and G1232A mutation sites occur in evolutionary conserved regions 
Structure of CYP27B1 with both mutations indicated relative to the full-length protein 
(A). Both mutations occur in evolutionary conserved regions across 17 orthologs (B and 
C) 
 
 
 
 
 
          G413T mutation 
| 
homo_sapiens  GGCAAAGGCTCCGCAGTCTCCTGGCCCCGCTCCTCCTCCGGCCTCAAGCGGCCGCCCGCT 
pan_troglodytes        GGCAAAGGCTCCGCAGTCTCCTGGCCCCGCTCCTCCTCCGGCCTCAAGCGGCCGCCCGAT 
gorilla_gorilla        GGCAAAGGCTCCGCAGTCTCCTGGCCCCGCTCCTCCTCCGGCCTCAAGCGGCCGCCCGCT 
pongo_abelii           GGCAAAGGCTCCGCAGTCTCCTGGCCCCGCTCCTCCTCCGGCCTCAAGCGGCCGCCCGCT 
chlorocebus_sabaeus    GGCAAAGGCTCCGCAGTCTCCTGGCCCCACTCCTCCTCCGGCCTCAAGCGGCCGCCCGCT 
macaca_mulatta         GGCAAAGGCTCCGCAGTCTCCTGGCCCCACTCCTCCTCCGGCCTCAAGCGGCCGCCCGCT 
papio_anubis           GGCAAAGGCTCCGCAGTCTCCTGGCCCCACTCCTCCTCCGGCCTCAAGCGGCCGCCCGCT 
callithrix_jacchus     GGCAAAGGCTCCGCAGTCTCCTGGCCCCGCTCCTCCTCCGGCCTCAAGCGGCAGCCCGCT 
mus_musculus           GGCAGAGGCTCCGAAGTCTTCTGGCCCCGCTCCTCCTCCGGCCACAAGCAGCCGCGGGCT 
rattus_norvegicus      GGCAGAGGCTCCGAAGTCTCCTGGCCCCGCTACTCCTCCGACCTCAAGCAGCCGCCGGCT 
oryctolagus_cuniculus  GGCAGAGGCTCCGCAGCCTCCTGGCCCCGCTCCTCCTCCGGCCTCAGGCGGCCGCGGGCT 
bos_taurus             GGCAGAGGCTTCGCAGCCTCCTGGCCCCGCTGCTCCTCCGGCCTCAAGCGGCCGCCCGCT 
ovis_aries             GGCAGAGGCTTCGCAGCCCCCCGGCCCCGCTGCTCCCCCCGCCCCAAGCGGCCGCCCCCC 
sus_scrofa             GGCAGAGGCTCCGCAGTCTCCTGGCCCCGTTGCTCCTCCGGCCTCAAGCGGCAGCCCGCT 
canis_familiaris       GGCAGAGGCTCCGCAGCCTCCTGGCCCCGCTGCTCCTCCGGCCTCGAGCCGCCGCCCGCT 
felis_catus            GGCAGAGGCTCCGCAGCCTCCTGGCCCCGCTGCTCCTCCGGCCTCAAGCTGCCGCCCGCT 
equus_caballus         GGCAGAGGCTCCGCAGCCTGCTGGCCCCGCTCCTCCTCCGGCCTCAAGCGGCCGCCCGCT 
                      
 
           G1232A mutation 
   | 
homo_sapiens           TCACTCTGTGTCACTATGCCACTTCAAGGGACCCTGCCCAGTTCCCAGAGCCAAATTCTT 
pan_troglodytes        TCACTCTGTGTCACTATGCCACTTCAAGGGACCCTGCCCAGTTCCCAGAGCCAAATTCTT 
gorilla_gorilla        TCACTCTGTGTCACTATGCCACTTCAAGGGACCCTGCCCAGTTCCCAGAGCCAAATTCTT 
pongo_abelii           TCACTCTGTGTCACTACGCCACTTCAAGGGACCCTGCCCAGTTCCCAGAGCCGAATTCTT 
chlorocebus_sabaeus    TCACTCTGTGTCACTATGCCACTTCAAGGGACCCTGCCCAGTTCCCAGAGCCAAATTCTT 
macaca_mulatta         TCACTCTGTGTCACTATGCCACTTCAAGGGACCCTGCCCAGTTCCCAGAGCCAAATTCTT 
papio_anubis          TCACTCTGTGTCACTATGCCACTTCAAGGGACCCTGCCCAGTTCCCAGAGCCAAATTCTT 
callithrix_jacchus    TCACTCTGTGTCACTATGCCACTTCAAGGGACCCTGCCCAGTTCCCAGAGCCAAATTCTT 
mus_musculus           TCTCCCTATGTCACTATGCCACTTCAAGGGACCCCACACAGTTTCCAGACCCCAACTCTT 
rattus_norvegicus     TTTCCCTCTGTCACTATGCCACTTCAAGGGACCCCGCCCAGTTTCGGGAACCCAACTCTT 
oryctolagus_cuniculus  TCACTCTGTGTCACTATGCCACTTCAAGGGACCCTGCCCAGTTCCCAGAGCCAAATTCTT 
bos_taurus           TCACTCTGTGTCACTATGCCACTTCAAGGGACCCTGCCCAGTTCCCAGAACCAAATTCTT 
ovis_aries             TCACTCTGTGTCACTATGCTACTTCAAGGGACCCTGCCCAGTTCCCAGAACCAAACTCTT 
sus_scrofa             TCACTCTGTGTCACTATGCCACTTCAAGGGACCCTGCCCAGTTCCCAGAGCCAAATTCTT 
canis_familiaris       TCACACTGTGTCATTATGCCACTTCAAGGGATCCTGCCCAGTTCCCAGAGCCAAATTCTT 
felis_catus            TCACACTGTGTCATTATGCCACTTCAAGGGATCCTGCCCAGTTCCCAGAGCCAAATTCTT 
equus caballus         TCACACTGTGTCATTATGCCACATCAAGGGACCCTGCTCAGTTTCCAGAGCCAAATTCTT  
A 
B 
C 
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In silico Analyses 
Using web-based prediction models, we assessed whether the two mutations 
affect the function of 1α-hydroxylase. Both the Polyphen 2 and Mutation 
Taster programs predict that the R138L and C411Y mutations are probably 
damaging to the protein or disease-causing, respectively. In addition, the 
Consurf software indicated that especially the R138L is highly conserved and 
predicted to be functional. These in silico findings are supported by compari-
son of the nucleotide sequences surrounding the orthologs of human 1α-
hydroxylase across 17 species, indicating the evolutionary conservation of 
each mutation site (Fig. 1b, c). Extensive research in current databases did not 
yield SNPs at the chromosomal locations where both mutations were found. 
 
1α-Hydroxylase Activity Assay in PBMCs 
In order to assess the 1α-hydroxylase activity of the patient and the parents 
compared to healthy controls, we measured 1,25-(OH)2D3 levels in PBMC 
cultures supplemented with 800 nmol of 25-(OH)D3 for a 24-h period (Fig. 2). 
After 24 h, 1,25-(OH)2D3 levels in the supernatant increased up to 355 pmol/l 
in the controls. The levels of 1,25-(OH)2D3 from the patient’s PBMC cultures 
were more then tenfold lower compared to the controls and increased up to 
30.7 pmol/l. Both parents showed higher 1,25-(OH)2D3 levels after admin-
istration of 25-(OH)D3 compared to the patient but these did not reach values 
of the control, i.e. 86.1 pmol/l for the father and 58.1 pmol/l for the mother. 
 
Figure 2: 1,25-(OH)2D3 levels after 24 hour incubation with 0 and 800 nmol/l 25-(OH)D3 
in PBMCs. 
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Discussion 
In this study, we found novel compound heterozygous mutations in a patient 
who presented with severe signs of pseudovitamin D deficiency at a young 
age. Sequence analyses revealed novel compound heterozygous mutations in 
exons 3 and 8 (R138L/C411Y) of CYP27B1, the 1α-hydroxylase gene, which 
led to diminished enzyme activity as shown by minimal conversion of 25-
(OH)D3 into 1,25-(OH)2D3 in PBMC cultures.  
The first to describe mutations responsible for the pseudovitamin D deficien-
cy were Kitanaka et al. [5]. They found four homozygous mutations in four 
different patients, two of them in exon 2, one in exon 6, and one in exon 7 of 
the 1α-hydroxylase gene. Fu et al. found compound heterozygote mutations in 
the keratinocytes of a girl with pseudovitamin D deficiency [6]. In 2007, Kim 
et al. reviewed 44 patients with a genetic defect in the gene encoding the 1α-
hydroxylase enzyme and added data on ten new patients where they con-
firmed pseudovitamin D deficiency using sequencing. As for the latter ten 
patients, five carried a homozygous mutation, four patients had compound 
heterozygous mutations, and in one patient only one heterozygous mutation 
was found [7]. An overview of the mutations in the CYP27B1 gene was pub-
lished in 2012 [8,9]. From 2012 onwards, eight novel mutations have been 
described to date [10-13] which we added in Table 2 to this paper including 
our own mutations. In total, we are aware of 34 missense mutations, four 
nonsense mutations, 11 deletions, 3 insertions, 2 deletion-insertions and 6 
splice-site mutations.  
 
Table 2: Mutations found in literature from 2012  
Nucleotide change Amino acid Change Exon 
1294C>A R432S Exon 8 [13] 
1079C>A S360 [10] 
195T>G Frameshift codon 65 Intron 1 [10] 
1022-1037del16 Frameshift T341Rfs*5 Exon 6 [12] 
1215+2T>A  L380Afs*57  Intron 7 [12] 
934_935delAC  T312Rfs*19  Exon 5 [12] 
1165C>T R389C  Exon 7 [11] 
1375C>T R459C  Exon 8 [11] 
413G > T Arg138Leu Exon 3 (this study) 
1232G > A Cys411Tyr Exon 8 (this study) 
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To our knowledge both mutations found in our patient have not been de-
scribed previously. Both are located in proximity of an α-helix structure and 
likely compromise the structure of the protein as was predicted by commonly 
used software programs. Unfortunately, no crystal structure for the 
CYP27B1 enzyme is available and therefore not much is known about how 
the mutations affect structure and how this is related to the function of the 
enzyme.  
 
Most functionality analyses to scrutinize protein defects are performed using 
cells transfected with the discovered mutation, or by obtaining keratinocytes 
from patients. Besides the kidney, keratinocytes have long been thought to be 
the only site of vitamin D metabolism acting in an autocrine/paracrine man-
ner [6,14]. However, 1α-hydoxylase activity has been found in many tissues 
since then, and van Driel et al. showed that human peripheral blood mono-
nuclear cells express CYP27B1 and exert 1α-hydroxylase activity when cells 
are stimulated with RANKL[15]. This prompted us to study our patient in a 
straightforward functionality assay, using easy-to-obtain peripheral blood 
mononuclear cells. We have demonstrated that this assay is a reliable assay 
to assess CYP27B1 functionality and that the mutation found in our patient 
led to a more than tenfold reduction in enzyme activity compared to control. 
Interestingly, while the parents had no vitamin D-related health problems, 
the in vitro functionality assay showed strongly reduced conversion of 25-
(OH)D3 to 1,25-(OH)2D3 compared to healthy control cultures. Smith et al. 
found normal values in the heterozygous parents of the patients when com-
pared to controls after stimulation of macrophages with INF-#, but with con-
siderable variation [16]. Currently, it seems there is not a clear-cut 
correlation between the mutation and residual enzyme activity and the clini-
cal phenotype. This is supported by the discrepancy in observations by 
Kitanaka et al. [17] and Wang et al. [18] on patients with mild clinical pheno-
types. However, we cannot definitively rule out a genotype-phenotype rela-
tion as various enzymatic assays and functional readouts including 
transfection assays and natural cells have been used reflecting different sen-
sitivities. There is still the possibility that a genotype-phenotype relation 
does exist since mild cases might not come to the attention of the doctor or 
might not be diagnosed as being pseudovitamin D deficiency. Since the auto-
crine/paracrine role of 1α-hydroxylase in tissues besides keratinocytes and 
kidney is only partly understood [14], we cannot completely rule out that 
there may be subclinical effects leading to symptoms later in life.  
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In conclusion, we describe a female patient with two novel compound hetero-
zygous mutations (R138L/C411Y) in CYP27B1, leading to vitamin D-
dependent rickets. We demonstrated that the patient had a diminished 1α-
hydroxylase activity as shown by minimal conversion of 25-(OH)D3 into 1,25-
(OH)2D3 in PBMC cultures, which occurred to a lesser extent in both the 
parents.
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Supplemental Material and Methods 
 
Strategies in analyzing DNA and assessing found mutations in silico 
and in vitro. 
Methods on the collection of DNA and sequencing and details on the in silico 
and in vitro analyses can be found as a supplementary file. 
 
Collection of DNA and sequencing 
After informed consent, genomic DNA was isolated from peripheral blood 
leucocytes of the patient and her parents, using a magnetic particle manipu-
lator according to the manufacturer’s protocol (Agowa, Berlin, Germany). 
Primers for the different exons of the CYP27B1 gene were previously de-
scribed by Smith et al.[9] and PCR was performed, using an Amplitaq Gold 
kit (Applied Biosystems). The PCR products corresponding to the different 
exons of the CYP27B1 gene were sequenced (BaseClear, Leiden, the Nether-
lands) and analyzed, using freely available software (Chromas lite, 
http://www.technelysium.com.au/chromas_lite.html). 
 
In silico analyses 
To evaluate mutations at protein level in silico, we used the web-based pro-
grams Mutation Taster (http://www.mutationtaster.org/) and Polyphen-2 
(http://genetics.bwh.harvard.edu/pph/) to predict if the mutation is disease 
causing or damaging, respectively. In addition, Consurf (http://consurf.tau.ac.il/) 
was utilized to determine whether the mutation is situated in a conserved 
area of the protein, indicating its importance for protein function.  
 
PBMC cultures 
Details on PBMC collection have been described previously by van der 
Eerden et al.[10]. In short, following collection of PBMCs from the patient 
and her parents, cells were seeded in a density of 500,000 cells/well in a 96-
well plate and incubated for 4 hours. Then, cells were washed once with 1x 
Phosphate-Buffered Saline and culture medium was supplemented with 800 
nmol/l 25-(OH)D3, generously provided by Dr. L. Binderup (Leo Pharmaceuti-
cals, Ballerup, Denmark). After 24 hours, the conditioned medium was col-
lected and stored at –20ºC until the samples were used for 1,25-(OH)2D3  
measurement, using a 125I-radioimmunoassay (IDS, Boldon, UK). As healthy 
control, PBMC samples derived from a blood bank buffy coat of pooled mixed 
healthy donors (Sanquin, Amsterdam, the Netherlands) were incubated with 
the same concentration of 25-(OH)D3. Ketaconozole (10-4M) served as a nega-
tive control in the blood bank-derived PBMC cultures.  
130

 Chapter 7 
Osteoclastogenic capacity of peripheral blood 
mononuclear cells is not different between 
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Abstract 
Introduction: Peripheral Blood Mononuclear Cells (PBMCs) have been exten-
sively used as a culture model to generate osteoclasts in vitro. The aim of this 
study was to assess the osteoclastogenic potential of PBMCs derived from 
postmenopausal women with longstanding osteoporosis and compare this 
with PBMCs from healthy controls. 
Material and Methods: We selected from the population-based Rotterdam 
Study 82 participants of which 43 were diagnosed with osteoporosis (T-score 
below -2.5 at the lumbar spine) and the presence of at least 1 fracture and 29 
healthy controls (T-score above 1; no fracture). PBMCs were differentiated 
into osteoclasts, and both differentiation capacity and activity were meas-
ured. Total RNA was obtained to assess gene expression of osteoclast mark-
ers. Deoxypyridinoline (DPD) was measured in plasma as a marker for bone 
resorption, in vivo.  
Results: Neither the number of osteoclasts nor cathepsin K (CTSK) and den-
dritic cell-specific transmembrane protein (TM7SF4) gene expression was 
significantly different between both groups. There was also no significant 
difference in resorption pit area and plasma DPD levels. Stratification by 
fracture type into a group with vertebral, non-vertebral, and both vertebral 
and non-vertebral fractures showed no difference in osteoclast formation or 
osteoclastic bone resorption. However, plasma DPD, but not the RNA expres-
sion markers, was significantly lower in the group of subjects with vertebral 
fractures and those with vertebral and non-vertebral fractures compared to 
the healthy controls. No differences in osteoclastogenesis, osteoclastic resorp-
tion, and plasma DPD levels were detected also after exclusion of past or 
present users of bisphosphonates and glucocorticoids. Stratification into high 
and low DPD levels showed higher osteoclastogenesis and more osteoclastic 
bone resorption in the high DPD group compared to the low DPD levels with-
in the group of osteoporotic subjects. 
Conclusion: This study showed no difference in PBMC osteoclastogenic ca-
pacity and activity between women with and without osteoporosis and at 
least one previous fracture, who were on average 29.5 years after menopause, 
suggesting that there is no difference in circulating osteoclast precursors. 
Although we cannot exclude that circulating precursors may behave differ-
ently at the bone site, it is possible that long after menopause a more stable 
phase of bone turnover is reached compared to earlier after the start of men-
opause in which differences in circulating osteoclast precursors and osteo-
clastogenic potential are more prominent.    
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Introduction 
Osteoporosis is an age-related disorder with a marked morbidity and mortali-
ty. In The Netherlands, the overall prevalence of osteoporosis is 16.1/1000 for 
women and 1.9/1000 for men [1]. The incidence of vertebral fractures in The 
Netherlands above 55 years is 14.7/1000 person years for women and 
5.9/1000 person years for men [2]. Osteoporosis results from a shift in the 
balanced bone remodeling towards increased bone resorption over bone for-
mation, resulting in bone loss and higher risk of fractures.  
Human peripheral blood mononuclear cells (PBMCs) are a good source for 
the generation of osteoclasts [3, 4]. A study by D’Amelio and coworkers 
showed an increase in spontaneous osteoclastogenesis and lacunar resorption 
area in women with postmenopausal osteoporosis compared to postmenopau-
sal women without osteoporosis but found no difference in osteoclast number 
and lacunar resorption when cultures were stimulated with growth factors 
[4]. A study by Jevon et. al., did not find a difference in osteoclast formation 
in PBMC cultures between osteoporotic women and healthy women but re-
ported an increased activity when PBMC’s were co-cultured with the rat 
osteosarcoma cells UMR106 [5], a cell-line with osteoblast characteristics [6].  
The aim of our study was to investigate whether elder women, who were on 
average 25 years after menopause, with established osteoporosis and at least 
one fracture after the age of 55 years, demonstrate increased PBMC-derived 
osteoclast formation and increased osteoclast activity in vitro compared to 
age- and years since menopause-matched healthy controls.  
 
 
Material and Methods 
Selection and inclusion procedure 
We selected women from the Rotterdam Study, a cohort of elderly Caucasian 
subjects from which long-term follow-up data are available on bone mineral 
density (BMD) and fractures. Details on study design and rationale have 
been described extensively [7]. For this study we selected women diagnosed 
with osteoporosis (osteoporotic group) and women with normal BMD (control 
group) that served as a control. The osteoporotic group included women who 
sustained either a vertebral fracture, clinical or radiological, or an non-
vertebral fracture defined as a fracture of the hip, wrist, or humerus, and a 
BMD T-score level ≤ -2.5 SD at the lumbar spine (LS), measured at their 4th 
visit at the center, which took place between January 2002 and July 2004. 
We chose LS BMD since it consists mostly of trabecular bone, which is con-
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sidered to be more metabolically active compared to cortical bone [8]. This 
group had also a highly significant reduced femoral neck BMD compared to 
the women that served as a control (Table 2). Fractures in the osteoporotic 
group had occurred between 1991 and 2001, excluding prevalent vertebral 
fractures at baseline. At the 4th visit, none of the participants had reported a 
new fracture. Details of the assessment of incident non-vertebral fractures 
and vertebral fractures have been described in detail previously [9]. For the 
control group we selected age- and years-since menopause-matched women 
who never experienced non-vertebral or vertebral fractures and with a LS 
BMD T-score between +1 and +2.5 SD as measured at the fourth visit be-
tween January 2002 and July 2004. Furthermore, their femoral neck BMD T-
score had to be above -1 SD. From this study, 171 potential participants were 
invited, of which 47% agreed to participate. We included 43 participants in 
the osteoporotic group and 29 in the control group. Reasons for potential 
participants not to participate varied from not being interested to not being 
able to come to the research facility due to deteriorating health. The Rotter-
dam Study design is approved by the Medical Ethics Committee and by the 
review committee of the Ministry of Health, Welfare and Sports. The approv-
al has been renewed every 5 years. The study design and rationale of the sub-
selection of the Rotterdam Study for the study described in this paper was 
approved by the Medical Ethics Committee (number NL20078.0780.07). 
Written informed consent was given by all participants.  
 
Intake and blood sampling 
Participants were invited for a single visit at the research centre between the 
4th of August and the 15th of October of 2008, where they underwent a short 
questionnaire, concerning their mobility, medical history, and smoking, and 
venous blood collection. Medication use was recorded and for 67 of the 72 
participants this could be verified with the participants’ general practitioner 
and pharmacy database (Medicom®). For 4 participants, data on medication 
use was lacking either due to the participant being absent in Medicom or not 
being able to inform us about medicine use. Data on nutritional supplement 
intake was recorded on basis of recollection. 7 ml of plasma and 30 ml of 
heparinized blood was collected from each participant for the measurement of 
plasma markers and collection of PBMCs for osteoclast cultures, respectively. 
All visits took place in the morning in order to isolate the PBMCs in the af-
ternoon. Between collection of blood and isolation of PBMCs the samples 
were stored at room temperature. 
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PBMC collection 
PBMCs from the participants were obtained from heparinized blood by Ficoll-
Hypaque (GE Healthcare Bio-Sciences AB, Uppsala, Sweden) density gradi-
ent centrifugation. In the afternoon after returning from the research centre, 
cells were resuspended in α-MEM culture medium (Gibco, Life Technologies, 
Breda, The Netherlands) supplemented with 100 units/ml penicillin, 100 
μg/ml streptomycin (Life Technologies, Breda, The Netherlands), 250 ng/ml 
amphotericin B (Sigma, St.Louis, MO, USA), 1.8 mM CaCl2 (Elitech Benelux, 
Spankeren, The Netherlands), and 15% (vol/vol) heat-inactivated fetal calf 
serum (FCS; Life Technologies). Cells were counted on a CASY TT cell coun-
ter (Innovatis AG, Reutlingen, Germany). From the total amount, 2 million 
cells were used for RNA isolation (time point 0; see below) and stored in Tri-
zol Reagent (Gibco BRL, Life Technologies) at –20ºC. The remainder of the 
cells was divided over 2 vials, frozen and stored in liquid nitrogen until fur-
ther use. 
 
PBMC cultures 
In order to minimize differences between culture conditions and handling the 
cells, the same two persons performed PBMC cultures of a maximum of 12 
randomly selected samples in the morning. Cells were thawed and taken up 
in α-MEM culture medium that was made in 1 batch to be used in all exper-
iments. To minimize inter-participant variability, PBMCs from 12 partici-
pants were cultured per day. 
The cells were counted and seeded in a density of 200,000 cells/well either on 
plastic or bovine cortical bone discs in 96-wells plates (Corning, # 3595). Per 
subject a minimum of 12 wells for Coommassie staining, 12 wells for RNA 
analyses and 8 to 16 wells for TRAP staining were used, depending on the 
total amount of cells available for culture. As mentioned above, cells from the 
participants were randomized over the plates.  
Following seeding, cells were incubated for 8 hours and then rinsed once with 
PBS to remove non-adherent cells. Next, culture medium was added contain-
ing 25 ng/ml human macrophage-colony stimulating factor (M-CSF; R&D 
Systems, Abingdone, UK). From day 4 onward, cells were cultured in the 
presence of both M-CSF and 30 ng/ml human receptor-activated NF-κB lig-
and (RANKL; PeproTech, London, UK). In order to minimize differences 
between test conditions medium and growth factors, the amounts of each 
product necessary for the experiment was calculated before the start of the 
culture experiment and were batched in advance to establish identical cul-
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ture conditions. Half of the media/well was refreshed twice a week until day 
21 of culture. 
 
TRAP staining assay 
At day 21 of culture, cells on plastic were fixed with 70% ethanol and stained, 
using a Tartrate Resistance Acid Phosphatase (TRAP) leucocyte kit (Sigma, 
St.Louis, MO, USA) as described previously by van der Eerden et al. [10]. Per 
well 5 photos were taken to limit the effect of unequal development of osteo-
clasts over the plate and to minimize variation between wells. The number of 
osteoclasts and nuclei per osteoclast were counted by an independent observ-
er who was blinded to the data concerning the experimental layout, using 
online available Image J software (https://imagej.nih.gov/ij/).  
 
Resorption pit assay 
In order to assess bone resorption, cells cultured on bovine cortical bone discs 
were stopped at day 21 and lysed with water. After this the discs were 
stained with filtered Coomassie brilliant blue (Phastgel Blue R; Amersham 
Pharmacia Biotech, Roosendaal, The Netherlands) for 5 seconds as described 
previously [10]. Bone resorption was quantified by measuring the mean re-
sorbed bone area, using Image J software, which was performed by an inde-
pendent observer, who was blinded towards the data. 
 
DPD assay 
Total Deoxypyridinoline (DPD) cross-links were determined in the plasma, 
taken at the single visit at the research centre, from all participants by per-
forming an ELISA (MicroVue total DPD, Quidel Corporation, San Diego, 
USA) according to the manufacturer’s protocol.  
 
RNA isolation, cDNA synthesis and Q-PCR  
Cells were collected direct after PBMC collection (time point 0, see above) 
and after 21 days of culture on bone discs. RNA isolation, cDNA synthesis 
and Q-PCR have been carried out as described before by Bruedigam et al. 
[11]. Oligonucleotide primer pairs, all being either on exon boundaries or 
spanning at least one intron, were purchased from Sigma-Aldrich (Table 1). 
Gene expression was normalized against GAPDH according to the equation 2-
∆Ct (∆Ct = Ct of gene of interest minus Ct of housekeeping gene). 
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Table 1: Primer sequences used 
Primers Forward primer (5’- 3’) Reverse primer (5’- 3’) 
GAPDH ATGGGGAAGGTGAAGGTCG TAAAAGCAGCCCTGGTGACC 
CTSK TGCCCACACTTTGCTGCCGA GCAGCAGAACCTTGAGCCCCC 
TM7SF4 AAGCAGCCGCTGGGAGAAGT TTTTCAGGACTGGAAGCCAGAAATGAA 
Statistics 
Spearman’s non-parametric bivariate correlation model was used for as-
sessing associations between variables. A One-Way Anova was used to test 
for group differences, and if homogeneity of variances could not be assumed, 
we performed the Welch test. Post-hoc test were included in the One-Way 
Anova analyses in order to assess associations between the type of fracture 
sustained and the observed variables that were not specified a priori. Statis-
tics were performed using the statistical program SPSS 19.  
 
 
Results 
Study group characteristics are shown in Table 2. Participants were on aver-
age 78.9 years old. For 17 controls and 31 osteoporotic participants data on 
age of menopause was known. Controls were on average 27.9 years after 
menopause and osteoporotic subjects were 30.8 years after menopause, which 
was not significantly different (data not shown). Age was not significantly 
different between the groups, but body height, weight, and BMI were signifi-
cantly lower in the osteoporotic group compared to the control group.  
In the osteoporotic group 20 subjects had sustained a clinical vertebral frac-
ture, 15 subjects sustained a non-vertebral fracture e.g. hip, wrist, or humer-
us, and 8 subjects had sustained both a vertebral fracture and a non-
vertebral fracture. 
 
Osteoclast formation and function is not different between osteopo-
rotic patients and controls 
When comparing participants with osteoporosis to controls we found no dif-
ferences in PBMC-derived osteoclast formation, the amount of single-, bi-, 
multi-nucleated, or total osteoclasts in vitro or in the mean resorbed bone 
area (Table 3 and Figure 1). The mRNA expression levels at day 21 of ca-
thepsin K (CTSK, an enzymatic bone resorption marker) and dendritic cell-
specific transmembrane protein (TM7SF4, a cell surface receptor important 
for the fusion of mononucleated osteoclasts) were not significantly different 
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between subjects with and without osteoporosis. Moreover, DPD, a plasma 
marker of bone resorption, was not significantly different between both 
groups. Additional adjustments for weight and BMI did not alter any of the 
results. 
 
Table 2: Baseline characteristics  
 Controls (CI) Osteoporosis (CI) P-value 
Number 29 43  
Age (years) 77.23 (75.32-79.12) 79.51 (78.00-81.02) 0.06 
Height (cm) 164.76 (160.59-164.85) 161.89 (157.75-160.95) 0.011 
Weight (kg) 78.00 (74.00-82.01) 64.36 (61.89-66.83) 3.46x10-9 * 
BMI (kg/m2) 29.60 (27.77-31.44) 25.41 (24.33-26.48) 6.00x10-5 
Lumbar spine BMD (g/cm2) 1.37 (1.35-1.39) 0.81 (0.79-0.83) 6.87x10-52 * 
Femoral neck BMD (g/cm2) 1.00 (0.96-1.03) 0.73 (0.70-0.77) 2.99X10-16 
*Welch test due to significant inhomogeneity of variances. Shown is mean with 95% 
confidence intervals between parentheses. 
 
 
Figure 1: No differences in PBMC-derived osteoclast differentiation and resorption 
between healthy and osteoportic subjects. Panel A and B represents TRAP stained oste-
oclasts from control subject (A) and from an osteoporotic subject (C). Panels B and D 
represent resorption pits stained with Coommassie Blue staining from a controls subject 
(B) and from and osteoporotic subject (D) (Magnification 100X). 
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Table 3: Osteoclast formation and resorption parameters 
 Controls (CI) Osteoporosis (CI) P-value 
Mononuclear osteoclasts (#) 14.30 (7.29-21.30) 12.31 (9.52-15.09) 0.54 
Binuclear osteoclasts (#) 5.44 (3.34-7.53) 8.58 (1.55-15.62) 0.47 
Multinuclear osteoclasts (#) 7.71 (3.68-11.75) 7.79 (4.57-11.00) 0.98 
Total number of osteoclasts (#) 27.44 (16.90-37.99) 28.66 (18.20-39.12) 0.87 
Mean resorption area (mm2) 0.011 (0.005-0.015) 0.012 (0.006-0.018) 0.77 
CTSK expression (rel. to GAPDH) 3.40 (2.48-4.32) 3.10 (2.00-4.21) 0.70 
TM7SF4 expression (rel. to GAPDH) 0.07 (0.04-0.10) 0.10 (0.07-0.13) 0.16a 
DPD (nmol/l) 10.99 (10.25-11.73) 10.86 (10.86-13.90) 0.94 
aWelch test due to significant inhomogeneity of variances. Shown is mean with 95% 
confidence intervals between parentheses. 
 
In the combined study population of osteoporotic participants and controls 
the osteoclast formation ability of the PBMCs in vitro was significantly corre-
lated with the mean resorbed bone area on the bone slices, with the highest 
correlation found for multinucleated TRAP positive cells (R = 0.56; p = 
4.1x10-8) (Table 4). The mRNA expression of CTSK and TM7SF4 in these 
cultures was significantly correlated with the osteoclast formation ability (R 
= 0.65, p = 3.9x10-11 and R = -0.63; p = 3.1x10-10, respectively) and mean re-
sorbed bone area (R = 0.75, p = 1.3x10-15 and R = -0.55; p = 1.4x10-7, respec-
tively). However, we found no correlation between plasma DPD and 
osteoclast formation, mean resorbed bone area (Table 4), and gene expression 
of CTSK and TM7SF4 (data not shown). Lumbar spine BMD and femoral 
neck BMD were not correlated with osteoclast formation ability, resorbed 
bone area, and CTSK and TM7SF4 gene expression. However, DPD was 
significantly and positively correlated with lumbar spine and femoral neck 
BMD in combined osteoporotic and control population (R = 0.52, p = 1.1x10-6 
and R = 0.49; p = 1.7x10-5, respectively) (Table 4). 
To assess whether there was a difference in osteoclast formation and function 
depending on DPD levels we stratified the osteoporotic group as well as the 
control group into high and low DPD levels based on the median value for 
that group. As shown in Table 5, osteoporotic subjects with a DPD level be-
low the median had significantly lower mean resorbed bone area and a signif-
icantly reduced number of osteoclasts compared to osteoporotic subjects with 
high DPD levels (mean resorbed bone area 0.020 versus 0.004, p = 0.009 and 
number of multiple nucleated osteoclast 11.94 versus 4.19, p = 0.017). This 
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remained significant after exclusion of the two subjects with very high DPD 
levels (data not shown). Stratification of controls above and below their me-
dian DPD level did not show any significant differences in osteoclast for-
mation ability, osteoclastic bone resorption ability or CTSK and TM7SF4 
mRNA expression levels. 
 
Table 4: Correlation coefficients (R) for the number of osteoclast, bone resorption area, 
gene expression, BMD and DPD for the combined osteoporotic and control group. 
 Multi-nucleated  osteoclasts (#) 
Mean resorption  
area (mm2) 
Lumbar spine  
BMD (g/cm2) 
Femoral neck  
BMD (g/cm2) 
 R P-value R P-value R P-value R P-value 
Multinucleated  
osteoclasts (#) - - 0.57 1.6.x10
-7 0.02 0.90 0.08 0.54 
Mean resorption  
area (mm2) 0.57 1.6x10
-7 - - 0.11 0.36 0.19 0.12 
CTSK expression 0.64 2.9x10-9 0.75 3.8x10-14 0.13 0.30 0.22 0.07 
TM7SF4 expression -0.61 1.1x10-8 -0.57 2.3x10-7 -0.11 0.34 -0.82 0.51 
DPD (nmol/l) 0.19 0.12 0.24 0.05 0.48 2.9x10-5 0.54 4.0x10-6 
Table 5: Study parameters, stratified according to DPD above and below the median in 
osteoporotic subjects and in controls 
 Osteoporotic group  Control group  
 DPD  > median  
DPD  
< median  
P- 
anova 
DPD  
> median  
DPD  
< median  
P- 
anova 
Number  
individuals 21 20  12 16  
Mononuclear 
 osteoclasts (#) 
14.77 
(10.32-19.21) 
10.63 
(6.94-14.31) 0.14 
17.22 
(9.26-25.18) 
12.10 
(5.21-19.00) 0.57 
Binuclear  
osteoclasts (#) 
14.51 
(0.03-28.99) 
3.14 
(1.51-4.78) 0.12
a 4.12 (-6.54-14.77) 
5.90 
(-3.32-15.13) 0.68 
Multinuclear  
osteoclasts (#) 
11.94 
(6.79-17.08) 
4.19 
(0.32-8.06) 0.017
a 7.40 1.31013.48) 
6.95 
(-1.68-12.22) 0.92 
Total number  
of osteoclasts (#) 
41.21 
(21.75-60.67) 
17.93 
(3.67-25.61) 0.028 
28.73 
(10.23-47.24) 
24.95 
(8.93-40.98) 0.87 
Mean resorption  
area (mm2) 
0.012 
(0.009-0.031) 
0.004 
(0.001-0.007) 0.009
a 0.009 (-0.001-0.019) 
0.012 
(0.004-0.021) 0.82 
CTSK  
expression 
3.99 
(2.10-5.88) 
2.36 
(0.99-3.73) 0.16 
3.51 
(1.63-5.38) 
3.29 
(1.67-4.92) 0.96 
TM7SF4  
expression 
0.06 
(0.04-0.10) 
0.13 
(0.07-0.19) 0.04
a 0.06 (0.00-0.11) 
0.08 
(0.04-0.13) 0.44 
aWelch test due to significant inhomogeneity of variances. Shown is mean with 95% 
confidence intervals between parentheses 
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Fracture type 
To evaluate whether there was an association between fracture type and 
osteoclast formation and resorption, we stratified the osteoporotic group 
according to different types of fractures (vertebral fractures, non-vertebral 
fractures, and a group of subjects with both vertebral and non-vertebral frac-
ture). These analyses did not reveal differences between the control group 
and any of the fracture groups (Table 6). Although the difference in total 
number of osteoclasts between controls and subjects with vertebral fractures 
was considerable, with controls having higher values, it was not statistically 
significant.  
 
Table 6: Study parameters, stratified according to fracture type 
 
Control Vertebral fractures 
Non-vertebral 
fractures 
Vertebral and 
non-vertebral 
fractures 
P-value 
(anova) 
 29 15 20 8  
Mononuclear  
osteoclasts (#) 
14.30 
(7.29-21.30) 
10.88 
(7.16-14.60) 
13.19 
(8.58-17.81) 
12.76 
(3.25-22.27) 0.89 
Binuclear  
osteoclasts (#) 
5.44 
(3.34-7.53) 
2.71 
(1.26-4.16) 
12.17 
(-2.56-26.89) 
10.64 
(-4.20-25.48) 0.39 
Multinuclear  
osteoclasts (#) 
7.71 
(3.68-11.75) 
3.80 
(0.52-7.08) 
11.19 
(5.33-17.06) 
6.75 
(-1.24-14.74) 0.22 * 
Total number  
of osteoclasts (#) 
27.44 
(16.90-37.99) 
17.39 
(10.11-26.66) 
36.52 
(15.81-57.23) 
30.15 
(6.22-54.08) 0.36 *
 
Mean resorption  
area (mm2) 
0.011 
(0.005-0.015) 
0.008 
(0.000-0.017) 
0.014 
(0.000-0.024) 
0.014 
(0.000-0.028) 0.73 
CTSK  
expression 
3.40 
(2.48-4.32) 
2.08 
(1.13-3.04) 
3.25 
(1.72-4.78) 
4.66 
(-0.45-9.78)) 0.30 * 
TM7SF4  
expression 
0.07 
(0.04-0.10) 
0.11 
(0.051-0.160) 
0.08 
(0.032-0.119) 
0.15 
(0.021-0.270) 0.18 * 
DPD (nmol/l) 10.99 (10.25-11.73) 
8.68 
(8.08-9.28) 
13.31 
(6.62-19.99) 
8.85 
(7.61-10.09) 0.003 *
 
*Welch test due to significant inhomogeneity of variances. Shown is mean with 95% 
confidence intervals between parentheses. 
 
Influence of potentially confounding medication 
In order to exclude possible influence of bisphosphonate use in this study we 
performed additional analyses in a subgroup of participants who never used 
bisphosphonates. From all 72 participants we could retrieve whether they 
had been given prescriptions of bisphosphonates. From 68 out of these 72 we 
had data on current bisphosphonate use. One person stopped taking bisphos-
phonates 2 weeks prior to the blood sampling and was therefore scored as a 
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bisphosphonate user. The data lacking with regard to current bisphospho-
nate use concerned 3 participants in the control group and 1 participant in 
the osteoporosis group. In the osteoporotic group, 14 participants had never 
used and 12 had stopped using bisphosphonates more than 8 months prior to 
the sample extraction. A total of 26 participants in the osteoporotic group 
were not on any bisphosphonate prescription around the time of participa-
tion. None of the control subjects used bisphosphonates when participating in 
this study. One control subject had been prescribed bisphosphonates until 
two years before participating, due to glucocorticoid use.  
No significant difference between the osteoporotic and control group was 
detected concerning number of TRAP positive single, bi-nucleated, or multi-
nucleated cells, mean resorbed bone area and CTSK and TM7SF4 expression 
after exclusion of ever-users of bisphosphonates (data not shown). Further-
more, serum DPD levels did not differ significantly between the osteoporotic 
and the control group either after additional adjustment for bisphosphonate 
use or after exclusion of users of bisphosphonates (data not shown). 
 
 
Discussion 
The current study demonstrates no difference in osteoclastogenic potential 
from circulating precursors in women with and without osteoporosis 29.5 
years after cessation of regular menses. In ex vivo osteoclastogenic cultures of 
PBMCs no differences in osteoclast formation and bone resorption activity 
was observed. A possible explanation might be the age of the participants at 
the time of inclusion in the study. It is known that there is an accelerated 
bone loss shortly after menopause that is mainly due to decreased estrogen 
levels leading to uncoupling of bone formation and bone resorption [12]. 
Sometime after this initial phase, osteoclast activity may slow down to be-
come undistinguishable from healthy controls. 
Two smaller studies on in vitro osteoclastogenesis and osteoclastic bone re-
sorption found similar results. The first was performed in 2003 by Jevon et 
al. whom found no differences in TRAP-positive cells and bone resorption 
between 11 osteoporotic participants and 12 controls [5]. In agreement with 
this, D’ Amelio et al. did not observe differences in osteoclastogenesis and 
bone resorption when comparing 18 postmenopausal osteoporotic women 
with 15 healthy controls after stimulation of PBMCs with M-CSF and 
RANKL [4]. Unfortunately, both studies lack data on participant characteris-
tics concerning age, height and weight, and years since menopause. Fur-
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thermore, they selected the participants on basis of their T-score in contrast 
to our study where we selected on basis of the presence of at least one non-
vertebral or vertebral fracture in addition to a low T-score. Our study has 
been conducted in a population of elderly women who have been extensively 
followed and from whom a detailed history on fractures exists.  
We sampled at an average age of 78.7 years and therefore potential differ-
ences in the marked increased postmenopausal osteoclastogenesis as the 
result of rapid decrease in estrogen levels may have been missed. Supporting 
this theory is the observation that the bone turnover marker DPD was not 
significantly different between controls and osteoporotic subjects. However, 
given the fact that low estrogen levels persist at older age despite the ob-
served absence of increased bone turnover markers in this study, fracture 
risk may not be associated with increased bone turnover, since fracture risk 
increases with age, well after the onset of menopause [2]. Moreover we 
showed that DPD was significantly positively correlated with lumbar spine 
BMD and femoral neck BMD. Nevertheless, in a longitudinal study on bone 
turnover markers and the risk of fracture in 75-year-old women it was found 
that elevated bone resorption markers CTX and S-TRACP5b were associated 
with fracture risk [13]. In contrast to our observation of osteoporotic subjects 
having similar DPD levels as their age-matched controls without osteoporo-
sis, Garnero showed that bone resorption markers remain elevated even in 
late menopause up to 40 years after menopause [14]. However, other studies 
have suggested that increased bone turnover in late menopause as measured 
by bone resorption markers was due to vitamin D deficiency and/or hy-
pocalcaemia or secondary hyperparathyroidism [15-17]. Unfortunately, we 
did not have data on calcium, vitamin D, or PTH levels, during sampling so 
we could not investigate whether these values were normal in our subjects.  
We found an opposite correlation of TM7SF4 and CTSK gene expression with 
osteoclast formation and resorbed bone area, being negative and positive, 
respectively. Both correlations can be explained when considering the func-
tion of TM7SF4 and CTSK. TM7SF4 is necessary for cell fusion and multinu-
cleation of mononuclear osteoclasts [18]. Hence, reduced expression in 
combination with increased resorbed bone area is indicative for fully matured 
osteoclasts that have developed beyond the stage of fusion. CTSK is a lyso-
somal cysteine protease, and catabolizes elastin, collagen and gelatin, which 
is necessary for osteoclasts to resorb the organic fraction of bone [19]. Indeed, 
the positive correlation implicates that mature, resorbing osteoclasts are 
associated with higher CTSK expression. These findings suggest that our 
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culture system is a valid tool to correlate human osteoclast function with 
gene expression. 
Considering the culture system used, several discrepancies were noted com-
pared to other studies, where PBMCs were used for the generation of osteo-
clasts. First of all, we used PBMCs whereas other studies have used CD14+ 
cells for the generation of osteoclasts [20]. Furthermore, one can argue about 
the addition of M-CSF and RANKL in these PBMC cultures. The study by 
d’Amelio et al. showed enhanced PBMC-derived osteoclastogenesis in osteo-
porotic patients compared to controls without using M-CSF and RANKL, but 
as expected, in this study the overall numbers of osteoclasts and the amount 
of resorption for both groups were much lower compared to when M-CSF and 
RANKL were administered [4]. We cannot exclude other potential reasons for 
our results and those by others such as the assay itself and the fact that 
circulating precursors may not be different in their activation state, but po-
tentially in situ at local sites e.g. around recent fractures they may be. To 
date, a standard curve of osteoclastogenic potential and capacity does not 
exist, but if there are means to develop an alternative way to assess the oste-
oclastogenic capacity in an easy and robust manner, it would constitute an 
interesting and applicable approach.  
Stratification of osteoporotic subjects into those with high and low DPD lev-
els showed differences in in vitro osteoclastogenesis and osteoclastic bone 
resorption. The subjects with lower DPD levels might reflect a late stage of 
osteoporosis with lower bone metabolic activity as is the case in senile osteo-
porosis [21] or osteoporosis with more uncoupling of bone formation and re-
sorption. Unfortunately we had no availability of markers of bone formation 
to support this theory. It could be that osteoporosis patients with high PBMC 
osteoclastogenesis and DPD levels above the median represent a group with 
higher risk of fracture compared to the osteoporosis patients with DPD levels 
below the median. Considering the fact that the drug of first choice in the 
treatment of osteoporosis is the administration of anti-resorptive therapy, 
one can argue whether giving anti-resorptive therapy in the subgroup of 
patients with low bone resorption would be the most beneficial form of thera-
py or that an anabolic agent would be more effective in reducing fracture risk 
in this particular subgroup.  
 
Fractures and bisphosphonate use 
To our knowledge, this is the first study to assess fracture type in osteoporot-
ic patients in relation to in vitro osteoclast formation and bone resorption. We 
only found DPD levels to be significantly lower in persons with vertebral 
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fractures and with vertebral and osteoporotic fractures compared to the 
healthy controls, which could not be attributed to bisphosphonate use. In a 
previous study conducted by d’Amelio et al. the influence of risedronate in-
take on in vitro osteoclastogenesis and osteoclast activity from human 
PBMCs was studied. They found a 68% reduction of osteoclast formation and 
activity with risedronate treatment but not following calcium and vitamin D 
administration [23]. A study conducted to assess the effect of alendronate on 
BMD and bone turnover markers showed that after discontinuation of alen-
dronate, a gradual decline in BMD of about 3% was observed and a gradual 
rise in bone turnover markers over 5 years to levels still slightly below pre-
treatment levels [24]. In our study, we found no difference in osteoclastogen-
esis, osteoclastic bone resorption and DPD serum markers between the oste-
oporotic and the control group, even after the exclusion of bisphosphonate 
users, but numbers of individuals might be limited to detect small differ-
ences.  
 
In conclusion, in this study no differences in PBMC-derived osteoclastogene-
sis and osteoclastic bone resorption were observed between elderly women 
with osteoporosis and healthy controls, suggesting that there is no difference 
in circulating osteoclast precursors. Although we cannot exclude that circu-
lating precursors may behave differently at the bone site, it is conceivable 
that long after menopause a more stable phase of bone turnover is reached 
compared to shortly following the initiation of menopause in which differ-
ences in circulating osteoclast precursors and osteoclastogenic potential are 
more prominent. To gain more insight in osteoclastogenesis and lacunar bone 
resorption in osteoporosis, we suggest obtaining PBMCs from women shortly 
after menopause, when bone resorption activity is high due to rapidly declin-
ing estrogen levels. Finally, large prospective data and a more robust assay 
would be needed to evaluate whether the assessment of osteoclastogenesis 
and bone resorption in vitro will aid to the identification of subjects who are 
at higher risk for future fracture and thus in a better selection of those who 
may benefit most from a treatment with anti-resorptive therapy. 
  
147
References  
[1] G.A. Poos MJJC, Prevalentie en incidentie naar leeftijd en geslacht. 
<http://www.nationaalkompas.nl/gezondheid-en-ziekte/ziekten-en-
aandoeningen/bewegingsstelsel-en-bindweefsel/osteoporose/prevalentie-en-
incidentie-naar-leeftijd-en-geslacht/>, 2009). 
[2] M. Van der Klift, C.E. De Laet, E.V. McCloskey, A. Hofman, H.A. Pols, 
The incidence of vertebral fractures in men and women: the Rotterdam 
Study, J Bone Miner Res 17(6) (2002) 1051-6. 
[3] A. Agrawal, J.A. Gallagher, A. Gartland, Human osteoclast culture and 
phenotypic characterization, Methods Mol Biol 806 (2012) 357-75. 
[4] P. D'Amelio, A. Grimaldi, G.P. Pescarmona, C. Tamone, I. Roato, G. Isaia, 
Spontaneous osteoclast formation from peripheral blood mononuclear cells in 
postmenopausal osteoporosis, FASEB J 19(3) (2005) 410-2. 
[5] M. Jevon, T. Hirayama, M.A. Brown, J.A. Wass, A. Sabokbar, S. Ostelere, 
N.A. Athenasou, Osteoclast formation from circulating precursors in 
osteoporosis, Scand J Rheumatol 32(2) (2003) 95-100. 
[6] J.C. Underwood, R.A. Melick, R.S. Loomes, V.M. Dangerfield, A. 
Crawford, L. Coulton, P.M. Ingleton, T.J. Martin, Structural and functional 
correlations in parathyroid hormone responsive transplantable osteogenic 
sarcomas, Eur J Cancer 15(9) (1979) 1151-8. 
[7] A. Hofman, G.G. Brusselle, S. Darwish Murad, C.M. van Duijn, O.H. 
Franco, A. Goedegebure, M.A. Ikram, C.C. Klaver, T.E. Nijsten, R.P. Peeters, 
B.H. Stricker, H.W. Tiemeier, A.G. Uitterlinden, M.W. Vernooij, The 
Rotterdam Study: 2016 objectives and design update, Eur J Epidemiol 30(8) 
(2015) 661-708. 
[8] X. Feng, J.M. McDonald, Disorders of bone remodeling, Annu Rev Pathol 
6 (2011) 121-45. 
[9] L. Stolk, J.B. van Meurs, P.P. Arp, A. Hofman, H.A. Pols, A.G. 
Uitterlinden, The RIZ Pro704 insertion-deletion polymorphism, bone mineral 
density and fracture risk: the Rotterdam study, Bone 42(2) (2008) 286-93. 
[10] B.C. van der Eerden, J.G. Hoenderop, T.J. de Vries, T. Schoenmaker, 
C.J. Buurman, A.G. Uitterlinden, H.A. Pols, R.J. Bindels, J.P. van Leeuwen, 
The epithelial Ca2+ channel TRPV5 is essential for proper osteoclastic bone 
resorption, Proc Natl Acad Sci U S A 102(48) (2005) 17507-12. 
[11] C. Bruedigam, M. Koedam, H. Chiba, M. Eijken, J.P. van Leeuwen, 
Evidence for multiple peroxisome proliferator-activated receptor gamma 
transcripts in bone: fine-tuning by hormonal regulation and mRNA stability, 
FEBS Lett 582(11) (2008) 1618-24. 
148
[12] S. Khosla, L.J. Melton, 3rd, B.L. Riggs, The unitary model for estrogen 
deficiency and the pathogenesis of osteoporosis: is a revision needed?, J Bone 
Miner Res 26(3) (2011) 441-51. 
[13] K.K. Ivaska, P. Gerdhem, H.K. Vaananen, K. Akesson, K.J. Obrant, 
Bone turnover markers and prediction of fracture: a prospective follow-up 
study of 1040 elderly women for a mean of 9 years, J Bone Miner Res 25(2) 
(2010) 393-403. 
[14] P. Garnero, E. Sornay-Rendu, M.C. Chapuy, P.D. Delmas, Increased 
bone turnover in late postmenopausal women is a major determinant of 
osteoporosis, Journal of bone and mineral research : the official journal of the 
American Society for Bone and Mineral Research 11(3) (1996) 337-49. 
[15] P. Mezquita-Raya, M. Munoz-Torres, J.D. Luna, V. Luna, F. Lopez-
Rodriguez, E. Torres-Vela, F. Escobar-Jimenez, Relation between vitamin D 
insufficiency, bone density, and bone metabolism in healthy postmenopausal 
women, J Bone Miner Res 16(8) (2001) 1408-15. 
[16] S.S. Harris, E. Soteriades, B. Dawson-Hughes, S. Framingham Heart, S. 
Boston Low-Income Elderly Osteoporosis, Secondary hyperparathyroidism 
and bone turnover in elderly blacks and whites, J Clin Endocrinol Metab 
86(8) (2001) 3801-4. 
[17] P.N. Sambrook, J.S. Chen, L.M. March, I.D. Cameron, R.G. Cumming, 
S.R. Lord, J. Schwarz, M.J. Seibel, Serum parathyroid hormone is associated 
with increased mortality independent of 25-hydroxy vitamin d status, bone 
mass, and renal function in the frail and very old: a cohort study, J Clin 
Endocrinol Metab 89(11) (2004) 5477-81. 
[18] C. Zhang, C.E. Dou, J. Xu, S. Dong, DC-STAMP, the key fusion-mediating 
molecule in osteoclastogenesis, J Cell Physiol 229(10) (2014) 1330-5. 
[19] Q. Zhao, Y. Jia, Y. Xiao, Cathepsin K: a therapeutic target for bone 
diseases, Biochem Biophys Res Commun 380(4) (2009) 721-3. 
[20] F. Hemingway, X. Cheng, H.J. Knowles, F.M. Estrada, S. Gordon, N.A. 
Athanasou, In vitro generation of mature human osteoclasts, Calcif Tissue 
Int 89(5) (2011) 389-95. 
[21] B.L. Riggs, L.J. Melton, 3rd, Involutional osteoporosis, N Engl J Med 
314(26) (1986) 1676-86. 
[22] P.L. van Daele, M.J. Seibel, H. Burger, A. Hofman, D.E. Grobbee, J.P. 
van Leeuwen, J.C. Birkenhager, H.A. Pols, Case-control analysis of bone 
resorption markers, disability, and hip fracture risk: the Rotterdam study, 
Bmj 312(7029) (1996) 482-3. 
149
[23] P. D'Amelio, A. Grimaldi, S. Di Bella, C. Tamone, S.Z. Brianza, M.G. 
Ravazzoli, P. Bernabei, M.A. Cristofaro, G.P. Pescarmona, G. Isaia, 
Risedronate reduces osteoclast precursors and cytokine production in 
postmenopausal osteoporotic women, J Bone Miner Res 23(3) (2008) 373-9. 
[24] D.M. Black, A.V. Schwartz, K.E. Ensrud, J.A. Cauley, S. Levis, S.A. 
Quandt, S. Satterfield, R.B. Wallace, D.C. Bauer, L. Palermo, L.E. Wehren, 
A. Lombardi, A.C. Santora, S.R. Cummings, Effects of continuing or stopping 
alendronate after 5 years of treatment: the Fracture Intervention Trial Long-
term Extension (FLEX): a randomized trial, JAMA 296(24) (2006) 2927-38. 
 
150

 Chapter 8 
Lifelong challenge of calcium homeostasis in 
male mice lacking TRPV5 leads to 
changes in bone and calcium metabolism 
Bram C.J. van der Eerden1*, W. Nadia H. Koek1*, Paul Roschger2, M. Carola 
Zillikens1, Jan H. Waarsing3, Annemiete van der Kemp4, Marijke Schreuders-
Koedam1, Nadja Fratzl-Zelman2, Pieter J.M. Leenen5, Joost G.J. Hoenderop4, 
Klaus Klaushofer2, René J.M. Bindels4 and Johannes P.T.M. van Leeuwen1 
1Department of Internal Medicine, 3Department of Orthopedics and 
5Department of Immunology, Erasmus MC, Rotterdam, the Netherlands 
2Ludwig Boltzman Institute of Osteology at Hanusch Hospital of 
WGKK and AUVA Trauma Centre Meidling, 4th Medical Department, 
Hanusch Hospital, Vienna, Austria 
4Department of Physiology, Nijmegen Centre for Molecular Life Sciences, 
Radboud University Nijmegen Medical Centre, the Netherlands 
* These authors contributed equally to this paper 
Oncotarget. 2016 May 3;7(18):24928-41 
  
  
Abstract 
Background: Trpv5 plays an important role in calcium (Ca2+) homeostasis, 
among others by mediating renal calcium reabsorption. Accordingly, Trpv5 
deficiency strongly stresses calcium (Ca2+) homeostasis in order to maintain 
stable serum Ca2+. Previous studies have shown that Trpv5-/- mice display 
vitamin D resistance with aging at the level of the kidneys and intestines 
with hypercalciuria. Therefore, we addressed the impact of lifelong challenge 
of calcium homeostasis on the bone phenotype of these mice. 
Material and methods: Trpv5+/+ and Trpv5-/- male mice were studied at 10, 
52 and 78 weeks of age. Serum Ca2+, PTH and vitamin D were assessed to 
evaluate homeostasis. Femurs were studied for microarchitecture, degree of 
mineralization and frailty by means of microcomputed tomography, quantita-
tive backscattered electron imaging and 3-point-bending. Osteoclast for-
mation and function were assessed ex vivo. Osteoclast precursors were 
evaluated by flowcytometric analysis. 
Results: Aging significantly increased serum 1,25(OH)2D3 and PTH levels in 
both genotypes but they were more elevated in Trpv5-/- mice, whereas serum 
Ca2+ was not affected by age or genotype. Age-related changes in trabecular 
and cortical bone mass were accelerated in Trpv5-/- mice, including reduced 
trabecular and cortical bone thickness as well as reduced bone mineraliza-
tion. No effect of Trpv5 deficiency on bone strength was observed. In 78-
week-old mice no differences were observed between the genotypes regarding 
urinary deoxypyridinoline, osteoclast number, differentiation and activity. 
Conclusion: Life-long challenge of Ca2+ homeostasis as present in Trpv5-/- 
mice causes accelerated bone aging and a low cortical and trabecular bone 
mass phenotype. The phenotype of the Trpv5-/- mice suggests that mainte-
nance of adequate circulatory Ca2+ levels in patients with disturbances in 
Ca2+ homeostasis should be a priority in order to prevent bone loss at older 
age. The Trpv5-deficient mouse appears to be a suitable model for lifelong 
challenge of calcium homeostasis and its consequences for bone metabolism. 
 
 
Introduction 
Maintenance of adequate Ca2+ levels is of crucial importance for many physi-
ological processes in the body including neuronal excitability, muscle contrac-
tion and bone formation. Bone is the major site of Ca2+ storage in the body, 
and formation and mineralization by osteoblasts as well as osteoclastic bone 
resorption, contribute to the maintenance of Ca2+ equilibrium in the circula-
tion. Serum Ca2+ is tightly regulated through the concerted interactions of 
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kidneys, intestines and bone. Transcellular Ca2+ (re)absorption is an im-
portant process in maintaining Ca2+ balance by these tissues [1, 2].  
Previously, we published on the phenotype of mice lacking the epithelial Ca2+ 
channel Trpv5 (Trpv5-/-) [3]. TRPV5 is a Ca2+-selective transient receptor 
potential channel that is expressed in renal epithelial cells and crucial for 
reabsorption of calcium. In Trpv5-/- mice, besides hypercalciuria, intestinal 
Ca2+ hyperabsorption takes place by upregulation of the close homolog of 
Trpv5, Trpv6. This process is impaired when 1,25(OH)2D3 bioactivity is dis-
turbed as shown in double knockout mice for TRPV5 and 1α-hydroxylase 
(synthesizes 1,25(OH)2D3) and by treatment of Trpv5-/- mice with a vitamin 
D receptor antagonist, ZK191784 [4, 5].  
A detailed study on bone in these mice revealed that Trpv5 has a direct role 
in bone [6]. Trpv5-/- mice display an aberrant bone phenotype, including 
reduced cortical and trabecular bone thickness. Within bone, TRPV5 appears 
to be expressed by osteoclasts exclusively at the site where bone resorption 
takes place. Despite enhanced osteoclastogenesis, both in vivo and in vitro, 
bone resorption is seriously disturbed in mice lacking Trpv5, indicating that 
TRPV5 is required for proper osteoclast function.  
It is known that increasing age is accompanied by changes in Ca2+ homeosta-
sis, including reduced Ca2+ absorption from the diet, reduced vitamin D 
availability, which predisposes older persons to disorders related to Ca2+ 
homeostasis, particularly secondary hyperparathyroidism and osteoporosis 
[7, 8]. In addition, the capacity of 1,25(OH)2D3 to stimulate intestinal Ca2+ 
absorption declines with age, whereas circulating levels of PTH rise with age 
in rats and humans [9, 10]. Moreover, age-related increase in PTH levels may 
play an important role in changes in bone remodeling. Bone loss occurs uni-
versally with aging, leading to a reduction in bone mass and strength even-
tually leading to bone fragility and increased risk of osteoporotic fractures in 
the elderly [7, 11]. 
We previously demonstrated that compared to wildtype (Trpv5+/+) mice, both 
renal Ca2+ reabsorption and intestinal Ca2+ absorption were reduced during 
aging in Trpv5-/- mice, of which the latter was associated with Trpv6 expres-
sion [12]. Moreover, elevated vitamin D receptor protein levels observed in 
the intestine in older mice are indicative for vitamin D resistance.  
In this study we aimed to investigate the bone phenotype of aging Trpv5+/+ 
and Trpv5-/- mice by detailed analyses of serum and urine parameters related 
to calcium homeostasis and bone resorption, bone microarchitecture, mineral-
ization and strength in vivo. Moreover, bone marrow cultures from long 
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bones were performed to assess osteoblast and osteoclast differentiation in 
78-week-old Trpv5+/+ and Trpv5-/- mice. Finally, the impact of aging on calci-
um homeostasis and bone-related gene expression was examined in femurs 
and bone marrow cultures from both genotypes. 
 
 
Results  
Serum 1,25(OH)2D3 and PTH are age-dependently elevated in Trpv5-/- mice 
No difference in serum Ca2+ levels were observed between Trpv5+/+ and 
Trpv5-/- mice at all three ages (Table 1). Serum Ca2+ in the oldest age group 
(78 weeks) was measured with a different calcium assay, which hampers 
direct comparison between the younger 2 age cohorts with the 78-week-old 
mice. 
  
Table 1: Serum and urine measurements in Trpv5+/+ and Trpv5-/- mice during aging 
 10 weeks 52 weeks 78 weeks 
 Trpv5+/+ Trpv5-/- Trpv5+/+ Trpv5-/- Trpv5+/+ Trpv5-/- 
 mean ± sem 
mean 
± sem 
mean 
± sem 
mean 
± sem 
mean 
± sem 
mean 
± sem 
Serum       
Calcium (mmol/l) * # 2.76 ± 0.02 
2.84 
± 0.02 
2.71 
± 0.04 
2.79 
± 0.04 
2.02 
± 0.27 
1.70 
± 0.29 
1,25(OH)2D3 (pmol/l) 
121 
± 24 
686 
± 77 b 
542 
± 41 
518 
± 108 
474 
± 50 c 
1321 
± 133 b,d 
Parathyroid hormone (pg/ml) # 9.9 ± 1.9 
22.6 
± 6.0 
30.7 
± 6.2 
100 
± 20.6 a 
84.8 
± 21.9 c 
60.2 
± 18.1 
a p<0.05 vs Trpv5+/+ mice of same age, b p<0.001 vs Trpv5+/+ mice of same age. c P<0.05 
for age trend in Trpv5+/+ mice. d p<0.05 for age trend in Trpv5-/- mice.  
*Levels at 78 weeks of age were measured by different assay compared to 10 and 52 
weeks 
#Published previously by Abel et al.[1]  
1. van Abel, M., et al., Age-dependent alterations in Ca2+ homeostasis: role of TRPV5 
and TRPV6. Am J Physiol Renal Physiol, 2006. 291(6): p. F1177-83. 
 
However, using the same assay, previous measurements in an aging cohort of 
wild type mice up to 2 years of age yielded similar Ca2+ levels compared to 
the 78-week-old mice in this study (Supplementary table 2). In Trpv5+/+ mice, 
1,25(OH)2D3 (pmol/l) and PTH (pg/ml) levels increased significantly with 
aging (Figure 1 and Table 1). In Trpv5-/- mice a similar age-related increase 
in serum 1,25(OH)2D3 was observed but serum 1,25(OH)2D3 levels were sig-
nificantly higher in Trpv5-/- compared to their Trpv5+/+ littermates at 10 and 
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78 weeks of age. PTH level in Trpv5-/- mice increased with age but was only 
significantly higher at 52 weeks age compared to Trpv5+/+ mice. In 10-week-
old Trpv5-/- mice, both PTH and 1,25(OH)2D3 were at a level that is not 
reached before 52 weeks of age in Trpv5+/+ littermates (Figure 1 and Table 1).  
 
Trabecular and cortical bone mass are reduced in TRPV5-/- mice 
In Trpv5+/+ mice, trabecular bone thickness (Figure 2A), trabecular spacing 
and structure model index (SMI) were increased in older mice, whereas tra-
becular number and connectivity density demonstrated an age-related de-
cline (Supplementary table 3). Trpv5-/- mice showed similar age-related 
changes as Trpv5+/+ mice in the trabecular compartment although their tra-
becular bone thickness increased less pronounced during aging resulting in 
significantly lower bone mass in 52- and 78-week-old mice compared to their 
Trpv5+/+ littermates (Figure 2A). 
 
Figure 1
 
 
Figure 1: TRPV5 deficiency leads to elevated serum 1,25(OH)2D3 and PTH levels  
Depicted is an illustration of temporal changes in serum levels of hormones involved in 
calcium homeostasis. Based on the measured serum calcium levels in the 10 and 52-
week old animals and calcium measured of 78-week-old male mice in this and a previ-
ous study, we have depicted calcium to be constant irrespective of age and genotype 
(black dotted line, not representing an actual value). Both 1,25(OH)2D3 (triangle sym-
bols) and PTH (round symbols) levels are elevated in 10-week-old Trpv5-/- (open sym-
bols) compared to Trpv5+/+ mice (closed symbols). In fact, the serum levels for both 
hormones in 10-week-old TRPV5 deficient mice are similar to those in 52-week-old 
Trpv5+/+ mice. The data presented are not longitudinal and hence should not be pre-
sented as a line graph but they serve solely as an illustration for temporal serum chang-
es in mice lacking Trpv5. We emphasized this by disconnecting the lines from the actual 
measurements.  
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Within the cortical bone compartment, an age-related decrease in cortical 
thickness (Figure 2B) was seen in Trpv5+/+ mice, while a stable cortical bone 
volume was maintained throughout life. Consistent with these findings, we 
found the endocortical volume (i.e. marrow cavity volume) to be increased 
with aging (Figure 2C-D). TRPV5 deficiency led to similar age-related chang-
es, but cortical thickness (Figure 2B) and cortical volume (Supplementary 
table 3) were reduced at all ages compared to the Trpv5+/+ mice. At 78 weeks 
of age, both endocortical volume and cortical porosity were significantly 
greater in the Trpv5-/- mice compared to their non-deficient littermates (Fig-
ures 2C and 2D, respectively). Other cortical parameters, such as moment of 
inertia and perimeter also increased during aging but they were not different 
between the genotypes (Supplementary table 3). 
 
Mineralization of the trabecular structure is reduced in Trpv5-/- mice 
Tibial quantitative backscattered electron (qBEI) imaging showed in trabecu-
lar bone an age-related increase in the average and most abundant minerali-
zation densities (CaMean and CaPeak, respectively) and an age-related 
reduction in the areas undergoing primary mineralization (CaLow) in 
wildtype mice (Figures 3A, B and D). The heterogeneity of mineralization 
(CaWidth) did not alter during aging in Trpv5+/+ mice (Figure 3C). Trpv5-/- 
mice demonstrated age-related changes for all qBEI parameters measured 
being positively correlated with age for CaMean, CaPeak and CaWidth (Fig-
ures 3A, B and C, respectively), whereas CaLow was negatively correlated 
(Figure 3D). Both CaMean and CaPeak were reduced in the younger Trpv5-/- 
mice, being significant at 52 weeks and 10 weeks of age versus Trpv5+/+ mice, 
respectively (Figures 3A and 3B, respectively). In the metaphyseal cortical 
bone, all parameters changed with age in both genotypes (Supplementary 
table 4). In contrast to the trabecular data, in cortical bone no difference for 
any of the parameters at any age was observed between the genotypes (Sup-
plementary table 4). Both in Trpv5+/+ and Trpv5-/- mice, cortical CaMean, 
CaPeak and CaWidth increased with age, whereas CaLow was negatively 
correlated (Supplementary table 4). In the cortices of both genotypes osteo-
cyte lacunae number and size were assessed. No difference was found for both 
parameters when corrected for cortical bone area (Supplementary figure 1). 
 
Bone resorption in Trpv5+/+ and Trpv5-/- bones during aging 
Bone resorption as assessed by urinary DPD was similar between the 
Trpv5+/+ mice age groups (Figure 4A). In contrast, Trpv5-/- mice demonstrat-
ed an age-related increase in DPD levels. At 10 and 52 weeks of age, Trpv5-/- 
158
mice had significantly lower DPD levels compared to Trpv5+/+ mice but at 78 
weeks of age, these were similar in both genotypes (Figure 4A). Osteoclast 
numbers and surface in femoral bone sections of 78-week-old were reduced in 
Trpv5-/- mice but this did not reach statistical significance (Figures 4B and 
4C, respectively). In bone marrow cultures derived from 78-week-old mice, 
osteoclast numbers generated from Trpv5-/- precursor cells were significantly 
lower (Figure 4D), but this caused no difference in in vitro bone resorption 
(Figures 4E). Frequencies of bone marrow populations containing osteoclast 
precursors (i.e. immature blasts, myeloid blasts, and monocytes [13] as eval-
uated by flowcytometry were not different between Trpv5+/+ and Trpv5-/- 
mice (Supplementary table 5). The only different cell population in the bone 
marrow pool was the lymphoid precursor cells, which were significantly lower 
in the Trpv5-/- mice at 78 weeks. 
 
Trpv5 deficiency does not affect bone strength 
Three-point-bending tests were performed on a subset of femurs from male 
78-week-old Trpv5+/+ and Trpv5-/- mice. There were no differences in maxi-
mum load, stiffness or energy of the femurs between the genotypes (Supple-
mentary figures 2A-C). Moreover, Young’s modulus, a measure for elasticity 
of the bone, was unaffected (Supplementary figure 2D).  
 
Old Trpv5-/- and Trpv5+/+ mice show differences in femoral gene ex-
pression patterns 
Next, we generated femoral bone gene expression profiles for both genotypes 
at 10, 52 and 78 weeks of age by focusing at genes involved in calcium 
transport and homeostasis, osteoclast function, bone metabolism and phos-
phate homeostasis.  Calcium transport and homeostasis: Trpv6 mRNA ex-
pression in femurs of Trpv5+/+ mice was lower in the 78-week-old animals 
compared to younger age groups, though not significant (Figure 5A). Calcium 
sensing receptor (Casr) and vitamin D receptor (Vdr) mRNA expression were 
negatively and positively correlated with age in Trpv5+/+ mice, respectively 
(Figure 5B and C, respectively). Other genes involved in transcellular Ca2+ 
transport, i.e. calbindin-D9K (S100g), sodium/calcium exchanger 1 (Ncx1) and 
plasma membrane calcium ATPase 1 (Atp2b1) did not change during aging of 
Trpv5+/+ mice (Supplementary table 6). Comparing Trpv5-/- and Trpv5+/+ 
mice, no significant differences were observed for any of the genes related to 
calcium homeostasis at any time point. Besides reduced Vdr expression at 52 
and 78 weeks of age (Figure 5C) and increased Ncx1 expression at 78 weeks 
of age (Supplementary table 6). 
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Figure 2 
Figure 2: TRPV5 deficiency leads to reduced bone thickness 
Bone microarchitectural parameters from male Trpv5+/+ (white bars) and Trpv5-/- (black 
bars) mice at 10, 52 and 78 weeks of age were determined by μCT analysis (n=5-11). A) 
trabecular thickness in the metaphysis, B) cortical thickness, C) endocortical volume and 
D) cortical porosity in the diaphysis. Data are presented as means ± SEM. * p<0.05 ver-
sus Trpv5+/+. # p<0.01 vs Trpv5+/+. $ p<0.001 vs Trpv5+/+. Significant aging effects for a 
genotype are indicated by horizontal lines. 
 
Osteoclast function: The mRNA expression of the osteoclast marker genes for 
tartrate-resistant acid phosphatase (Acp5), cathepsin K (Ctsk) and the calci-
tonin receptor (Ctr) was negatively correlated with age in both genotypes 
(Figures 5D-E and Supplementary table 6). All osteoclast marker genes as-
sessed were slightly but consistently elevated in the Trpv5-/- compared to 
Trpv5+/+ mice (Figures 5D-E and Supplementary table 6), but only reached 
significance for Acp5 and Ctsk. Bone metabolism and phosphate homeostasis: 
We also assessed several genes associated with bone metabolism and phos-
phate homeostasis. Among them, phosphate regulating endopeptidase homo-
log, X-linked (Phex), osteopontin (Spp1) and sclerostin (Sost)) showed reduced 
mRNA expression with aging in Trpv5+/+ mice (Figure 5F and Supplemen-
tary table 6). Ankylosis, progressive homolog (Ank), Fibroblast growth factor 
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23 (Fgf23) and Klotho (Kl) were not modulated in an age-related manner in 
these mice (Supplementary table 6). As for the Trpv5+/+ mice, Phex, Spp1 and 
Sost expression showed a negative correlation with age in Trpv5-/- mice (Fig-
ure 5F and Supplementary table 5). Only Phex expression at 78 weeks of age 
was significantly different in Trpv5-/- mice compared to Trpv5+/+ mice (Fig-
ure 5F).  Overall, the Trpv5-/- mice showed similar age-related trends as did 
the Trpv5+/+ mice but for some genes significantly higher expression of bone-
related genes was observed at 78 weeks of age compared to the Trpv5+/+ mice. 
In bone marrow-derived osteoblasts and osteoclasts, all marker genes studied 
were expressed at lower levels in the Trpv5-/- mice, but none of these differ-
ences reached significance (Supplementary table 7).  
 
Figure 3 
Figure 3: Bone mineralization is affected in Trpv5-/- mice 
Using quantitative backscattered electron imaging, the tibial BMDD was assessed from 
male Trpv5+/+ (white bars) and Trpv5-/- (black bars) mice at 10, 52 and 78 weeks of age 
(n=3-6). Parameters were measured in the metaphyseal spongious bone compartment 
with respect to A) CaPeak, B) CaMean, C) CaWidth (all expressed as units of [wt%Ca]) 
and D) CaLow (expressed as percentage bone area). Values are presented as mean ± 
SEM. * p<0.05 versus Trpv5+/+. # p<0.01 vs Trpv5+/+. $ p<0.001 vs Trpv5+/+. Significant 
aging effects for a genotype are indicated by horizontal lines. 
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Figure 4 
Figure 4: Bone resorption is reduced in Trpv5-/- mice until 52 weeks of age 
A) Urinary DPD measurement in 10, 52 and 78-week-old male Trpv5+/+ (white bars) and 
Trpv5-/- (black bars) mice. B) osteoclast number and C) osteoclast surface per bone 
surface in TRAP-stained femoral bone section of 78-week-old male Trpv5+/+ and Trpv5-/- 
mice. D) osteoclast number and E) osteoclast surface assessed in bone marrow-derived 
osteoclast cultures from 78-week-old male Trpv5+/+ and Trpv5-/- mice. Values are pre-
sented as mean ± SEM. * p<0.05 versus Trpv5+/+. $ p<0.001 vs Trpv5+/+. 
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Figure 5 
Figure 5: Aging Trpv5-/- mice demonstrate high Vdr expression 
Total femoral RNA was isolated from male Trpv5+/+ (white bars) and Trpv5-/- (black bars) 
mice at 10, 52 and 78 weeks of age (n=3-12). A) Trpv6, B) Casr, C) Vdr, D) Acp5, E) Ctsk 
and F) Phex mRNA. Gene expression was corrected for the housekeeping gene Hprt and 
expression in Trpv5+/+ at 10 weeks was set to 1. Normalized for the housekeeping gene 
Values are presented as mean ± SEM. * p<0.05 versus Trpv5+/+. # p<0.01 vs Trpv5+/+. $ 
p<0.001 vs Trpv5+/+. Significant aging effects for a genotype are indicated by horizontal 
lines. 
Discussion 
Trpv5 deficiency strongly stresses the Ca2+ homeostasis in order to maintain 
stable plasma Ca2+ levels [3, 6]. Here, we demonstrate that mice lacking 
Trpv5 are able to maintain similar serum Ca2+ levels as their Trpv5-
expressing counterparts during aging up to at least 78 weeks of age. This is 
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achieved by pronounced age-related increments in serum 1,25(OH)2D3 and 
PTH. Age-related increases of these hormones were also observed in Trpv5-/- 
mice but interestingly at 10 weeks of age 1,25(OH)2D3 levels were already at 
the level of older (52 weeks) Trpv5+/+ mice, pointing to premature aging in 
this respect in Trpv5-/- mice. The stress on the Ca2+ homeostasis is paralleled 
by a reduced degree of bone mineralization and accelerated changes in bone 
microarchitecture as exemplified by reduced bone thickness.  
 
Normocalcemia in Trpv5-/- mice is associated with elevated serum 
1,25(OH)2D3 and PTH 
Trpv5-/- mice predominantly suffer from renal calcium loss, which is initially 
compensated by increased intestinal calcium hyperabsorption through 
TRPV6 followed by reduced bone mass and mineralization, to retain 
normocalcemia [3]. This compensatory mechanism is accompanied by elevat-
ed levels of 1,25(OH)2D3 and PTH already at 10 weeks of age. Later in life, 
1,25(OH)2D3 levels further increase in Trpv5+/+ mice even to levels exceeding 
1300 pmol/l. These extremely high 1,25(OH)2D3 levels may explain that at 78 
weeks of age the PTH levels in the Trpv5-/- are lower than in the Trpv5+/+ 
mice. The continuous exposure of an organism to elevated PTH and 
1,25(OH)2D3 levels has adverse consequences for the skeleton. Circulating 
levels of PTH rise with age in rats and humans [9, 10]. From human clinical 
studies, it has become apparent that prolonged exposure to high PTH (p.e. 
primary hyperparathyroidism) indirectly increases osteoclast activity and 
decreases age-related osteoblast replicative activity [14-17], both contributing 
to bone loss. 
Lieben et al. showed that exposure to high 1,25(OH)2D3 levels leads to re-
duced bone mineralization in mice [18]. In the current study, we demonstrate 
upregulation of the Vdr gene at the level of the femoral bone and strongly 
elevated 1,25(OH)2D3 levels in the oldest Trpv5-/- age group. Although we 
have no data to support this, upregulation of Vdr expression and high serum 
1,25(OH)2D3 levels would facilitate enhanced vitamin D signaling within 
bone. Enhanced vitamin D signaling may thus be a mechanism to limit the 
influx of Ca2+ into bone, which would contribute to retaining serum Ca2+ but 
at the expense of bone mineralization. 
Another mechanism that may contribute to retaining normocalcemia is oste-
ocytic osteolysis. Through this process, osteocytes are capable of resorbing 
the lacunae around them, resulting in the liberation of ions in case of a 
strong Ca2+ demand, such as lactation [19-21]. Suffering from a chronic nega-
tive Ca2+ balance but keeping serum levels constant, osteocytic osteolysis in 
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Trpv5-/- mice may suffice to restore serum Ca2+, which in turn would cause 
the observed increased cortical porosity. Although minute changes in osteo-
cyte function may have great impact due to their numbers within bone, we 
failed to show detectable changes in osteocytic lacunar size or number at 78 
weeks of age. 
 
Mineralization of bone is affected in Trpv5-/- mice 
In concordance with a chronic Ca2+ insufficiency in Trpv5-/- mice are our 
findings on bone mineralization density. Although no effects were seen at the 
level of the tibial cortex, mineralization density was decreased in the trabecu-
lar bone along with non-significantly larger areas of low mineralized bone 
observed in the 52- and 78-week-old Trpv5-/- mice compared to Trpv5+/+ mice. 
As we have shown previously, the enhanced intestinal Ca2+ uptake could not 
fully compensate for the renal Ca2+ loss in young Trpv5-/- mice, leading to 
reduced skeletal mineralization [6]. Later in life, the persisting stress on Ca2+ 
homeostasis may have led to the observed increased undermineralization in 
old Trpv5-/- mice but also to the increased endocortical osteoclast and osteo-
cyte activity. 
 
Trpv5 deficiency accelerates bone loss 
Aging is associated with bone loss by thinning of cortical bone and loss of the 
trabecular network [22]. Indeed, we found a decrease in cortical thickness 
with aging and a reduction of the trabecular bone volume fraction and con-
nectivity, despite increased thickness of the remaining trabecular bone. Pre-
vious studies looking at bone microarchitecture in aging mice found similar 
results [23-25]. Glatt et al observed an age-related decline in the trabecular 
bone volume fraction (BV/TV) [23], something we saw until the age of 52 
weeks but not thereafter, despite a significant age trend. In line with our 
data, Ferguson et al. described cortical expansion by periosteal apposition in 
male mice to compensate for trabecular bone loss and reduced mineralization 
[24]. Hamrick and coworkers showed BMD loss, periosteal expansion and 
endosteal resorption up to 29 months of age [25]. Interestingly, a concurrent 
increase in endosteal apposition was observed at this age, for which no ex-
planation was provided but it may be to counteract excessive endosteal bone 
loss. Nevertheless, it may provide an anabolic time-window for interventions 
to improve bone quantity/quality later in life. We did not observe differences 
in bone resorption between 10 and 78 weeks of life as measured by urinary 
DPD, which corresponds with the study by Hamrick, who showed increased 
bone resorption only after 18 months of age [25].  
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Trpv5 deficiency led to a more accelerated bone aging phenotype, including 
reduced trabecular and cortical bone mass as well as increased endocortical 
bone volume later in life compared to Trpv5+/+ mice. For example, the Trpv5-
/- mice have a cortical thickness at 10 weeks of age that is not reached until 
Trpv5+/+ at 78 weeks of age. Despite having a bone resorption defect in early 
life [6] and reduced urinary DPD levels in Trpv5-/- mice at 52 weeks, the 
current study showed that endocortical bone resorption in Trpv5-/- mice ex-
ceeds that of Trpv5+/+ mice between 52 and 78 weeks of age, resulting in an 
enlargement of the marrow space (endocortical volume) at the level of the 
diaphysis. In fact, bone resorption was not different between the genotypes, 
in vivo and ex vivo, as shown by DPD levels, histomorphometry and bone 
marrow-derived osteoclast cultures. Apparently, old Trpv5-/- mice seem to be 
able to regain their bone resorption capacity, independent of TRPV5. Per-
haps, prolonged high levels of circulating 1,25(OH)2D3, PTH or another yet 
unknown mechanism following TRPV5 deficiency has a restorative effect at 
the level of osteoclast activity on the skeleton of these mice. This suggests 
that the reduced bone resorption caused by TRPV5 deficiency that we report-
ed previously for mice at 10 weeks of age [6] and is apparent by the decreased 
DPD levels at 52 weeks, may not have been entirely intrinsic and is overcome 
at older age. 
 
Bone strength is not compromised in old Trpv5-/- mice 
The combination of reduced bone mass and increased endosteal resorption 
suggests that life-long stress on calcium homeostasis due to TRPV5 deficien-
cy weakens the skeleton of old mice. Besides the effects on cortical bone 
mass, we observed increased cortical porosity during aging but especially in 
the 78-week-old mice lacking TRPV5. Cortical porosity has been appreciated 
as an age-related phenomenon in the elderly and an important determinant 
of bone strength but the precise mechanism behind this process remains 
unclear [26]. Besides these effects on the skeleton of Trpv5-/- mice, the 3-
point-bending tests yielded similar outcomes for both genotypes at 78 weeks 
of age. The reason for this remains obscure, but may be due to a combination 
of 1) changes in the composition or the organization of the extracellular ma-
trix leading to structural changes within the skeleton that could not be as-
sessed through 3-point bending; 2) reduced mineralization in Trpv5-/- mice 
that renders bone to be more flexible; 3) non-significantly increased cortical 
perimeter in Trpv5-/- mice between 52 and 78 weeks of age (1.5 mm3) com-
pared to Trpv5+/+ mice (1.2 mm3) that may aid to counteract loss of bone 
strength. Finally, mice may possess a yet unknown ‘compensation’ mecha-
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nism that in case of bone loss protects them from a fracture, something that 
is rarely seen in mice. 
 
Human Ca2+ homeostasis and bone metabolism 
Several disease states, such as chronic kidney diseases and intestinal malab-
sorption syndromes (e.g. celiac disease, intestinal surgery, aging and vitamin 
D deficient nutrition) in humans cause continuous stress on the maintenance 
of adequate serum Ca2+ levels, and a clear relationship has been established 
with bone deterioration [27-30]. The phenotype of the Trpv5-/- mice suggests 
that maintenance of adequate circulatory Ca2+ in these patients should be a 
priority in order to prevent bone loss and increased risk fractures at older age. 
In conclusion, this study demonstrates that TRPV5 is important for normal 
bone development and that an unfavorable Ca2+ balance persisting during 
aging leads to accelerated bone loss in Trpv5-deficient mice. The strongly 
elevated vitamin D levels in Trpv5-/- mice may aid in restoring serum Ca2+ 
but at the expense of maintaining bone mass and/or mineralization in vivo. 
The TRPV5 deficient mouse appears to be a suitable model for lifelong chal-
lenge of calcium homeostasis and its consequences for bone metabolism. 
 
Material and Methods 
Animals 
Male homozygous TRPV5 null (Trpv5-/-) and Trpv5+/+ mice were generated as 
described before [3]. and were fed standard chow and given water ad libitum. 
At the age of 10, 52 and 78 weeks, mice were sacrificed (group sizes varied 
between 4-12) and serum, urine and bones were collected. The animal ethics 
board of the Radboud University Nijmegen approved all animal experimental 
procedures. 
 
Analytical procedures 
Serum Ca2+ was calorimetrically determined with a Ca2+ assay kit (Sigma) 
according to the manufacturer’s description at 595 nm, using a Bio-Rad mi-
croplate reader (Bio-Rad) or using a home-made calcium assay as described 
before [31]. Serum PTH levels were measured using a mouse intact PTH 
ELISA kit following standard procedure (Immutopics, San Clemente, CA, 
USA). Serum 1,25(OH)2D3 concentrations were measured by immunoextrac-
tion followed by quantitation by 125I-RIA (IDS, Boldon, UK) [6]. Urinary total 
deoxypyridinoline (DPD) cross-links were determined, using the Metra DPD 
assay according to the guidelines (Quidel).  
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Microcomputed tomography (μCT) 
Femurs were scanned using the SkyScan 1072 microtomograph (Bruker 
MicroCT) with a resolution of 7 µm and subsequently analyzed as described 
in detail before [6]. According to guidelines recently published [32] the follow-
ing settings were used: X-Ray power and tube current were 40 kV and 0.25 
mA, respectively. Beam hardening (20%) was reduced using a 1 mm alumi-
num filter, ring-artefacts were reduced (set at 5), exposure time was 5.9 se-
conds and an average of three pictures was taken at each angle (0.9º) to 
generate final images. Using different software packages from Bruker Mi-
croCT (NRecon, CtAn and Dataviewer), bone microarchitectural parameters 
were assessed in trabecular and cortical bone of all mice (n=14 for both geno-
types). The trabecular bone parameters trabecular tissue volume, bone vol-
ume, trabecular volume fraction (BV/TV), trabecular thickness, trabecular 
number, connectivity density and structure model index were determined in 
the distal metaphysis of the femur (scan area 0 – 3.25 mm of proximal fe-
mur). In the mid-diaphysis (scan area 3.25 - 6.3 mm from trochanter), cortical 
volume, cortical thickness, cortical porosity, polar moment of inertia (MOI; 
proxy for bone strength) and perimeter were analyzed. For image processing, 
trabecular bone was manually selected and cortical bone was automatically 
selected. We used global thresholding for segmentation, followed by applying 
optimized threshold levels for trabecular and cortical bone measurements.  
 
Bone mechanical properties (3-point bending) 
Femurs were stored in phosphate-buffered saline at -20°C until further use. 
Before the 3-point bending test, femurs were scanned according to the set-
tings mentioned above. The procedure was carried out as previously de-
scribed in detail [33]. Briefly, femurs were placed in a custom made 3-point 
bending device, with the lower loading posts 10 mm apart. Mechanical test-
ing was performed, using a Single Column Lloyd LRX System (Lloyd Instru-
ments). Displacement (mm) and force (N) were registered. Using the same 
settings for filtration, segmentation and binarization as mentioned above in 
the μCT section, the MOI, reflecting the ability of the bone to withstand tor-
sion, was calculated using Ct Analyzer software (Bruker MicroCT). This was 
determined in the μCT scan-derived cross-section that corresponded to the 
fracture site resulting from the bending test. From the resulting displace-
ment to force graphs as well as the MOI values, ultimate force (N), stiffness 
(N/mm), energy (Nmm) and elastic modulus (MPa) were determined as de-
scribed before [34]. 
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Quantitative backscattered electron imaging 
Dissected tibiae were routinely fixed and dehydrated in ethanol, and embed-
ded in polymethylmethacrylate. Sample blocks were trimmed using a low 
speed diamond saw (Isomet-R, Buehler Ltd.). Sectioned bone surfaces were 
sequentially ground with sand paper with increasing grid number followed 
by polishing with diamond grains (size down to 1 micron) on hard polishing 
clothes by a precision polishing device (PM5 Logitech, Glasgow, Scotland). 
Finally the sample surface was carbon coated by vacuum evaporation (Agar 
SEM Carbon Coater) for scanning electron microscopy. 
Bone mineralization density distribution (BMDD) was determined in the 
metaphyseal spongiosa and in the midshaft cortical bone by qBEI using a 
digital scanning electron microscope (DSM 962, Zeiss) equipped with a four-
quadrant semiconductor backscattered electron detector as extensively de-
scribed before [35, 36]. The accelerating voltage of the electron beam was set 
to 20 kV, the probe current to 110 pA, and the working distance to 15 mm. 
The cancellous and cortical bone areas were imaged at 200x nominal magni-
fication (corresponding to a pixel resolution of 1 µm/pixel. From these digital 
images, grey level histograms were deduced, displaying the percentage of 
bone area occupied by pixels of a certain gray level. The transformation of 
these into calcium weight percent (wt%Ca) histograms led to a bin width of 
0.17 wt%Ca. A technical precision of 0.3% was achieved. The BMDD parame-
ters like the mean (weighted mean) CaMean and most frequently occurring 
calcium concentration CaPeak (peak position of the BMDD) in the sample, 
the width of the distribution CaWidth (full width at half maximum; ∆wt%Ca) 
reflecting the heterogeneity in matrix mineralization and CaLow, the per-
centage of bone below 17.68 wt%Ca  (primary mineralization)[37]. 
 
Osteocyte density measurements 
qBEI Images of cortical bone (nominal magnification 200X) with 1  pixel 
resolution were used to determine osteocyte lacunae number. The mean size 
was evaluated from the 2D images of the lacunae as well as the percentage of 
the sectioned bone surface occupied by these lacunae (density). This was 
done, using the software package Bioquant (Version 7.20; Bioquant image 
analysis corporation). 
 
Bone histomorphometry 
After excision, femurs were routinely embedded in methylmetacrylate as 
described before [6]. Six µm sections were subjected to tartrate-resistant acid 
phosphatase (TRAP) staining. Sections were deacrylated, hydrated and 
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rinsed in 0.2 M sodium acetate / 50 mM tartaric acid for 5 minutes. Naphtol 
AS-MX (0.5 mg/ml) and 1.1 mg/ml Fast red TR salt (both from Sigma) were 
added and incubated for 120 minutes at 37°C. Counterstaining was per-
formed with haematoxylin for 5 seconds and after air-drying, the sections 
were embedded in Permount (Thermo Fischer Scientific). Images were taken 
with a Nikon Eclipse E400 system (Nikon, Lijnden, the Netherlands) and 
osteoclast number (Oc.N) and surface (Oc.S) were determined per total bone 
surface (BS), using Bioquant software.  
 
Bone marrow cultures 
Bone marrow cells derived from 78-week-old mice stimulated towards osteo-
clasts and osteoblasts were cultured as described in detail [6, 38]. After 6 
days of osteoclast culture, TRAP and coomassie brilliant blue stainings were 
used to stain for osteoclasts and resorption pits on bone slices left behind by 
osteoclasts, respectively [6]. Osteoclast number and resorption surface were 
determined and resorption surface per osteoclast was calculated, using the 
freely available ImageJ software (version 1.41; http://rsbweb.nih.gov/ij/). 
Osteoblast at day 14 cells were washed with PBS and taken up in TriZol for 
isolation of total RNA as described below. 
 
Flowcytometric analysis 
Frequencies of bone marrow populations containing osteoclast precursors 
were determined by flowcytometry, essentially as described in de Vries et al. 
[13]. Bone marrow cells from approximately 10- and 22-month-old mice were 
collected, washed and counted. All immunofluorescent labelings and washes 
took place in FACS buffer (PBS containing 1% BSA). Bone marrow cell sus-
pensions were spun down at 1500 rpm for 5 min at 4ºC) and incubated for 30 
min in 25 μl per 106 cells biotinylated ER-MP12, recognizing CD31 [39]. Cells 
were washed once and incubated in 25 μl per 106 cells FACS-buffer contain-
ing FITC–conjugated ER-MP20, recognizing Ly6C [39], and streptavidine-
phycoerythrin (PE; Becton Dickinson; 10 μl per 106cells) for 30 min. Finally, 
cells were fixed in 1% vol/vol paraformaldehyde in PBS for 15 min, washed 
and taken up in PBS. Cells were analyzed using a BD FACS Calibur and 
data were processed using Diva software (Becton Dickinson). 
 
RNA isolation, cDNA synthesis and real-time PCR 
Pulverized material from mouse femurs (including bone marrow) was resus-
pended in Trizol Reagent (Gibco). RNA isolation, cDNA synthesis and real-
time PCR on these femur samples as well as on the samples from the bone 
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marrow cultures were performed as described previously [40]. Primer and 
probe sequences and concentrations used for real-time PCR are listed in 
Supplementary table 1. The gene hypoxanthine-guanine phosphoribosyl 
transferase (HPRT) was used as an internal control to normalize for differ-
ences in RNA extraction and degradation as well as for efficiency of the 
cDNA synthesis. Data were presented as relative mRNA levels calculated by 
the equation 2-∆Ct (∆Ct (cycle threshold) = Ct of gene of interest minus Ct of 
housekeeping gene). 
 
2.11 Statistics 
In all experiments values are expressed as mean ± SEM unless stated other-
wise. Differences between genotypes were tested for significance by 
AN(C)OVA and adjusted for age. In the in vivo studies, regression analyses 
were performed to assess age-related changes. Two-way ANOVA was per-
formed to assess for interaction between age and genotype. Values were con-
sidered significantly different at p < 0.05. 
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Supplemental figures  
Supplementary figure 1 
 
 
Supplementary figure 1: Osteocyte lacunae are not affected in old Trpv5-/- mice 
Femoral bone sections of male Trpv5+/+ (white bars) and Trpv5-/- (black bars) mice were 
used to determine A) osteocyte lacunae number, B) osteocyte lacunae size and C) per-
centage osteocyte lacunae surface/bone surface. Values are presented as mean ± SEM. 
  
Supplementary figure 2 
 
Supplementary figure 2: Bone strength is not affected in old Trpv5-/- mice 
Femurs of male Trpv5+/+ (white bars) and Trpv5-/- (black bars) mice were subjected to 3-
point-bending (n=6-9). A) Maximum load, B) Stiffness, C) Energy and D) Young’s modu-
lus were measured. Values are presented as mean ± SEM. 
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Supplemental tables  
 
Supplementary table 1: Murine primer sequences for SYBR-green-based Q-PCR 
Gene Forward (5’-3’) Reverse (5’-3’) Quantity (pmol) 
Hprt TTATCAGACTGAAGAGCTACTGTAATGATC TTACCAGTGTCAATTATATCTTCAACAATC 2.5 
Trpv6 TTCCAGCAACAAGATGGCCTCTACTCTGA ATCCGCCGCTATGCACA 10 
S100g CCTGCAGAAATGAAGAGCATTTT CTCCATCGCCATTCTTATCCA 10 
Ncx1 TCCCTACAAAACTATTGAAGGCACA TTTCTCATACTCCTCGTCATCGATT 10 
Atp2b1 CGCCATCTTCTGCACCATT CAGCCATTGCTCTATTGAAAGTTC 10 
Ctsk TGATGAAAATTGTGACCGTGATAA CTCTCTCCCCAGCTGTTTTTAATTA 2.5 
Clcn7 CCTGTGGTGGAGGATGTAGGA TCTCCACAAACACCTTATGCTT 5 
Acp5 AAGAACTTGCGACCATTGTTAGC CCTGAAGATACTGCAGGTTGTGG 2.5 
Tcirg1 TCAGATCCTAAGCCGAAGTTGAG GACCAAGGCCACCTCTTCAC 5 
Vdr GATCTTGTCAGTTACAGCATCCAAAA CGCAACATGATCACCTCAATG 2.5 
Casr CTTTCCTATCCATTTTGGAGTAGCA GCAAAGATCATGGCTTGTAACCA 10 
Ctr GTGATGAAAATGGAGAGTGGTTTAGA AAGAACGTACGCATTTTGCAGT 2.5 
Kl CCAAAAGCTGATAGAGGACAATGG GTGTCCACTTGAACGTAGTTGTCAA 5 
Sost ACCTCCCCACCATCCCTATG TGTCAGGAAGCGGGTGTAGTG 2.5 
Ankh TACAGAGGCAGTGGCCATTCT GTTGCTTGTGTTCGCCAGTTT 5 
Spp1 AAGGATGACTTTAAGCAAGAAACTCTTC TCCTCGCTCTCTGCATGGT 2.5 
Fgf23 CATCTACAGTGCCCTGATGATTACA CTTCGAGTCATGGCTCCTGTT 5 
Phex AACCGAACCAGTGAGGCTATGT TAGAGTCTGGTATCAATGACCTTCTTG 2.5 
 
Supplementary table 2: Comparison of serum calcium levels in Trpv5+/+ and Trpv5-/- mice 
during aging 
 10 weeks 52 weeks WT mice  previous cohort 
 Trpv5+/+ Trpv5+/+ WT 
 mean ± sem mean ± sem mean ± sem 
Serum    
Calcium (mmol/l) 2.76 ± 0.02 2.71 ± 0.04 2.56 ± 0.04 
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Supplementary table 3: µCT data of femurs from male Trpv5+/+ and Trpv5-/- mice during 
aging 
 10 weeks 52 weeks 78 weeks 
 Trpv5+/+ Trpv5-/- Trpv5+/+ Trpv5-/- Trpv5+/+ Trpv5-/- 
 mean ± sem 
mean 
± sem 
mean 
± sem 
mean 
± sem 
mean 
± sem 
mean 
± sem 
Metaphysis       
Trabecular thickness  
(μm) 
69.5 
± 1.5 
68.0 
± 1.6 
75.2 
± 2.3 
68.1 
± 0.8 a 
80.3 
± 2.5 d 
72.5 
± 1.5 a,e 
Trabecular volume  
(mm3) 
1.5 
± 0.1 
1.3 
± 0.1 
0.9 
± 0.0 
1.0 
± 0.1 
1.2 
± 0.1 
1.2 
± 0.1 
Trabecular bone volume 
fraction (BV/TV; %) 
30.6 
± 1.7 
26.4 
± 1.5 
16.6 
± 1.1 
18.4 
± 2.5 
20.6 
± 1.4 
19.5 
± 2.0 
Trabecular number  
(mm-1) 
0.73 
± 0.02 
0.75 
± 0.02 
0.41 
± 0.04 
0.53 
± 0.06 a 
0.46 
± 0.05 d 
0.50 
± 0.04 e 
Trabecular separation  
(μm) 
271 
± 8 
285 
± 9 
383 
± 16 
380 
± 45 
407 
± 21 d 
391 
± 26 e 
Connectivity density  
(mm-1) 
449 
± 59 
317 
± 17 
51 
± 16 
121 
± 43 
89 
± 24 d 
122 
± 33 e 
Structure model index  1.6 ± 0.1 
1.7 
± 0.1 
2.1 
± 0.1 
1.9 
± 0.1 
1.9 
± 0.1 d 
2.0 
± 0.1 e 
Diaphysis       
Cortical volume  
(mm3) 
4.0 
± 0.2 
3.4 
± 0.2 a 
4.1 
± 0.1 
3.7 
± 0.1 a 
4.1 
± 0.2 
3.6 
± 0.1 a 
Cortical thickness  
(μm) 
275 
± 6 
238 
± 7 
256 
± 8 
224 
± 2 
225 
± 10 d 
195 
± 10 e 
Endocortical volume  
(mm3) 
2.7 
± 0.2 
2.8 
± 0.2 
4.3 
± 0.2 
4.4 
± 0.1 
4.6 
± 0.2 d 
5.9 
± 0.3 e 
Cortical porosity  
(% of Ct.V) 
0.22 
± 0.06 
0.16 
± 0.04 
0.25 
± 0.08 
0.32 
± 0.06 
0.56 
± 0.06 d 
0.93 
± 0.14 a,e 
Polar moment of inertia  
(mm4) 
0.68 
± 0.07 
0.54 
± 0.06 
0.90 
± 0.05 
0.83 
± 0.05 
1.02 
± 0.05 d 
1.04 
± 0.05 e 
Perimeter  
(mm) 
5.6 
± 0.1 
5.32 
± 0.15 
6.4 
± 0.3 
6.3 
± 0.4 
7.6 
± 0.1 d 
7.8 
± 0.2 e 
a p<0.05 versus Trpv5+/+ mice of the same age, b p<0.01 versus Trpv5+/+ mice of the same 
age, c p<0.001 versus Trpv5+/+ mice of the same age. d P<0.05 for age trend in Trpv5+/+ 
mice. e p<0.05 for age trend in Trpv5-/- mice.  
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Supplementary table 4: qBEI data of cortical bone from male Trpv5+/+ and Trpv5-/-  mice 
during aging 
 10 weeks 52 weeks 78 weeks 
 Trpv5+/+ Trpv5-/- Trpv5+/+ Trpv5-/- Trpv5+/+ Trpv5-/- 
 mean  ± sem 
mean  
± sem 
mean  
± sem 
mean  
± sem 
mean  
± sem 
mean  
± sem 
Diaphyseal cortex       
CaMean (wt% Ca) 22.8  ± 0.3 
23.3  
± 0.4 
25.6  
± 0.2 
24.5  
± 0.3 
 26.1  
± 0.6 a 
26.6  
± 0.2 b  
CaPeak (wt% Ca) 23.7  ± 0.3  
24.1  
± 0.4 
26.5  
± 0.2 
25.5  
± 0.3 
 27.0  
± 0.6 a 
27.4  
± 0.3 b 
CaWidth (∆wt% Ca)  3.12  ± 0.09 
 3.02  
± 0.09 
 2.98  
± 0.17 
 3.06  
± 0.12 
  4.39  
± 0.35 a 
  3.70  
± 0.21 b  
CaLow (% bone area)  4.49  ± 0.45 
 3.76  
± 0.33 
 3.17  
± 0.11 
 3.51  
± 0.39 
  2.32  
± 0.42 a 
  2.38  
± 0.37 b 
a p<0.05 for age trend in Trpv5+/+ mice. b p<0.05 for age trend in Trpv5-/- mice. 
 
 
 
Supplementary table 5: Mouse bone marrow composition analyzed by flowcytometry in 
Trpv5+/+ and Trpv5-/- mice1 
  10 months 22 months 
 phenotype Trpv5+/+ Trpv5-/- Trpv5+/+ Trpv5-/- 
Cell population (%)  mean  ± sem 
mean  
± sem 
mean  
± sem 
mean  
± sem 
Early blasts  CD31hi Ly-6Cneg 1.5  ± 0.2 
1.6  
± 0.0 
1.3  
± 0.3 
1.3  
± 0.1 
Lymphoid cells CD31int Ly-6Cneg 17.3  ± 1.9 
17.4  
± 2.8 
19.5  
± 1.5 
10.7  
± 1.2 a 
Erythroid precursors CD31neg Ly-6Cneg 16.8  ± 1.8 
18.9  
± 2.0 
14.2  
± 0.9 
15.3  
± 1.8 
Myeloid blasts CD31pos Ly-6Cpos 7.8  ± 0.2 
6.5  
± 0.8 
8.2  
± 0.2 
8.9  
± 0.8 
Neutrophils CD31neg Ly-6Cint 22.6  ± 1.4 
23.4  
± 1.8 
24.1  
± 1.0 
29.2  
± 2.4  
Monocytes CD31neg Ly-6Chi 5.6  ± 0.6 
3.5  
± 1.0 
4.6  
± 0.5 
5.5  
± 0.3 
a p<0.05 versus Trpv5+/+ mice of the same age 
1 Bone marrow populations were identified as described in de Vries et al. 2009 
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Supplementary table 6: Gene expression in femurs from Trpv5+/+ and Trpv5-/-  mice 
during aging 
 10 weeks 52 weeks 78 weeks 
 Trpv5+/+ Trpv5-/- Trpv5+/+ Trpv5-/- Trpv5+/+ Trpv5-/- 
 mean  ± sem 
mean  
± sem 
mean  
± sem 
mean  
± sem 
mean  
± sem 
mean  
± sem 
Calcium homeostasis       
Calbindin-D9K  
(S100g) 
1.0  
± 0.1 
1.6  
± 0.2 
0.7  
± 0.1 
0.7  
± 0.1 
1.0  
± 0.2 
  0.8  
± 0.2 c 
Sodium/calcium  
exchanger 1 (Ncx1) 
1.0  
± 0.2 
1.1  
± 0.1 
0.8  
± 0.1 
0.8  
± 0.2 
1.0  
± 0.1 
  1.4  
± 0.1 a 
Plasma membrane calcium  
ATPase 1 (ATP2b1) 
1.0  
± 0.1 
0.8  
± 0.1 
1.1  
± 0.2 
1.4  
± 0.3 
0.9  
± 0.1 
1.3  
± 0.2 
Osteoclast markers       
Calcitonin receptor 
(Ctr) 
1.0  
± 0.2 
1.1  
± 0.2 
0.8  
± 0.3 
1.3  
± 0.3 
  0.4  
± 0.1 b 
  0.5  
± 0.1 c 
Chloride channel 7  
(Clcn7) 
1.0  
± 0.1 
1.3  
± 0.2 
0.7  
± 0.1 
1.0  
± 0.1 
1.2  
± 0.1 
1.2  
± 0.1 
H+-ATPase  
(Tcirg1) 
1.0  
± 0.1 
1.2  
± 0.2 
0.7  
± 0.1 
1.0  
± 0.1 
1.2  
± 0.1 
1.4  
± 0.1 
Aging of bone       
Osteopontin  
(Spp1) 
1.0  
± 0.0 
1.1  
± 0.0 
0.8  
± 0.2 
0.9  
± 0.2 
  0.5  
± 0.1 b 
  0.7  
± 0.1 c 
Sclerostin  
(Sost) 
1.0  
± 0.2 
1.6  
± 0.4 
0.5  
± 0.1 
0.5  
± 0.1 
  0.6  
± 0.0 b 
  0.7  
± 0.1 c 
Ankylosis, progressive  
homolog (Ank) 
1.0  
± 0.2 
1.0  
± 0.2 
0.6  
± 0.1 
0.6  
± 0.1 
0.7  
± 0.1 
0.8  
± 0.0 
Fibroblast growth  
actor 23 (Fgf23) 
1.0  
± 0.3 
1.5  
± 0.4 
3.1  
± 0.7 
1.4  
± 0.3 
1.7  
± 0.3 
1.8  
± 0.5 
Klotho  
(Kl) 
1.0  
± 0.3 
0.7  
± 0.1 
1.4  
± 0.3 
0.8  
± 0.3 
1.1  
± 0.3 
1.0  
± 0.3 
Data were normalized to Trpv5+/+ mice at 10 weeks of age (set to 1.0). a p<0.05 vs 
Trpv5+/+ mice of same age. b p<0.05 for age trend in Trpv5+/+ mice. c p<0.05 for age trend 
in Trpv5-/- mice.  
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Supplementary table 7: Gene expression in Trpv5+/+ and Trpv5-/-  bone marrow-derived 
osteoblasts and osteoclasts 
 78 weeks 
 Trpv5+/+ Trpv5-/- 
 mean ± sem mean ± sem 
Osteoblast genes   
Collagen 1a1 (Col1a1) 108.2 ± 43.9 61.1 ± 9.7 
Osteocalcin (Bglap) 0.58 ± 0.31 0.22 ± 0.05 
Runt-related transcription factor 2 (Runx2) 0.48 ± 0.19 0.28 ± 0.02 
Osteoclast genes   
Acid phosphatase 5, tartrate resistant (Acp5) 39.1 ± 10.7 34.1 ± 7.2 
Chloride channel, voltage-sensitive 7 (Clcn7) 0.32 ± 0.08 0.28 ± 0.04 
T-Cell, Immune Regulator 1, ATPase, H+ Transporting,  
Lysosomal V0 Subunit A3 (Tcirg1) 1.53 ± 0.39 1.22 ± 0.29 
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 Chapter 9 
General discussion 
 
 
  
 
  
 
General discussion 
In this thesis, studies are presented on sex- and age-related challenges in 
calcium and phosphate homeostasis.  
First of all, the findings related to the effects of aging on calcium and phos-
phate homeostasis from the different studies presented in this thesis will be 
integrated in the following chapter. Secondly, sex-specific results with re-
spect to calcium and phosphate homeostasis are discussed. The chapter will 
close with a paragraph on future perspectives based on the findings present-
ed in this thesis. 
 
1. Aging and its relationship with calcium and  
phosphate homeostasis 
The average lifespan has steadily increased since the start of the nineteenth 
century [1]. Although aging is a natural phenomenon, to date senectitude is 
still associated with increasing prevalence of chronic illnesses such as cardio-
vascular diseases, chronic kidney diseases and metabolic diseases like type 2 
diabetes and osteoporosis [2-4]. Despite the population getting older, the age 
when these illnesses manifest has not increased much and in some cases, 
such as in patients suffering from type 2 diabetes, the age of first manifesta-
tion has even gone down [5]. Hence, people live longer but with a reduced 
quality of life due to impaired health. Health is considered to be a concept 
described as a continuum between health and a disease state and reflected as 
a dynamic balance between the demands and the self-management of people. 
The presence of chronic diseases can put an extra demand on people and 
potentially reduce self-management [6]. Preventing or postponing the occur-
rence of chronic diseases with aging can therefore aid the individual’s per-
ceived health. At a conference for international health experts in The Hague, 
The Netherlands in 2009, one of the discussed areas related to health was 
the ability to maintain homeostasis despite changing circumstances [7, 8]. In 
order to address healthy aging it is therefore important to understand possi-
ble age-related alterations in homeostasis and factors that influence said 
homeostasis. Serum calcium and phosphate are part of a tightly regulated 
homeostatic system and both have an important role in many physiological 
processes. Both serum calcium and phosphate are necessary for the adequate 
mineralization of bone and are incorporated in the bone matrix as part of 
hydroxapatite [9]. Furthermore, calcium is necessary for many metabolic 
processes such as neural transmission, blood coagulation, and cell prolifera-
tion, whereas phosphate is both a part of DNA as well as RNA structures and 
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an important factor in energy metabolism. Age-related alterations in calcium 
and phosphate homeostasis are examined in this thesis, as they may affect 
health in various ways.  
In chapter 2 we found both sex differences and an age-related decline in se-
rum calcium and phosphate levels. Women above 45 years of age had higher 
serum calcium and phosphate levels compared to men of a similar age. This 
sex difference in serum calcium and phosphate levels was not explained by 
vitamin D or ALP levels. We showed that serum testosterone influenced the 
sex differences in serum phosphate, but not calcium. Estradiol did not affect 
sex differences in either serum calcium or phosphate. In chapter 3 we discov-
ered that these sex differences in calcium and phosphate levels became ap-
parent with aging. In three different hospital cohorts, with subjects aged 1-97 
years, a sex-dependent difference became apparent, with women having 
higher serum calcium and phosphate levels than men above the age of 45, 
but not in younger age groups. Analyses per decade showed that sex differ-
ences in serum phosphate appeared roughly 10 years before sex differences in 
serum calcium were observed. Overall, there were associations related to 
both sex and age with serum calcium and phosphate throughout the popula-
tion. In chapter 4 the influence of higher phosphate levels on the risk of frac-
tures and bone mineral density (BMD) in community-dwelling elderly people 
is described. Higher serum phosphate levels, even within the normal range, 
were associated with increased fracture risk in both men and women, and 
decreased lumbar spine BMD in men. The increased fracture risk of the par-
ticipants in this study could not be explained by BMD. For serum calcium 
levels no association with fracture risk and BMD was found in either sex 
(chapter 4).   
Calcium homeostasis is maintained by an intricate endocrine system involv-
ing multiple organs and hormones. Calcium intake attributes to a small ex-
tent to calcium homeostasis, as calcium intake does not equal intestinal 
absorption. Nevertheless, adequate calcium intake and adequate vitamin D 
levels are considered important for optimal treatment of osteoporosis [10]. 
Vitamin D facilitates calcium uptake in the intestines, and is therefore one of 
the hormones that is important in the maintenance of adequate serum calci-
um levels.  
We wanted to address intestinal calcium handling in relation to bone param-
eters and calcium levels. In order to study the influence of calcium intake on 
bone we assessed the influence of lactose intolerance in elderly subjects. Lac-
tose intolerance is associated with reduced calcium intake and in some stud-
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ies an association with bone parameters has been found [11-13]. In chapter 5 
we describe that lactose intolerance, genetically defined by a polymorphism 
in the LPH gene, is associated with lower calcium intake and lower serum 
levels of calcium, but not with BMD and fracture risk, suggesting that serum 
calcium levels within the normal range are adequate for good bone health. A 
recent genome wide association study and a two-sample mendelian randomi-
sation study confirmed that there was no increased fracture risk in relation 
to lower vitamin D levels as well as lower estimated calcium intake from 
dairy sources [14]. Fractures at older age are considered to be one of the ma-
jor health burdens, since they are associated with both morbidity and mortal-
ity [7, 15-17]. People previously living independently might need to move to a 
nursing home, suffer from pain and have significantly declining physical 
conditions by decreased mobility [17, 18]. Therefore, it is important to study 
those aspects of deteriorating bone health with aging, including adequate 
calcium and phosphate homeostasis, which can lead to more insight into the 
prevention of fractures. A meta-analysis in 2015 from Bolland et al. found no 
association between use of calcium supplements and fracture risk [19]. In a 
subsequent meta-analysis, an influence of calcium intake and supplementa-
tion on BMD was found, although this was considered to be marginal with an 
increase in BMD of 1-2% [20]. Extrapolation of previous epidemiological stud-
ies was used to estimate that this increase of 1-2% in BMD would result in a 
fracture risk reduction of 5-10% [20]. However, the aforementioned research-
ers could not find a reduced fracture risk with the use of calcium supple-
ments in their previous meta-analysis [19]. In a Cochrane systematic review 
by Avenell et al., associations were found between calcium and vitamin D 
supplementation and decreased fracture risk, but not for vitamin D alone 
[21]. This implicates that supplementation of either calcium or vitamin D 
alone is insufficient to reduce fracture risk. However, calcium and vitamin D 
supplementation together seems to be a beneficial combination when trying 
to reduce fracture risk. Moreover, it has been shown that patients with condi-
tions that affect intestinal calcium uptake and vitamin D absorption, such as 
celiac disease and short bowel syndrome, have lower BMD and increased 
fracture risk [22, 23]. Calcium and vitamin D supplements are therefore 
recommended in order to prevent further bone loss [24-26].  
Low levels of serum calcium and phosphate levels can result in severe bone 
phenotypes such as rickets in children and osteomalacia in adults due to 
inadequate bone mineralization in, for example, patients with chronic kidney 
disease, and in severe vitamin D deficiency or in hypophosphatemic rickets. 
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We describe a case of pseudovitamin D-deficient rickets in chapter 6. These 
diseases illustrate the importance of an adequate calcium and phosphate 
homeostasis for the healthy development of bone. To date, no reference val-
ues for serum calcium and phosphate are established for people > 60 years of 
age and abnormalities in serum calcium and phosphate levels in people > 60 
years of age are based on the reference values of younger people [27, 28]. 
Misinterpretation of the adequacy of serum values, such as serum calcium 
and phosphate, can occur when the possibility of alterations in homeostasis 
with healthy aging is ignored. Therefore, a Swiss study group started in 2011 
recruiting people aged > 60 older in the SENIORLAB study, in order to set 
reference values for different markers of metabolism and electrolytes for 
healthy elderly people [29]. Presently, these reference values are not availa-
ble, but in the future, these reference values might help in addressing ab-
normalities in serum calcium and phosphate homeostasis in people >60 years 
of age. 
One of the gatekeepers in renal calcium handling is transient receptor poten-
tial (TRP) cation channel subfamily V, member 5 (TRPV5). TRPV5 is a calci-
um channel that is present in the distal part of the nephron in the kidney, 
where it is involved in the reabsorption of calcium [30]. Moreover, TRPV5 is 
present in osteoclasts, where it plays a role in adequate osteoclastic bone 
resorption [31]. In chapter 8 we describe an aging study in mice in which the 
maintenance of adequate calcium levels was challenged as a consequence of a 
defective calcium channel TRPV5. Lacking this calcium channel disturbs the 
reabsorption of calcium in the kidneys and impairs osteoclastogenic bone 
resorption. During aging, Trpv5 null mice developed accelerated bone loss 
and a diminished bone mineralization phenotype. A previous study involving 
similar mice showed that in both Trpv5 null mice and wild types, aging in-
creased urinary calcium excretion. However, Trpv5 null mice had significant-
ly higher urinary calcium excretion compared to wild types [32]. Intriguingly, 
we found that Trpv5 null mice had increased levels of Vitamin D and para-
thyroid hormone (PTH) at an earlier age compared to control mice, while 
serum calcium levels were not different between the different genotypes. The 
increased Vitamin D and PTH levels, together with the previously found 
increased urinary calcium excretion, in these Trpv5 null mice, while serum 
calcium levels remain normal, implicates that the body attempts to maintain 
serum calcium levels. We concluded that serum changes in vitamin D and 
PTH may be responsible for the observed accelerated bone loss in mice lack-
ing Trpv5. Previous studies using mice without a functional Vitamin D re-
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cepetor, Vdr null mice, and mice with a deletion of the 25-hydroxyvitamin D3 
1a-hydroxylase enzyme, the so called Cyp27b1 null mice, have shown delete-
rious effects of these mutations on bone mineralization. A rescue diet rich in 
calcium, phosphorus and lactose resulted in normalization of calcium, phos-
phorus and PTH levels, but not always in complete normalization of the bone 
phenotype. This indicates the importance of vitamin D in bone mineralization 
[33, 34]. It has to be mentioned that compared to humans, vitamin D affects 
bone of mice differently. In both species the most potent form of vitamin D, 
1,25-dihydroxyvitamin D3, is synthesized by hydroxylation of 25-
hydroxyvitamin D3 via the CYP27B1 enzyme in the kidney. In humans, the 
main effect of 1,25-dihydroxyvitamin D3 on bone is the ability of 1,25-
dihydroxyvitamin D3 to stimulate the intestinal uptake of calcium and phos-
phate, thereby providing sufficient minerals available for incorporation in 
bone [35]. In contrast to humans, 1,25-dihydroxyvitamin D3 can have both 
anabolic as well as catabolic effects on bone in mice [33]. In mice, the direct 
anabolic effect of 1,25-dihydroxyvitamin D3 occurs through activation of the 
VDR receptor in mature osteoblast, which leads to a reduced RANKL-OPG 
ratio, inhibiting osteoclast maturation and activity. Furthermore, 1,25-
dihydroxyvitamin D3 stimulates the LRP5 pathway, leading to bone for-
mation. Indirectly, in mice 1,25-dihydroxyvitamin D3 exerts its anabolic ef-
fects via intestinal calcium and phosphate uptake in order to facilitate 
sufficient minerals for bone mineralization. The catabolic action of 1,25-
dihydroxyvitamin D3 on bone in mice also has a direct and an indirect effect. 
The direct catabolic effect of 1,25-dihydroxyvitamin D3 in mice affects bone 
through the VDR receptor in early osteoblasts, which increases the RANKL-
OPG ratio under the influence of 1,25-dihydroxyvitamin D3, resulting in 
increased osteoclastogenesis and, consequently, in bone resorption. In mature 
osteoblast and osteocytes in mice, 1,25-dihydroxyvitamin D3 can lead to in-
creased production of local inhibitors of bone mineralization such as ENPP1, 
ENPP2 and ANK [33]. Furthermore, in mice, 1,25-dihydroxyvitamin D3 in-
creases FGF23 levels, resulting in lower serum phosphate levels, as a conse-
quence of which less phosphate is available for incorporation in the bone 
matrix [33]. Because the different actions of 1,25-dihdroxyvitamin D3 in mice 
are both catabolic and anabolic, whereas 1,25-dihydroxyvitamin D3 is only 
anabolic on human bone,  
the results in chapter 8 are not directly translational to humans. Neverthe-
less, the importance of the TRPV5 channel in maintaining adequate calcium 
balance in mice has provided insight into the molecular mechanism of calci-
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um homeostasis in aging; that is, when calcium homeostasis is put under 
stress.  
In 2015, a nonsynonymous SNP (rs4236480) in the TRPV5 gene was found to 
be associated with nephrolithiasis [36], but to date no case reports on TRPV5 
gene malfunctioning in humans have been published. Despite the clear func-
tion of the TRPV5 calcium channel in the epithelial cells in the kidney, as 
well as in osteoclasts, overall malfunctioning of the TRPV5 gene might only 
lead to a clinical phenotype in conditions when calcium homeostasis is put 
under severe stress. It could therefore be that TRPV5 in humans, over the 
course of life, has an indirect impact on bone health when the maintenance of 
calcium homeostasis is challenged due to decreased intestinal calcium up-
take, decreased renal function and/or lower levels of vitamin D.  
Besides osteoporosis, our findings on disturbances of calcium and phosphate 
homeostasis in this thesis may also be relevant for cardiovascular diseases 
such as coronary artery disease, another chronic age-related condition which 
is associated with increased extra-skeletal calcification. Foley and coworkers 
found serum calcium, serum phosphate and the calcium-phosphate product 
to be associated with cardiovascular disease and stroke [37]. Osteoporosis 
and atherosclerosis have been linked as reviewed by Anagnostis et al. [38]. 
Two distinct molecular pathways that are activated with aging are consid-
ered to play an important role in osteoporosis as well as atherosclerosis [39]. 
The first pathway is through inflammation, resulting in cytokine release, 
which leads to increased bone resorption and diminished bone formation in 
the bone microenvironment. In vascular tissue the same molecular pathway 
of cytokine release causes vascular smooth muscle cells to adopt a more oste-
ogenic phenotype, partly via the activation of the Wnt-Beta catenin signaling 
cascade, causing calcification of the vascular tissue [40]. The second molecu-
lar pathway, activated later in life in bone and vascular tissues, is a pathway 
that is stimulated by oxidative stress. In bone, the increased product of lipid 
oxidation due to oxidative stress leads to increased osteoclast differentiation 
and decreased osteoblast formation [41]. In vascular smooth muscle cells 
oxidative stress has been shown to cause lipid oxidation in vitro, leading to 
increased calcification of these vascular smooth muscle cells [41].  
Overall, it is clear that understanding the molecular pathways behind calci-
um and phosphate homeostasis with aging is crucial not only for bone, but 
also for other tissues and processes. It helps to understand how changes in 
serum calcium and phosphate levels can be related to certain conditions such 
as osteoporosis and cardiovascular diseases. Unraveling the common denom-
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inators of the molecular basis in diseases such as osteoporosis and athero-
sclerosis may yield new targets for therapeutic interventions influencing both 
conditions.  
 
1.2 Biomarkers and aging 
With advancing age there is an increase in osteoclastic bone resorption, caus-
ing calcium and phosphate to be released from the bone matrix into the circu-
lation [42, 43]. When osteoclastic bone resorption is not matched with bone 
formation, BMD decreases and fracture risk increases [44]. In chapter 7 we 
studied the osteoclastogenic potential of peripheral mononuclear cells in 
elderly women with and without osteoporosis. We found an association be-
tween deoxypyridinoline (DPD) levels, a marker of bone resorption, and oste-
oclastogenic potential in women diagnosed with osteoporosis, but not in 
women without osteoporosis. There was a difference in osteoclastogenic po-
tential in osteoporotic subjects stratified according to high or low DPD levels. 
Osteoporotic subjects with high DPD levels had a higher osteoclastogenic 
potential compared to osteoporotic subjects with low DPD levels. It appears 
that osteoporotic subjects can be divided in two distinct metabolic groups: a 
group with high and a group with low DPD levels. Considering the finding 
that osteoclastogenic bone resorption is associated with DPD levels, we spec-
ulate that there might be a difference in fracture risk in these metabolically 
distinct groups. Notable is that in our study in chapter 7 the overall DPD 
levels were low, whereas in previous studies high bone resorption markers 
were found in women shortly after menopause [45-48]. Since the women in 
our study were on average 78 years of age, we may consider that the body’s 
metabolism is low due to older age, and that bone frailty in the elderly osteo-
porotic subjects with low DPD levels in chapter 7 may be more associated 
with an overall decreased formation and a stable, but not increased, bone 
resorption. This phenotype of decreased bone formation, combined with sta-
ble bone resorption, was previously called senile osteoporosis by Riggs et al. 
[49]. Unfortunately, we were not able to assess bone formation markers in 
our cohort, which might have revealed whether there was indeed decreased 
osteoblast activity, making the case of senile osteoporosis more likely.  
 
2. Sexual Dimorphism 
Sex differences in medical research have recently received globally increased 
attention. Bone is one of the best investigated tissues for sexual dimorphism, 
but potential sex-differences in calcium and phosphate homeostasis have 
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been less-well studied [50]. Since a disbalance in calcium and phosphate 
homeostasis is associated with decreased bone health, these subjects are 
most definitely worthy of extended research. In chapter 2 we focused on sex-
ual dimorphism in calcium and phosphate homeostasis and found, in a popu-
lation-based study of elderly subjects, women above 45 years of age to have 
higher total serum calcium, as well as higher phosphate levels compared to 
men of the same age. Adjusting for the sex hormones estradiol and testos-
terone revealed differential effects: testosterone diminished the effect size for 
sex differences in serum phosphate but had no clear influence on sex differ-
ences in serum calcium. Estradiol did not influence the sex difference in ei-
ther serum phosphate or calcium. Furthermore, data from the MrOs study 
showed an association between both higher estradiol and testosterone and 
lower levels of serum phosphate in aging men. Both these studies show that 
an important role for estradiol and testosterone in the calcium and phosphate 
balance may be anticipated, but to what extent and whether these influences 
are different between men and women remains to be further elucidated [51]. 
As mentioned before, the maintenance of adequate serum calcium and phos-
phate levels may be important for other conditions as well, such as cardio-
vascular diseases. There are clear sex differences in these conditions, as 
exemplified by several studies. A prevalence study with 883982 participants 
who were followed for a decade showed a higher prevalence of hypertension, 
hyperlipidemia, diabetes mellitus, and coronary artery disease in men com-
pared to women [2]. However, there is an increase in incidence of cardiovas-
cular diseases in women after menopause, when the incidence in women 
approaches the one in men [52-55]. It is unclear how alterations in sex hor-
mones after menopause impact the occurrence of cardiovascular diseases. We 
observed an association with menopause and the evolution of sex differences 
in calcium and phosphate levels. Therefore, factors that underlie sex differ-
ences in calcium and phosphate homeostasis may also be important indica-
tors for cardiovascular outcomes. Furthermore, osteoporosis and 
cardiovascular diseases appear to be associated as mentioned before. One 
study reported that women with osteoporosis, defined as having a BMD T-
score < -2.5, have a 3.9-fold increased risk for cardiovascular events com-
pared to women having a BMD with a T-score between -2.5 and -1 [56]. In a 
study by Campos-Obando et al., which used data from the Rotterdam Study, 
an association between lower BMD and a higher coronary artery calcification 
(CAC) score was found in women but not in men [57]. However, no associa-
tion between higher CAC score and increased fracture risk was found in the 
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aforementioned study. In a meta-analysis by Ye et al., an association was 
found between lower BMD and atherosclerotic vascular abnormalities such 
as carotid artery calcifications and coronary artery disease [58]. However, a 
part of the associations between coronary artery disease and lower BMD or 
fracture risk can probably be explained by age and comorbid conditions such 
as diabetes mellitus, estrogen deficiency, hyperhomocysteinemia, and by 
common lifestyle factors such as physical inactivity and smoking [38, 56].  
The need for scrutiny regarding sex differences in health and disease is obvi-
ous. However, much research outside of the osteoporosis field is predomi-
nantly performed in male subjects, both in animal and in human studies, 
which may lead to missing sex-specific effects [59, 60]. In order to understand 
sex-specific influences on homeostasis it is essential to understand male and 
female physiology. Assessment of differences in physiology may aid in the 
understanding of the underlying mechanisms of sex differences in various 
diseases. Moreover, this could help with sex-specific strategies in prevention 
and treatment of diseases such as osteoporosis and cardiovascular diseases.  
 
3. Future perspectives 
The results found in this thesis have provided new insights into calcium and 
phosphate homeostasis as well as the insight that failure to maintain ade-
quate calcium and phosphate homeostasis may have an impact on both bone 
quality and on general health. Our findings also raise questions regarding 
the way in which to elaborate on our observations. There are several ways of 
approaching this in future research. Firstly, since the maintenance of calci-
um and phosphate homeostasis is part of a complicated and integrated sys-
tem, whereby the hormones vitamin D, PTH and fibroblast growth factor 
(FGF23) play key roles, it is of interest to study these hormones in relation to 
the sex differences that arise with aging.  
The maintenance of adequate serum ionized calcium levels in the body is 
tightly regulated by the parathyroid glands. When lower ionized calcium 
levels are detected via the calcium sensing receptor (CaSR), the parathyroid 
glands increase PTH secretion [61]. Chronically increased PTH levels, as in 
secondary hyperparathyroidism, result in pleiotropic effects. One of these 
effects is an increase in bone turnover via the RANKL/OPG system causing 
release of calcium and phosphate from the bone and reduced bone quality 
[62-64]. One would expect that the lower ionized calcium levels that we found 
in lactose intolerant people in chapter 5 would lead to secondary hyperpara-
thyroidism, and could therefore reduce bone mineral density. However, in our 
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study, lactose intolerant subjects showed no difference in bone mass com-
pared to controls, allowing one to question whether these subjects do indeed 
have secondary hyperparathyroidism. An alternative hypothesis could be 
that lactose intolerant people have a different setpoint of their CaSR, thereby 
diminishing the effects of lower calcium levels on BMD. The latter hypothesis 
would fit with findings in patients with Autosomal Dominant Hypocalcaemia 
(ADH), a condition characterized by low calcium levels but without a clear 
bone phenotype [65]. To study whether lower ionized and serum calcium 
levels in lactose intolerant subjects cause secondary hyperparathyroidism we 
need to address PTH levels. 
Besides PTH, the phosphaturic hormone FGF23 coupled with the transmem-
brane protein Klotho, both associated with longevity in animal models, also 
play a role in the maintenance of serum calcium and phosphate levels [66-
68]. FGF23 promotes phosphaturia by downregulating the Na-phosphate co-
transporters (NaPi2a and NaPi2c) in the kidney, both by inhibiting 1,25-
dihydroxyvitamin D3 synthesis indirectly via suppression of CYP27B and by 
inhibition of PTH release [69]. Klotho is a co-receptor for FGF23 and Klotho 
deficient mice exhibit the same premature aging phenotype as Fgf23 defi-
cient mice, with higher levels of serum calcium, phosphate, and 1,25-
dihydroxyvitamin D3 [67]. In humans, malfunction of Klotho has been de-
scribed in a case report of a girl with ectopic calcifications and increased 
serum calcium, phosphate, and 1,25-dihydroxyvitamin D3 levels [70]. Loss of 
function mutations in FGF23 cause autosomal dominant hypophosphatemic 
rickets [71, 72]. Since women have increased serum calcium and serum phos-
phate after menopause, it will be important to study whether Klotho and 
FGF23 levels alter around menopause as well. Sex differences in calcium and 
phosphate homeostasis stress the need to assess whether these hormones 
show sex-dependent differences during aging.  
Another way to study the association between sex hormones and calcium and 
phosphate homeostasis will be to evaluate whether testosterone and estradiol 
have a direct effect on serum calcium and phosphate levels, or whether alter-
ations in serum calcium and phosphate levels are merely the result of the 
uncoupling of bone formation and bone resorption. It is therefore important 
to evaluate whether sex hormones influence calcium and phosphate homeo-
stasis throughout different stages in life, as the dynamics in bone metabolism 
differ from stage to stage. As stated in chapter 3, there are several ways to 
address the influence of estradiol and testosterone on serum calcium and 
phosphate homeostasis and their regulating hormones, such as PTH and 
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vitamin D. Assessing whether there are alterations in calcium and phosphate 
homeostasis in peripubertal boys and girls will help to elucidate whether 
there are sex differences at younger age as well. Moreover, women of repro-
ductive age might show variations in their serum calcium and phosphate 
levels related to the hormonal fluctuations during their menstrual cycle. 
Additionally, the investigation of serum calcium and phosphate levels in 
patients that receive gonadotropin-releasing hormone agonists (GnRH-
agonists) continuously in order to suppress luteinizing hormone (LH) and 
follicle stimulating hormone (FSH) production could yield new insights into 
the influence of sex hormones on calcium and phosphate homeostasis. Most 
suitable are patients that used the GnRH-agonists for non-malignant causes 
such as endometriosis and pubertas praecox. GnRH-agonists initially cause 
upregulation of LH and FSH, but with continuous use both are suppressed 
[73]. In order to address the effect of sex hormones, serum calcium, phos-
phate and their regulating hormones could be measured before they start 
treatment with a GnRH-agonist, during the first phase after initiation and 
after the initial upregulation when LH and FSH are suppressed. Further-
more, GnRH-agonists were shown to be associated with decreased BMD, and 
observational studies have demonstrated associations with cardiovascular 
mortality, making users of GnRH-agonists an interesting group to study with 
respect to the results described in this thesis [73, 74].  
As stated previously, increased serum calcium and phosphate levels have 
been associated with cardiovascular diseases and mortality [37]. A next step 
to address calcium and phosphate homeostasis and their impact on cardio-
vascular disease could be to evaluate whether single nucleotide polymor-
phisms (SNPs), which influence serum calcium, phosphate levels and BMD, 
are associated with the occurrence of cardiovascular diseases in a so-called 
mendelian randomization design. Recently, Larsson et al. studied whether 
SNPs related to serum calcium levels were associated with coronary artery 
calcification and myocardial infarction. They found an increased risk for 
coronary artery disease associated with SNPs that predisposed to higher 
serum calcium levels [75]. A previous study by Babinsky et al. in 2015 did not 
find an association of polymorphisms in CaSR with vascular calcifications in 
renal transplant recipients [76]. However, they did find renal transplant 
recipients heterozygous for a polymorphism in the promoter region 
(rs115759455) of this gene to have increased serum phosphate levels. The 
main limitation of this study in establishing an association is the low number 
of subjects included. Only 284 subjects were included, and the heterozygous 
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variant of rs1157559455 was present in only 23 subjects, not allowing for the 
study of sex differences. The studies presented in this thesis, as well as some 
other studies in the field, suggest that sex differences exist in serum calcium 
and phosphate homeostasis after menopause [77-84].  
Large cohort studies on cardiovascular events in both men and women are 
necessary to address whether genetic variants that influence calcium and 
phosphate levels are associated with either cardiovascular events, mortality, 
or fracture risk, or a combination of the three.  
As stated before, following stratification into high and low DPD levels within 
osteoporotic postmenopausal women, our study on osteoclastic bone resorp-
tion revealed higher osteoclastogenesis and more osteoclastic bone resorption 
in vitro in osteoporotic subjects with high DPD levels. This leads to the ques-
tion whether there are different types of osteoporosis present among these 
elderly women. Two previous studies on different types of osteoporosis in the 
elderly defined primary (type 1 osteoporosis) and senile osteoporosis (type 2 
osteoporosis) [49]. Primary or type 1 osteoporosis predominantly affects 
women during aging and is thought to be related to the loss of estrogens, 
causing an increased loss of mainly trabecular bone, and to a lesser extend 
loss of cortical bone, resulting in vertebral fractures and Colles fractures, 
which occur at the ultradistal forearm, a site rich in trabecular bone. Senile 
osteoporosis or type 2 osteoporosis is considered a proportionate loss of corti-
cal and trabecular bone, leading to hip and vertebral fractures, and is associ-
ated with aging in both men and women. It occurs in persons over 70 years of 
age and one of the mechanisms of senile osteoporosis is thought to be due to 
impaired production of 1,25-dihydroxyvitamin D3 and decreased osteoblast 
activity while normal osteoclast activity is maintained [49, 85]. Other pro-
cesses that are involved in the development of osteoporosis and fragility frac-
tures with aging are increased oxidative stress, cell senescence, 
inflammation, osteocyte apoptosis, DNA damage, formation of advanced gly-
cation end products, and a decrease in autophagy, mitochondria biogenesis, 
vascularity, hydration of bone, and alterations in musculoskeletal progenitor 
cells [86]. Recently, Ucer et al. studied the molecular basis of the way in 
which sex steroid deficiency as opposed to aging affects the skeleton in mice, 
and whether aging and sex steroid deficiency are two distinct mechanisms 
[87]. Both aging and sex steroid deficiency lead to accumulation of reactive 
oxygen species (ROS). In order to study whether there was a different molec-
ular basis between aging and sex steroid deficiency the aforementioned   
researchers used aged mice which were either ovariectomized or gonadecto-
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mized and compared them with aged transgenic mice with a genetic con-
struct that enhanced catalase activity in either the myeloid or the mesen-
chymal lineage, thereby lowering the levels of ROS. Additionally, some of the 
transgenic mice were ovariectomized or gonadectomized as well, in order to 
discriminate between the influence of sex steroid deficiency and aging. They 
found that lower ROS levels in gonadectomized transgenic mice in the mye-
loid lineage prevented the mice from cortical but not from cancellous bone 
loss caused by sex steroid deficiency [87].  
To date, people with osteoporotic fractures are not classified as suffering from 
either type 1 or type 2 osteoporosis, and first-line treatment is aimed at re-
ducing osteoclast activity with bisphosphonates orally, intravenous zoledron-
ic acid in case of intolerance, or other antiresorptive drugs such as 
denosumab [10]. Currently, there is no direct assessment of effectiveness of 
antiresorptive therapy possible with bisphosphonates, since changes in BMD 
are very modest and do not accurately reflect changes in fracture risk [88, 
89]. Bone resorption markers could be used as a tool to assess adherence to 
antiresorptive therapy but not in order to assess which therapy should be 
instituted [90]. Our study in chapter 7 showed a clear association between 
high DPD levels and osteoclast activity in in vitro assays, and a low osteo-
clast activity in osteoporotic subjects with low DPD levels. It could be that 
subjects with low osteoclastogenic potential and low DPD levels have a low 
bone turnover phenotype. To reduce fracture risk in this subgroup, anabolic 
therapy could potentially be more beneficial than antiresorptive therapy, 
which could be favorable in the osteoporotic subjects with high DPD levels 
and high osteoclast activity. Assessing whether osteoporotic subjects with low 
DPD and osteoclastogenic potential benefit in a similar manner from antire-
sorptive therapy compared to osteoporotic subjects with high DPD levels may 
lead to alternative therapeutic strategies for these different groups. Discrim-
inating between the types of osteoporosis based on a solid assay which evalu-
ates osteoclast function in addition to the assessment of markers of bone 
resorption and bone formation might be helpful for patients, allowing them to 
receive more targeted therapy or to switch sooner to a different form of ther-
apy. Such studies could potentially lead to increased fracture reduction, more 
personalized treatment, and improved quality of life. 
196
 
References 
1. Oeppen, J. and J.W. Vaupel, Demography. Broken limits to life 
expectancy. Science, 2002. 296(5570): p. 1029-31. 
2. Davis, J.W., R. Chung, and D.T. Juarez, Prevalence of comorbid 
conditions with aging among patients with diabetes and cardiovascular 
disease. Hawaii Med J, 2011. 70(10): p. 209-13. 
3. Iseki, K., Gender differences in chronic kidney disease. Kidney Int, 2008. 
74(4): p. 415-7. 
4. Svedbom, A., et al., Osteoporosis in the European Union: a compendium 
of country-specific reports. Arch Osteoporos, 2013. 8: p. 137. 
5. Engelgau, M.M., et al., The evolving diabetes burden in the United 
States. Ann Intern Med, 2004. 140(11): p. 945-50. 
6. Jaspers, L., et al., Health in middle-aged and elderly women: A 
conceptual framework for healthy menopause. Maturitas, 2015. 81(1): p. 
93-8. 
7. M, H., Invitational Conference ‘Is health a state or an ability? Towards a 
dynamic concept of health’. 2010. 
8. Huber, M., et al., How should we define health? BMJ, 2011. 343: p. 
d4163. 
9. Lian, J.B.S., G.S. Aubin, J.E., Bone Formation: Maturation and 
Functional Activities of Osteoblast Lineage Cells, in Primer on the 
Metabolic Bone Diseases and Disorders of Mineral Metabolism. 2003, 
American Society for Bone and Mineral Research: Washington. p. 13-28. 
10. CBO, Richtlijn Osteoporose en fractuurpreventie derde herziening. 2011: 
Utrecht. 
11. Enattah, N., et al., Molecularly defined lactose malabsorption, peak bone 
mass and bone turnover rate in young finnish men. Calcif Tissue Int, 
2004. 75(6): p. 488-93. 
12. Obermayer-Pietsch, B.M., et al., Genetic predisposition for adult lactose 
intolerance and relation to diet, bone density, and bone fractures. J Bone 
Miner Res, 2004. 19(1): p. 42-7. 
13. Honkanen, R., et al., Does lactose intolerance predispose to low bone 
density? A population-based study of perimenopausal Finnish women. 
Bone, 1996. 19(1): p. 23-8. 
14. Trajanoska, K., et al., Assessment of the genetic and clinical 
determinants of fracture risk: genome wide association and mendelian 
randomisation study. BMJ, 2018. 362: p. k3225. 
15. Brenneman, S.K., et al., Impact of recent fracture on health-related 
quality of life in postmenopausal women. J Bone Miner Res, 2006. 21(6): 
p. 809-16. 
197
 
16. Bliuc, D., et al., Mortality risk associated with low-trauma osteoporotic 
fracture and subsequent fracture in men and women. JAMA, 2009. 
301(5): p. 513-21. 
17. Ioannidis, G., et al., Relation between fractures and mortality: results 
from the Canadian Multicentre Osteoporosis Study. CMAJ, 2009. 181(5): 
p. 265-71. 
18. Lips, P. and N.M. van Schoor, Quality of life in patients with 
osteoporosis. Osteoporos Int, 2005. 16(5): p. 447-55. 
19. Bolland, M.J., et al., Calcium intake and risk of fracture: systematic 
review. BMJ, 2015. 351: p. h4580. 
20. Tai, V., et al., Calcium intake and bone mineral density: systematic 
review and meta-analysis. BMJ, 2015. 351: p. h4183. 
21. Avenell, A., J.C. Mak, and D. O'Connell, Vitamin D and vitamin D 
analogues for preventing fractures in post-menopausal women and older 
men. Cochrane Database Syst Rev, 2014(4): p. CD000227. 
22. Larussa, T., et al., Bone mineralization in celiac disease. Gastroenterol 
Res Pract, 2012. 2012: p. 198025. 
23. Casagrande, D.S., et al., Changes in bone mineral density in women 
following 1-year gastric bypass surgery. Obes Surg, 2012. 22(8): p. 1287-
92. 
24. Zanchetta, M.B., V. Longobardi, and J.C. Bai, Bone and Celiac Disease. 
Curr Osteoporos Rep, 2016. 14(2): p. 43-8. 
25. Kelman, A. and N.E. Lane, The management of secondary osteoporosis. 
Best Pract Res Clin Rheumatol, 2005. 19(6): p. 1021-37. 
26. Via, M.A. and J.I. Mechanick, Nutritional and Micronutrient Care of 
Bariatric Surgery Patients: Current Evidence Update. Curr Obes Rep, 
2017. 
27. G, S. Biological reference values. In vitro veritas  [cited 2; Available 
from: http://www.acclc.cat/continguts/ivv025.pdf. 
28. Plebani, M. and K. Lackner, Reference values: still a critical issue in 
laboratory medicine. Clin Chem Lab Med, 2010. 48(5): p. 577-8. 
29. Risch, M., U. Nydegger, and L. Risch, SENIORLAB: a prospective 
observational study investigating laboratory parameters and their 
reference intervals in the elderly. Medicine (Baltimore), 2017. 96(1): p. 
e5726. 
30. Hoenderop, J.G., et al., Molecular identification of the apical Ca2+ 
channel in 1, 25-dihydroxyvitamin D3-responsive epithelia. J Biol Chem, 
1999. 274(13): p. 8375-8. 
31. van der Eerden, B.C., et al., The epithelial Ca2+ channel TRPV5 is 
essential for proper osteoclastic bone resorption. Proc Natl Acad Sci U S 
A, 2005. 102(48): p. 17507-12. 
198
 
32. van Abel, M., et al., Age-dependent alterations in Ca2+ homeostasis: role 
of TRPV5 and TRPV6. Am J Physiol Renal Physiol, 2006. 291(6): p. 
F1177-83. 
33. Goltzman, D., Inferences from genetically modified mouse models on the 
skeletal actions of vitamin D. J Steroid Biochem Mol Biol, 2015. 148: p. 
219-24. 
34. Lieben, L., et al., Normocalcemia is maintained in mice under 
conditions of calcium malabsorption by vitamin D-induced inhibition of 
bone mineralization. J Clin Invest, 2012. 122(5): p. 1803-15. 
35. Jones, G., S.A. Strugnell, and H.F. DeLuca, Current understanding of 
the molecular actions of vitamin D. Physiol Rev, 1998. 78(4): p. 1193-
231. 
36. Khaleel, A., et al., A Single Nucleotide Polymorphism (rs4236480) in 
TRPV5 Calcium Channel Gene Is Associated with Stone Multiplicity in 
Calcium Nephrolithiasis Patients. Mediators Inflamm, 2015. 2015: p. 
375427. 
37. Foley, R.N., et al., Calcium-phosphate levels and cardiovascular disease 
in community-dwelling adults: the Atherosclerosis Risk in Communities 
(ARIC) Study. Am Heart J, 2008. 156(3): p. 556-63. 
38. Anagnostis, P., et al., Atherosclerosis and osteoporosis: age-dependent 
degenerative processes or related entities? Osteoporos Int, 2009. 20(2): p. 
197-207. 
39. Khosla, S., The bone and beyond: a shift in calcium. Nat Med, 2011. 17(4): 
p. 430-1. 
40. Al-Aly, Z., et al., Aortic Msx2-Wnt calcification cascade is regulated by 
TNF-alpha-dependent signals in diabetic Ldlr-/- mice. Arterioscler 
Thromb Vasc Biol, 2007. 27(12): p. 2589-96. 
41. Sage, A.P., Y. Tintut, and L.L. Demer, Regulatory mechanisms in 
vascular calcification. Nat Rev Cardiol, 2010. 7(9): p. 528-36. 
42. Datta, H.K., et al., The cell biology of bone metabolism. J Clin Pathol, 
2008. 61(5): p. 577-87. 
43. Seibel, M.J., Biochemical markers of bone turnover: part I: biochemistry 
and variability. Clin Biochem Rev, 2005. 26(4): p. 97-122. 
44. Lips, P., Epidemiology and predictors of fractures associated with 
osteoporosis. Am J Med, 1997. 103(2A): p. 3S-8S; discussion 8S-11S. 
45. Garnero, P., et al., Increased bone turnover in late postmenopausal 
women is a major determinant of osteoporosis. Journal of bone and 
mineral research : the official journal of the American Society for Bone 
and Mineral Research, 1996. 11(3): p. 337-49. 
199
 
46. Sowers, M.R., et al., Changes in bone resorption across the menopause 
transition: effects of reproductive hormones, body size, and ethnicity. J 
Clin Endocrinol Metab, 2013. 98(7): p. 2854-63. 
47. Charatcharoenwitthaya, N., et al., Effect of blockade of TNF-alpha and 
interleukin-1 action on bone resorption in early postmenopausal women. 
J Bone Miner Res, 2007. 22(5): p. 724-9. 
48. Wu, X.Y., et al., Age-related bone turnover markers and osteoporotic risk 
in native Chinese women. BMC Endocr Disord, 2014. 14: p. 8. 
49. Riggs, B.L. and L.J. Melton, 3rd, Involutional osteoporosis. N Engl J 
Med, 1986. 314(26): p. 1676-86. 
50. Oertelt-Prigione, S., et al., Analysis of sex and gender-specific research 
reveals a common increase in publications and marked differences 
between disciplines. BMC Med, 2010. 8: p. 70. 
51. Strozynska, E., et al., The Impact of Risk Burden Differences between 
Men and Women on the Clinical Course of Ischemic Stroke. J Stroke 
Cerebrovasc Dis, 2016. 25(4): p. 843-7. 
52. Roger, V.L., et al., Heart disease and stroke statistics--2012 update: a 
report from the American Heart Association. Circulation, 2012. 125(1): p. 
e2-e220. 
53. Dolor, R.J., et al., in Treatment Strategies for Women With Coronary 
Artery Disease. 2012: Rockville (MD). 
54. de Kat, A.C., et al., Unraveling the associations of age and menopause 
with cardiovascular risk factors in a large population-based study. BMC 
Med, 2017. 15(1): p. 2. 
55. den Ruijter, H.M., et al., Sex matters to the heart: A special issue 
dedicated to the impact of sex related differences of cardiovascular 
diseases. Atherosclerosis, 2015. 241(1): p. 205-7. 
56. Tanko, L.B., et al., Relationship between osteoporosis and 
cardiovascular disease in postmenopausal women. J Bone Miner Res, 
2005. 20(11): p. 1912-20. 
57. Campos-Obando, N., et al., Bone health and coronary artery 
calcification: The Rotterdam Study. Atherosclerosis, 2015. 241(1): p. 
278-83. 
58. Ye, C., et al., Decreased Bone Mineral Density Is an Independent 
Predictor for the Development of Atherosclerosis: A Systematic Review 
and Meta-Analysis. PLoS One, 2016. 11(5): p. e0154740. 
59. Kim, A.M., C.M. Tingen, and T.K. Woodruff, Sex bias in trials and 
treatment must end. Nature, 2010. 465(7299): p. 688-9. 
60. Zucker, I. and A.K. Beery, Males still dominate animal studies. Nature, 
2010. 465(7299): p. 690. 
200
 
61. Riccardi, D. and P.J. Kemp, The calcium-sensing receptor beyond 
extracellular calcium homeostasis: conception, development, adult 
physiology, and disease. Annu Rev Physiol, 2012. 74: p. 271-97. 
62. Portillo, M.R. and M.E. Rodriguez-Ortiz, Secondary 
Hyperparthyroidism: Pathogenesis, Diagnosis, Preventive and 
Therapeutic Strategies. Rev Endocr Metab Disord, 2017. 18(1): p. 79-95. 
63. Naveh-Many, T., et al., Parathyroid cell proliferation in normal and 
chronic renal failure rats. The effects of calcium, phosphate, and vitamin 
D. J Clin Invest, 1995. 96(4): p. 1786-93. 
64. Huang, J.C., et al., PTH differentially regulates expression of RANKL 
and OPG. J Bone Miner Res, 2004. 19(2): p. 235-44. 
65. Ward, B.K., et al., The role of the calcium-sensing receptor in human 
disease. Clin Biochem, 2012. 45(12): p. 943-53. 
66. Shimada, T., et al., FGF-23 is a potent regulator of vitamin D 
metabolism and phosphate homeostasis. J Bone Miner Res, 2004. 19(3): 
p. 429-35. 
67. Kuro-o, M., Klotho and aging. Biochim Biophys Acta, 2009. 1790(10): p. 
1049-58. 
68. Shimada, T., et al., Targeted ablation of Fgf23 demonstrates an essential 
physiological role of FGF23 in phosphate and vitamin D metabolism. J 
Clin Invest, 2004. 113(4): p. 561-8. 
69. Dusso, A.S., A.J. Brown, and E. Slatopolsky, Vitamin D. Am J Physiol 
Renal Physiol, 2005. 289(1): p. F8-28. 
70. Ichikawa, S., et al., A homozygous missense mutation in human 
KLOTHO causes severe tumoral calcinosis. J Clin Invest, 2007. 117(9): 
p. 2684-91. 
71. Consortium, A., Autosomal dominant hypophosphataemic rickets is 
associated with mutations in FGF23. Nat Genet, 2000. 26(3): p. 345-8. 
72. Yu, X. and K.E. White, FGF23 and disorders of phosphate homeostasis. 
Cytokine Growth Factor Rev, 2005. 16(2): p. 221-32. 
73. Sagsveen, M., et al., Gonadotrophin-releasing hormone analogues for 
endometriosis: bone mineral density. Cochrane Database Syst Rev, 
2003(4): p. CD001297. 
74. Romo, M.L., et al., Pharmacologic androgen deprivation and 
cardiovascular disease risk factors: a systematic review. Eur J Clin 
Invest, 2015. 45(5): p. 475-84. 
75. Larsson, S.C., S. Burgess, and K. Michaelsson, Association of Genetic 
Variants Related to Serum Calcium Levels With Coronary Artery 
Disease and Myocardial Infarction. JAMA, 2017. 318(4): p. 371-380. 
76. Babinsky, V.N., et al., Association studies of calcium-sensing receptor 
(CaSR) polymorphisms with serum concentrations of glucose and 
201
 
phosphate, and vascular calcification in renal transplant recipients. 
PLoS One, 2015. 10(3): p. e0119459. 
77. Haglin, L., L. Backman, and B. Tornkvist, A structural equation model 
for assessment of links between changes in serum triglycerides, -urate, 
and -glucose and changes in serum calcium, -magnesium and -
phosphate in type 2 diabetes and non-diabetes metabolism. Cardiovasc 
Diabetol, 2011. 10: p. 116. 
78. Keating, F.R., Jr., et al., The relation of age and sex to distribution of 
values in healthy adults of serum calcium, inorganic phosphorus, 
magnesium, alkaline phosphatase, total proteins, albumin, and blood 
urea. J Lab Clin Med, 1969. 73(5): p. 825-34. 
79. Nordin, B.E., et al., Biochemical variables in pre- and postmenopausal 
women: reconciling the calcium and estrogen hypotheses. Osteoporos Int, 
1999. 9(4): p. 351-7. 
80. Cirillo, M., C. Ciacci, and N.G. De Santo, Age, renal tubular phosphate 
reabsorption, and serum phosphate levels in adults. N Engl J Med, 2008. 
359(8): p. 864-6. 
81. de Boer, I.H., T.C. Rue, and B. Kestenbaum, Serum phosphorus 
concentrations in the third National Health and Nutrition Examination 
Survey (NHANES III). Am J Kidney Dis, 2009. 53(3): p. 399-407. 
82. Dhingra, R., et al., Relations of serum phosphorus and calcium levels to 
the incidence of cardiovascular disease in the community. Arch Intern 
Med, 2007. 167(9): p. 879-85. 
83. Onufrak, S.J., et al., Investigation of gender heterogeneity in the 
associations of serum phosphorus with incident coronary artery disease 
and all-cause mortality. Am J Epidemiol, 2009. 169(1): p. 67-77. 
84. Tonelli, M., et al., Relation between serum phosphate level and 
cardiovascular event rate in people with coronary disease. Circulation, 
2005. 112(17): p. 2627-33. 
85. Simpson, A.H. and I.R. Murray, Osteoporotic fracture models. Curr 
Osteoporos Rep, 2015. 13(1): p. 9-15. 
86. van den Beld, A.W., et al., The physiology of endocrine systems with 
ageing. Lancet Diabetes Endocrinol, 2018. 6(8): p. 647-658. 
87. Ucer, S., et al., The Effects of Aging and Sex Steroid Deficiency on the 
Murine Skeleton Are Independent and Mechanistically Distinct. J Bone 
Miner Res, 2017. 32(3): p. 560-574. 
88. Rabenda, V., O. Bruyere, and J.Y. Reginster, Relationship between bone 
mineral density changes and risk of fractures among patients receiving 
calcium with or without vitamin D supplementation: a meta-regression. 
Osteoporos Int, 2011. 22(3): p. 893-901. 
202
 
89. Bell, K.J., et al., Value of routine monitoring of bone mineral density 
after starting bisphosphonate treatment: secondary analysis of trial data. 
BMJ, 2009. 338: p. b2266. 
90. Diez-Perez, A., et al., International Osteoporosis Foundation and 
European Calcified Tissue Society Working Group. Recommendations for 
the screening of adherence to oral bisphosphonates. Osteoporos Int, 2017. 
28(3): p. 767-774.  
203
Summary 
Bone is a dynamic tissue with several cell types that each have their own 
function. The main component of bone is hydroxyapatite which is a molecular 
structure that contains calcium and phosphate ions. Apart from being incor-
porated in hydroxyapatite these two ions are important in several processes 
in the body. Key regulators in calcium and phosphate homeostasis are the 
hormones vitamin D, parathyroid hormone (PTH) and fibroblast growth fac-
tor 23 (FGF23). A condition affecting bone is osteoporosis, which mainly oc-
curs with aging and predominantly in women. The general aim of this thesis 
was to study calcium and phosphate homeostasis in relation to aging and the 
age-related disorder osteoporosis. Chapter 1 presents the introduction and 
aim of the thesis.  
Sex differences in serum calcium and phosphate have been reported but that 
to date their nature and underlying regulatory mechanisms have remained 
unclear.  
Chapter 2 presents the data of a prospective population-based cohort study 
in total 9253 subjects from three independent cohorts of the Rotterdam Study 
(RS) on sex differences in calcium and phosphate levels. Furthermore, alka-
line phosphatase (ALP), 25-hydroxyvitamin D3 (25(OH)D3), 1,25-
dihydroxyvitamin D3 (1,25(OH)2D3), estradiol and testosterone as potential 
covariates to elucidate underlying mechanisms of sex differences were stud-
ied in this cohort. Women, compared to men, had significantly higher total 
serum calcium and phosphate. The potential covariates ALP, 25(OH)D3 or 
1,25(OH)2D3 could not be accounted for this sex difference. Adjustments for 
serum testosterone but not for estradiol diminished sex differences in serum 
phosphate levels. Pre-menopausal women had higher serum phosphate but 
not calcium compared to men but their serum phosphate levels were lower 
compared to postmenopausal women. In the total group, both serum calcium 
and phosphate levels decreased with age with a significant interaction for sex 
differences for serum calcium but not phosphate. 
Chapter 3 shows the results of a study that examined whether a relation 
between sex differences in calcium and phosphate had a relation with age. In 
a total of 15211 samples from subjects derived from a clinical chemistry da-
tabase from the Erasmus MC from three separate years, there was a signifi-
cant sex*age interaction for serum calcium and phosphate levels and the 
calcium*phosphate product. Serum calcium, phosphate and the calci-
um*phosphate product were higher in women above 45 years of age com-
pared to men of similar age. In two younger age groups no sex-differences 
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were found. In men, serum calcium and phosphate levels were highest in the 
youngest age group compared to the age groups of 18-44 and ุ45 years. In 
women, serum calcium levels were also significantly higher in the age group 
1-17 and the age  
group ุ45 years compared to the 18-44 years age group, while no significant 
difference was found between the highest and the youngest age group. In 
women, serum phosphate was different between the three different age 
groups with highest level in the group 1-17 years and lowest in the group 18-
44 years. 
Extreme phosphate levels have been associated with mineralization defects 
and increased fracture risk. Whether phosphate levels within the normal 
range are related to bone health in the general population is not well under-
stood. In Chapter 4 the results are described of an association study of 
phosphate with bone mineral density (BMD) and fracture risk in two popula-
tion-based cohorts: the Dutch Rotterdam Study (RS-I, RS-II, RS-III; n=6791) 
and the US Osteoporotic Fractures in Men (MrOS; n=5425) study. This study 
showed that serum phosphate levels were positively associated with fracture 
risk in men and women from RS, and findings were replicated in MrOS 
(pooled HR all [95% CI]: 1.47 [1.31-1.65]). Phosphate was associated with 
fracture risk in subjects without chronic kidney disease (CKD): all (1.44 
[1.26-1.63]) and in men with CKD (1.93 [1.42-2.62]). Phosphate was inversely 
related to lumbar spine BMD (LS-BMD) in men (β: -0.06 [-0.11 to -0.02]) and 
not to femoral neck BMD (FN-BMD) in either sex. Adjustments were made 
for age, body mass index, smoking, serum levels of calcium, potassium, 
25(OH)D3, estimated glomerular filtration rate (eGFR), FN-BMD, prevalent 
diabetes, and cardiovascular disease. Additional adjustments were made for 
phosphate intake, PTH, and FGF 23 levels in MrOS. 
Chapter 5 presents the results of an association study between genetically 
defined lactose intolerance and body height, bone parameters and calcium 
homeostasis. 6367 individuals from the Rotterdam Study and 844 individuals 
from the Longitudinal Aging Study Amsterdam (LASA) were genotyped for 
genetically defined lactose intolerance, the C-variant of the T-13910C poly-
morphism upstream the lactase phlorizin hydrolase (LPH) gene. Further-
more, subjects were genotyped for vitamin D receptor (VDR) polymorphisms. 
Associations with body height (p = 2.7x10-8) and vertebral area (p = 0.048) 
found in the Rotterdam study were explained by population stratification, as 
assessed by principal component analyses, and disappeared after additional 
adjustments. The C-allele of the T-13910C polymorphism causing lactose 
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intolerance was shown to be associated with lower dietary calcium intake (p= 
9.2x10-7) and serum calcium levels (p = 0.02) but not with BMD or fractures. 
For none of the parameters studied was interaction between the T-13910C 
polymorphism and VDR block 5 haplotype 1 observed. This study demon-
strated the impact of population stratification and urges researchers to care-
fully take this into account in genetic associations, in particular, in dietary 
intake-related phenotypes, of which LPH and lactose intolerance are a strong 
example. 
Peripheral blood mononuclear cells (PBMCs) are cells that are circulating in 
the blood with osteoclastogenic potential. Growth factors can stimulate these 
cells to differentiate into osteoclasts. Furthermore, these cells have 1α-
hydroxylase activity and are therefore capable of converting 25(OH)D3 into 
1,25(OH)2D3.  The ability of PBMCs to convert 25(OH)D3 into 1,25(OH)2D3 is 
used in Chapter 6 where a case of a young girl with pseudovitamin D defi-
ciency is described with nearly absent 1α-hydroxylase activity in PBMCs 
compared to those of healthy blood donors. With DNA sequencing a new 
compound heterozygous mutation was found in the CYP27B1 gene; a 
(c413G>T) mutation in exon 3 (R138L) and a (c1232G>A) mutation in exon 8 
(C411Y). In silico analyses confirmed that mutations at these positions are 
probably damaging for the protein since the amino acids are situated in a 
highly conserved region. Her healthy parents each of whom carried one of the 
mutations also had compromised conversion of 25(OH)D3 into 1,25(OH)2D3 in 
PBMCs, being only marginally higher than the patient. 
In Chapter 7 the results are presented of a study on the osteoclastogenic 
potential of PBMCs derived from the blood of postmenopausal women with 
longstanding osteoporosis compared with the osteoclastogenic potential of 
PBMCs derived from the blood of healthy age-matched controls. This study 
showed no difference in PBMC osteoclastogenic capacity and activity between 
women with and without osteoporosis and at least one previous fracture, who 
were on average 29.5 years after menopause, suggesting that there is no 
difference in circulating osteoclast precursors. Stratification into high and 
low deoxypyridinoline (DPD) levels, a biomarker of bone resorption, showed 
higher osteoclastogenesis and more osteoclastic bone resorption in the high 
DPD group compared to the low DPD levels within the group of osteoporotic 
subjects. 
Furthermore, this thesis focusses on TRPV5, which is a calcium channel and 
present in several tissues that play a role in calcium homeostasis like the 
osteoclast one of the cells types in the bone. In Chapter 8 it is shown that a 
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life-long challenge of calcium homeostasis as present in Trpv5-/- mice caused 
accelerated bone aging and a low cortical and trabecular bone mass pheno-
type. Previous studies have shown that  
Trpv5-/- mice display vitamin D resistance with aging at the level of the kid-
neys and intestines with hypercalciuria. Aging significantly increased serum 
1,25(OH)2D3 and PTH levels in both genotypes but they were more elevated 
in Trpv5-/- mice, whereas serum calcium was not affected by age or genotype. 
The phenotype of the Trpv5-/- mice suggests that maintenance of adequate 
serum calcium levels in patients with disturbances in calcium homeostasis 
should be a priority in order to prevent bone loss at older age. The Trpv5-
deficient mouse appears to be a suitable model for lifelong challenge of calci-
um homeostasis and its consequences for bone metabolism. 
In chapter 9 this thesis is concluded by focusing on the integration of three 
main topics that have been discussed throughout the chapters; aging and its 
relationship with calcium and phosphate homeostasis, biomarkers and aging, 
and sexual dimorphism. Furthermore, suggestions for future research are 
given.  
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Samenvatting 
Bot is een dynamisch weefsel dat bestaat uit verschillende celtypen die elk 
hun eigen functie hebben. Hydroxyapatiet is het hoofdbestanddeel van bot, 
calcium en fosfaat ionen zijn de belangrijkste bestanddelen van deze molecu-
laire structuur. Deze twee ionen zijn belangrijk voor verscheidene processen 
in het lichaam. Vitamine D, parathyroid hormoon (PTH) en fibroblast groei 
factor 23 (FGF23) zijn de belangrijkste hormonen die betrokken zijn bij het 
regelen van de calcium en de fosfaat homeostase. Osteoporose is een aandoen 
van het bot die voornamelijk bij het ouder worden voorkomt en vaker bij 
vrouwen dan bij mannen. Het doel van dit proefschrift was om de calcium en 
fosfaat homeostase te bestuderen in relatie tot veroudering en in relatie tot 
osteoporose. Hoofdstuk 1 geeft een algemene inleiding en het doel van dit 
proefschrift. 
Genderverschillen in serum calcium en fosfaat zijn reeds beschreven, deson-
danks is de reden van deze genderverschillen en de mechanismen die hieraan 
ten grondslag liggen nog onbekend. Hoofdstuk 2 beschrijft de uitkomsten 
van een prospectieve populatie studie met 9253 deelnemers uit drie onafhan-
kelijk cohorten van de Rotterdam studie (RS) naar genderverschillen in cal-
cium en fosfaat spiegels. Om onderliggende mechanismen die aan de 
genderverschillen ten grondslag kunnen liggen te analyseren, werd de in-
vloed van alkalisch fosfatase (ALP), 25-hydroxyvitamine D3 (25(OH)D3), 1,25-
dihydroxyvitamine D3 (1,25(OH)2D3), oestradiol en testosteron, zogenaamde 
co-variabelen, geanalyseerd. Vrouwen hadden vergleken met mannen hogere 
calcium en fosfaat spiegels. De potentiele co-variabelen ALP, 25(OH)D3 of 
1,25(OH)2D3 speelden geen rol bij deze genderverschillen. Adjusteren voor 
serum testosteron maar niet voor oestradiol verminderde de genderverschil-
len in serum fosfaat spiegels. Vrouwen die voor hun menopauze zaten had-
den hogere serum fosfaat spiegels vergeleken met mannen, maar hun serum 
fosfaat spiegels waren lager dan die van vrouwen na de menopauzes. In de 
totale groep gingen zowel de serum calcium als de serum fosfaat spiegels met 
de leeftijd omlaag, met daarbij een significante interactie voor genderver-
schillen aangaande serum calcium spiegels maar niet voor fosfaat.  
In Hoofdstuk 3 worden resultaten beschreven van een studie naar leeftijd 
gerelateerde genderverschillen in calcium en fosfaat spiegels. In totaal wer-
den 15211 personen geselecteerd uit een data base van het klinisch chemisch 
laboratorium van het Erasmus MC uit 3 verschillende jaren. In deze popula-
tie werd een significante gender*leeftijd interactie gevonden voor serum 
spiegels van calcium en fosfaat en het calcium*fosfaat product. Serum spie-
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gels van calcium en fosfaat en het calcium*fosfaat product waren hoger in 
vrouwen ouder dan 45 jaar in vergelijking tot mannen ouder dan 45 jaar. Er 
waren geen genderverschillen in de twee jongere leeftijdsgroepen die geana-
lyseerd werden. In mannen waren de serum spiegels voor calcium en fosfaat 
het hoogst in de jongste leeftijdsgroep in vergelijking tot de leeftijdsgroep 18-
44 jaar en de leeftijdsgroep ouder dan 45 jaar. In vrouwen waren serum cal-
cium spiegels ook significant hoger in de leeftijdsgroep 1-17 jaar en in de 
leeftijdsgroep ouder dan 45 jaar in vergelijking met de leeftijdsgroep vrouwen 
van 18-44 jaar, terwijl er geen significant verschil in serum calcium spiegels 
tussen de oudste en de jongste groep werd gevonden. Serum fosfaat spiegels 
in vrouwen waren verschillend tussen de drie leeftijdsgroepen met de hoogste 
waarde in de leeftijdsgroep 1-17 jaar en de laagste waarde in de leeftijds-
groep 18-44 jaar.   
Extreme fosfaat spiegels zijn geassocieerd met mineralisatie defecten in bot 
en verhoogd fractuurrisico. Of fosfaat spiegels binnen de normaalwaarden 
gerelateerd zijn aan de gezondheid van bot in de algemene bevolking is niet 
bekend. In Hoofdstuk 4 werd de associatie tussen fosfaat met bot mineraal 
dichtheid en fractuurrisico onderzocht in twee populatie gebaseerde cohorten: 
de Nederlandse Rotterdam Studie (RS-I, RS-II, RS-III; n=6791) en de Osteo-
porotische fractuur in mannen studie uit de Verenigde Staten (MrOS; 
n=5425). Deze studie laat zien dat serum fosfaat levels positief geassocieerd 
zijn met fractuurrisico in mannen en vrouwen van de RS-studie, deze bevin-
dingen werden gerepliceerd in MrOS (gepoolde HR alle cohorten [95% CI]: 
1.47 [1.31-1.65]). Fosfaat was geassocieerd met fractuurrisico in mensen met 
chronische nierziekte (CKD): (alle cohorten (1.44 [1.26-1.63]) en in mannen 
met CKD (1.93 [1.42-2.62]). Fosfaat was omgekeerd gerelateerd met lumbale 
wervelkolom bot minerale dichtheid (LS-BMD) in mannen (ß: -0.06 [-0.11 tot 
-0.02]) maar niet met bot minerale dichtheid van de femur nek (FN-BMD) in 
beide genders. Er werd gecorrigeerd voor leeftijd, body mass index (BMI), 
roken, serum calcium spiegels, kalium, 25(OH)D3, geschatte glomerulair 
filtratie snelheid (eGFR), FN-BMD, prevalente diabetes mellitus en hart- en 
vaatziekten. Tevens werd gecorrigeerd voor fosfaat inname, PTH en FGF23 
spiegels in MrOS. 
Hoofdstuk 5 beschrijft de resultaten van een associatie studie tussen gene-
tische gedefinieerde lactose-intolerantie en lichaamslengte, bot parameters 
en calcium homeostase. Genotypering voor genetische gedefinieerde lactose-
intolerantie, de C-variant van het T-13910C polymorfisme gelegen voor het 
lactase phlorizine hydrolase (LPH) gen werd gedaan in 6367 deelnemers van 
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de Rotterdam Studie en 844 deelnemers van de Longitudinal Aging Study 
Amsterdam (LASA). Tevens vond genotypering voor vitamine D receptor 
(VDR) polymorfisme plaats. Een hoofdcomponent analyse liet zien dat de 
associaties tussen genetische gedefinieerde lactose-intolerantie en lichaams-
lengte (p=2.7x10-8) en de associatie met wervelhoogte oppervlakte (p=0.048) 
in de Rotterdam Studie volledig konden worden toegeschreven aan popula-
tiestratificatie. Er werd gevonden dat het C-allel van het T-13910C polymorf-
isme, wat lactose-intolerantie veroorzaakt, geassocieerd was met een lagere 
calcium inname via voeding (p=9.2x10-7) en lagere geïoniseerde serum calci-
um spiegels (=0.02), maar niet met BMD of fracturen. Voor geen van de pa-
rameters die in deze studie geanalyseerd werden, werd er een interactie 
tussen het T-13919C polymorfisme en VDR blok 5 haplotype 1 gevonden. 
Deze studie laat duidelijk de invloed van populatie stratificatie zien en spoort 
wetenschappers aan om rekening te houden met populatie stratificatie, met 
name in voedingsgerelateerde fenotypes waar LPH en lactose-intolerantie 
voorbeelden van zijn.  
Perifere bloed mononucleaire cellen, zijn cellen die in het circulerende bloed 
aanwezig zijn. Deze cellen kunnen door middel van groefactoren gestimu-
leerd worden om te differentiëren naar osteoclasten. Daarnaast bezitten deze 
cellen 1α-hydroxylase activiteit waardoor ze 25(OH)D3 kunnen omzetten in 
1,25(OH)2D3. In Hoofdstuk 6 wordt doormiddel van deze techniek aange-
toond dat de haar perifere bloed mononucleaire cellen van een jong meisje 
met pseudovitamine D deficiëntie een fors verlaagde capaciteit hebben om 
25(OH)D3 om te zetten in 1,25(OH)2D3 in vergelijking met gezonde bloeddo-
noren. DNA-analyses laten zien het bij dit meisje gaat om een nieuw samen-
gestelde heterozygote mutatie; (c413G>T) in exon 3 (R138L) en een 
(c1232G>A) mutatie in exon 8 (C411Y). Software analyses bevestigden dat 
mutaties op deze posities in het DNA waarschijnlijk tot beschadigingen van 
het eiwit kunnen leiden aangezien de aminozuren zich in sterk geconserveer-
de gebieden van het DNA bevinden. Haar gezonde ouders, beide drager van 
een van de mutaties, hadden ook een verminderde omzetting van 25(OH)D3 
naar 1,25(OH)2D3 in perifere bloed mononucleaire cellen, deze was slechts 
marginaal hoger dan die van patiënte.  
In hoofdstuk 7 werd het potentieel van de perifere bloed mononucleaire 
cellen om zich tot osteoclast te ontwikkelen onderzocht bij vrouwen na de 
menopauze met osteoporose en vergeleken met die van gezonde leeftijd ge-
paarde vrouwen. De vrouwen waren gemiddeld 29,5 jaar na de menopauze. 
In deze studie werden geen verschillen gevonden in het osteoclast potentieel 
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van perifere bloed mononucleaire cellen tussen vrouwen met osteoporose en 
minimaal een fractuur, dit suggereert dat er geen verschil is in circulerende 
osteoclast voorloper cellen. Stratificatie van de vrouwen met osteoporose in 
hoge en lage deoxypyridinoline (DPD) spiegels, een biomarker van bot resorp-
tie, liet een hogere osteoclast vorming en een toegenomen bot resorptie van 
de perifere bloed mononucleaire cellen in vitro zien in de vrouwen met de 
hoge DPD spiegels. 
Dit proefschrift focust daarnaast ook nog op TRPV5, een calcium kanaal wat 
in verscheidene weefsels en celtypen waaronder osteoclasten, een van de 
celtypes in het bot, een rol speelt in de calcium homeostase. In Hoofdstuk 8 
wordt beschreven dat muizen die geen functioneel TRPV5 kanaal hebben, 
zogenaamde Trpv5-/- muizen, waarbij de calcium homeostase levenslang on-
der druk staat, een fenotype ontwikkelen van versnelde bot veroudering met 
daarbij een lagere corticale en trabeculaire bot massa. Voorgaande studies 
hebben laten zien dat Trpv5-/- muizen vitamine D resistent worden geduren-
de het leven op het niveau van de nieren en de darmen, resulterend in hyper-
calciurie. Veroudering verhoogde significant serum 1,25(OH)2D3 en PTH 
spiegels zowel in de Trpv5-/- als de Trpv5+/+ muizen, terwijl serum calcium 
spiegels niet beïnvloed werd door zowel de leeftijd als door het genotype van 
de muis. Het fenotype van de Trpv5-/- muis suggereert dat de handhaving van 
adequate serum calcium spiegels in patiënten met verstoringen in de calcium 
homeostase aandacht verdient om bot verlies op oudere leeftijd te voorkomen. 
De Trpv5-deficiente muis lijkt daarom een passend model te zijn voor onder-
zoek naar de consequenties van levenslange verstoringen in calcium homeo-
stase en de consequenties hiervan op het bot metabolisme. 
Hoofdstuk 9 is het laatste hoofdstuk van dit proefschrift, in dit hoofdstuk 
worden de drie belangrijkste onderwerpen die in de verschillende hoofdstuk-
ken aan bod komen; de relatie van calcium en fosfaat homeostase met verou-
dering, biomarkers en veroudering, en genderverschillen, geïntegreerd. 
Tevens worden er in dit hoofdstuk suggesties gedaan voor toekomstig onder-
zoek. 
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Dankwoord 
En dan het meest persoonlijke deel van het proefschrift, het dankwoord. Het 
is een lang traject geweest en hoewel de woorden zorgvuldig zijn gekozen 
doen ze niet volledig recht aan de dankbaarheid die ik voel. Daarnaast ben ik 
er zeker van dat ik een aantal mensen zal vergeten te noemen, want hoe 
klein de rol ook is die jullie gespeeld hebben, voor elk bemoedigend woord en 
elke glimlach ben ik dankbaar. Dus voor al die mensen die hier niet met 
naam en toenaam genoemd zijn, dank jullie wel! 
Op de eerste plaats van de namen die ik wel noem in dit dankwoord kom jij 
Prof. dr. J.P.T.M. van Leeuwen of te wel Hans zoals je me de eerste bespre-
king duidelijk maakte. Zonder jou was dit boekje er niet geweest. Mij als arts 
begeleiden in de biologische kant van de geneeskunde heeft bijgedragen om 
mijn kennis van de basis van de geneeskunde te verdiepen. Ik weet zeker dat 
de kennis die ik onder jouw hoede heb opgedaan tijdens mijn onderzoek, mij 
helpt een betere arts te zijn. 
Daarnaast wil ik mijn tweede promotor Prof. dr. M.C. Zillikens, Carola, be-
danken. Carola, in de eerste plaats ben ik door jou het onderzoek ingerold, 
van het verzamelen van gegevens tot mijn promotietraject bij Hans. Ondanks 
de (vele) grammaticale en taalkundige verbeteringen van mijn manuscripten, 
maakte jouw bemoedigende woorden de moeite om de draad weer op te pak-
ken, altijd minder groot. Wat vond ik het leuk om te horen dat jouw harde 
werken en expertise in het “bottenveld” beloond is met een leerstoel, waar-
door ik je tijdens mijn verdediging dan ook mag aanspreken met “hooggeleer-
de opponent”. 
Ook ben ik mijn begeleidende postdoc en copromotor dr. B.J. van der Eerden, 
Bram, dankbaar. Beste Bram, bedankt dat je met jouw hulp mij thuis hebt 
laten voelen in het lab en de kneepjes van het pipetteren en celkweken hebt 
bijgebracht.  
Ook wil ik de leden van de leescommissie bedanken voor het beoordelen van 
mijn manuscripten. Geachte Prof. dr. P Lips, als medeauteur op een van mijn 
manuscripten en het feit dat je plaats hebt genomen in de leescommissie van 
mijn proefschrift wil ik je op deze plaats graag bedanken.   
Geachte Prof. dr. A.G. Uitterlinden, beste André, via jouw laboratorium ben 
ik uiteindelijk het onderzoek in gerold. Bedankt voor jouw bijdrage aan een 
groot deel van mijn manuscripten en dat je hebt plaatsgenomen in de lees-
commissie van mijn proefschrift.  
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Geachte Prof. dr. R. Zietse, beste Bob, ik heb jou als dokter en begeleider 
tijdens mijn opleiding tot internist leren kennen. Je manier van kennis over-
dragen is laagdrempelig en leerzaam. Bedankt dat je hebt plaatsgenomen in 
de leescommissie van mijn proefschrift. 
Graag wil ik ook de overige leden van mijn promotiecommissie; Prof. dr. M.A. 
Ikram, Prof. dr. E.J. Hoorn en dr. J.E. Roeters van Lennep bedanken.  
Beste Arfan, ooit zijn we tegelijk afgestudeerd als basisarts. Indertijd werd je 
door je mede-co’s al aangeduid als professor, het mag dan ook geen verras-
sing zijn dat je inmiddels een leerstoel bekleed. Bedankt dat je vanuit die 
positie nu in mijn promotiecommissie hebt plaats genomen. Daarnaast wil ik 
je ook bedanken voor je verhelderende epidemiologische en statistische in-
zichten en je bijdrage aan een groot deel van mijn manuscripten.  
Beste Ewout, jouw presentatie van het onderwerp water en zout tijdens het 
COIG, heeft een onuitwisbare indruk op mij achtergelaten. Ik hoop dat mijn 
lekenpraatje net zo verhelderend mag zijn voor mijn publiek tijdens mijn 
promotie. Bedankt dat je plaats hebt genomen in mijn promotiecommissie. 
Beste Jeanine, naast je begeleiding als internist tijdens mijn opleiding tot 
vasculair internist, wil ik je ook bedanken voor de gesprekken die we hebben 
gevoerd over man vrouw verschillen, zowel binnen als buiten de geneeskun-
de. Bedankt dat je hebt plaats genomen in mijn promotiecommissie. 
Ik wil alle collega’s van het bottenlab bedanken, Marjolein, Marco (bedankt 
voor de skilessen, het heeft een nieuwe hobby opgeleverd), Irene, Sander, 
Martijn, Claudia N, Viola, Bianca, Jeroen, Ksenja, Ruben en dan in het bij-
zonder Marijke, Rodrigo en Dutmanee a.k.a. Poom en Annelies van Amen. 
Beste Marijke ik ben je veel dank verschuldigd voor het helpen met de PBMC 
kweken en al die “klusjes” die je voor me hebt gedaan toen ik weer in de kli-
niek zat. Hoewel je weleens zei “niemand is onmisbaar”, heb je jezelf volgens 
mij wel van onschatbare waarde gemaakt in het “bottenlab”. Rodrigo, it was 
a pleasure to work together with you in Ommoord to collect the samples we 
needed and the metro rides back to the ErasmusMC. Poom thank you for 
becoming my friend and staying in contact throughout the years, it is always 
fun talking/mailing with you.  
Dear Natalia, thank you for the energy you have put in several of my papers. 
Your insights into statistics have been very helpful. I wish you all the best 
with your own defense and your  future career. 
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Daarnaast wil ik de medewerkers Anneke, Inge en Toos van het ERGO cen-
trum bedanken voor het helpen verzamelen van mijn samples voor het 
PBMC stuk. 
Fernando en Joyce, jullie wil ik bedanken voor het delen van jullie kennis 
van statistiek en epidemiologie. 
Beste Libbe, bedankt voor je hulp met het in elkaar zetten van dit boekje. Je 
handigheid hierin en je kritische blik hebben ervoor gezorgd dat er nog een 
aantal fouten uit zijn gehaald. 
Beste ride-collega’s Marieke, Michel, Lisette en Wendy, jullie zijn me alle vier 
voorgegaan in de route naar dit boekje. Van ieder van jullie heb ik op zijn tijd 
aanmoedigende en opbeurende woorden ontvangen en ik kan niet anders 
zeggen dan dat het een goed gevoel geeft. 
Als je bezig bent met promotieonderzoek en je komt, als het nog niet af is, in 
opleiding tot specialist terecht, dan krijg je te maken met een scala aan op-
leiders en supervisoren. Iedereen die mij in de afgelopen jaren onder 
zijn/haar hoede heeft genomen ten tijde van mijn opleiding tot (vasculair) 
internist en vervolgens intensivist, wil ik dan ook heel erg bedanken. In het 
bijzonder wil ik Hans van der Wiel, Jan van Saase, Stephanie Klein Nagel-
voort, Eric Sijbrands, Paul van Daele en Dennis Bergmans bedanken. Jullie 
hebben allemaal geholpen door voor mij ruimte te creëren tijdens mijn oplei-
ding(en). Daarnaast, en nog belangrijker voor mij, lieten jullie merken dat er 
begrip was voor mijn situatie. Dat had ik nodig, zonder dat was dit dank-
woord waarschijnlijk niet geschreven. 
Lieve vriendinnen van de studie: Anja, mijn partner in crime als het om taart 
en koekjes eten gaat, hoewel we niet meer in Rotterdam wonen, en jij inmid-
dels moeder bent van 3 prachtige kinderen, is het contact gebleven. Ik vind 
het fantastisch om te zien hoe je in het leven staat en hoe je “lastige” proble-
men met verve aanpakt, je bent mij in alles altijd tot steun geweest. Danielle, 
je vastberadenheid, compassie en loyaliteit zijn bewonderenswaardig. 
Evelien, onze liefde voor het Afrikaanse continent heeft ons op het hoogste 
punt van Afrika doen belanden. Bedankt dat jij voor de meeste van mijn 
grillen wel te porren was, of het nu ging om salsadansen, op safari gaan of 
leren duiken, het heeft mooie herinneringen opgeleverd. Noortje, je kracht en 
doorzettingsvermogen, evenals keuzes maken, zijn dingen waaraan ik graag 
een voorbeeld neem, ondanks dat jouw weg nooit duidelijk aangegeven stond, 
heb je wel een route uitgestippeld die bij je past. Lieve meiden wat ik in de 
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inleiding schreef over dat woorden niet altijd recht doen aan de dankbaar-
heid die ik voel, geldt zeker voor jullie. Overal kan altijd over gepraat wor-
den, ook de minder leuke dingen. Dat maakt het voor mij een waardevolle 
vriendschap. 
Lieve Annemarie en Nanda, jullie ken ik sinds mijn tijd in Pamplona in 2002. 
Door jullie is Amsterdam voor mij lange tijd een tweede thuis geweest. Ik heb 
goede herinneringen aan het uitgaan, Koninginnedag vieren, Oud en Nieuw 
feestjes, maar vooral ook gewoon aan lekker kletsen en lachen, gemengd met 
de nodige gekkigheid. 
Lieve Marlous, altijd in voor een drankje/praatje/gezelligheid, je hebt me 
ingewijd in de geheimen van het IJsselland Ziekenhuis zowel tijdens de eer-
ste skireis als tijdens mijn eerste dienst. Op het medisch vlak ben jij altijd 
iemand geweest bij wie ik mijn gedachten kon toetsen en van wie ik ontzet-
tend veel geleerd heb. Ook dank voor de ruimte die Hajo en jij bij jullie thuis 
creëerde. Het schrijven van een deel van mijn artikelen aan jullie eettafel, 
tijdens je eerste zwangerschapsverlof, waar ik voorzien werd van de nodige 
koppen thee en maaltijden, hebben het hele proces zeker veraangenaamd. 
Oud (mede) fellows van de vasculaire geneeskunde: Swasti, Fazil, Jorie en 
Marianne. Ik geniet er enorm van dat, ondanks mijn switch naar de IC en 
mijn verhuizing naar Leeuwarden, we elkaar nog regelmatig zien en gezelli-
ge eetafspraken hebben.  
Seppe en Eva, collega’s in crime tijdens mijn IC-stage in het EramusMC, 
bedankt voor het delen van jullie kennis van de anesthesie en voor de vele 
borrels en momenten van gezelligheid en de vriendschap die tijdens die peri-
ode is ontstaan. 
Aan alle oud-collega’s A(N)IOSSEN, medisch specialisten, verpleegkundige 
uit het IJsselland, het ErasmusMC en het MUMC bedankt voor jullie inte-
resse, jullie gedeelde kennis, de bemoedigende woorden en de borrels. 
Sabrina, Claudia introduced me to you and I’m glad she did. Your down to 
earth no-nonsense character and your honesty make you a loyal friend. I’m 
proud of how you manage to follow your dream in becoming a pediatrician. 
Zeer gewaardeerde collega’s van het MCL, in het bijzonder Christiaan, Cori-
ne, Fellery, Hanneke, Marco, Michael, Niels, Nynke, Peter Egbers, Peter 
Koetsier, Peter Kingma, Rik en Sjieuwke, dank voor het warme bad waar ik 
in terecht ben gekomen. Ik kan het niet anders verwoorden dan dat door 
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jullie interesse, de mogelijkheid en tijd die ik kreeg om dit proefschrift af te 
ronden, ik het gevoel heb gekregen hierin “gedragen” te zijn. Dank daarvoor. 
Je bent als intensivist bij uitstek onderdeel van een team, daarom wil ik ook 
alle verpleegkundige, de facilitaire ondersteuning en de A(N)IOSSEN van de 
IC in het MCL bedanken voor de morele support en de fijne samenwerking. 
Lieve Mandy, mijn ski-/borrel-/stap-/zeilmaatje en (oud)collega, altijd gezel-
lig, heerlijk ontnuchterend. Je leven loopt op veel fronten parallel aan die 
van mij en ik hoef je ook nooit dingen toe te lichten, want meestal snap je het 
wel. Bedankt dat je naast me staat. 
Dear Claudia, saying you’ve become one of my best friends in the whole wide 
world is spot on. Despite that you have moved away for thousands and thou-
sands of kilometers, we’ve kept on sharing tears, laughter and thoughts. I 
can always count on you for helping me to find a better outlook on things, 
and the holidays we had together are of the best I remember and I hope that 
there are many more to come. Thank you for standing beside me. 
Lieve familie, lieve pap, lieve mam, het is een lang traject geweest waarin 
jullie me zo goed en kwaad als het ging hebben geprobeerd te steunen. Dat 
was niet altijd makkelijk maar nu is het dan echt af. Ik vind het leuk dat 
jullie zo enthousiast zijn om met Martien, zijn ouders en mij mee naar Afrika 
te gaan. Ik hoop dat jullie, nu beide gepensioneerd, nog lang van elkaar en 
van een zo goed mogelijke gezondheid mogen genieten. 
Lieve Henri en Jaco, wat een prachtige dames hebben jullie in je leven toege-
laten. Ik heb twee fantastische schoonzusjes in Ilse en Lucinda! Als broers en 
schoonzusjes hebben jullie me de nodige afleiding en wijze woorden tijdens 
mijn promotietraject bezorgd. Ik vind het fijn dat ik een goede band met jullie 
heb. Lieve Jente en Silke, jullie hebben van mij een trotse tante gemaakt. 
Het is een voorrecht om jullie zo dicht in de buurt te hebben wonen en jullie 
te zien opgroeien.  
Lieve Martien, het is inmiddels meer dan 4 jaar geleden dat ik je leerde ken-
nen en zei dat ik mijn proefschrift dat jaar af wilde ronden. Dat is dus niet 
helemaal gelukt, wel heb je me ontzettend gesteund in de tijd die er nog voor 
nodig was. Ik kreeg een werkplek bij je thuis en als het nodig was een knuf-
fel. Jij hebt me zeker door mijn promotietraject geholpen, waarvoor veel 
dank. “Nadat ik gepromoveerd ben gaan we:….” Een veel gesproken zin 
waarvan ik zin heb om met jou de puntjes te gaan invullen.  
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